BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gillen S, Schuster T, Meyer Zum Büschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 2010;7:e1000267. [PMID: 20422030 DOI: 10.1371/journal.pmed.1000267] [Cited by in Crossref: 923] [Cited by in F6Publishing: 846] [Article Influence: 76.9] [Reference Citation Analysis]
Number Citing Articles
1 Talamonti MS. Management Controversies and Treatment Strategies for Borderline Resectable Pancreatic Cancer. Cancer Treat Res 2016;168:59-75. [PMID: 29206020 DOI: 10.1007/978-3-319-34244-3_4] [Reference Citation Analysis]
2 Li L, Gai X. The association between dietary zinc intake and risk of pancreatic cancer: a meta-analysis. Biosci Rep 2017;37:BSR20170155. [PMID: 28428431 DOI: 10.1042/BSR20170155] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.4] [Reference Citation Analysis]
3 Conroy T, Bachet JB, Ayav A, Huguet F, Lambert A, Caramella C, Maréchal R, Van Laethem JL, Ducreux M. Current standards and new innovative approaches for treatment of pancreatic cancer. Eur J Cancer. 2016;57:10-22. [PMID: 26851397 DOI: 10.1016/j.ejca.2015.12.026] [Cited by in Crossref: 85] [Cited by in F6Publishing: 86] [Article Influence: 14.2] [Reference Citation Analysis]
4 Bachellier P, Rosso E, Fuchshuber P, Addeo P, David P, Oussoultzoglou E, Lucescu I. Use of a temporary intraoperative mesentericoportal shunt for pancreatic resection for locally advanced pancreatic cancer with portal vein occlusion and portal hypertension. Surgery. 2014;155:449-456. [PMID: 24462078 DOI: 10.1016/j.surg.2013.09.003] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
5 Tachezy M, Gebauer F, Petersen C, Arnold D, Trepel M, Wegscheider K, Schafhausen P, Bockhorn M, Izbicki JR, Yekebas E. Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma: NEOPA- a randomized multicenter phase III study (NCT01900327, DRKS00003893, ISRCTN82191749). BMC Cancer. 2014;14:411. [PMID: 24906700 DOI: 10.1186/1471-2407-14-411] [Cited by in Crossref: 61] [Cited by in F6Publishing: 50] [Article Influence: 7.6] [Reference Citation Analysis]
6 Fogel EL, Shahda S, Sandrasegaran K, DeWitt J, Easler JJ, Agarwal DM, Eagleson M, Zyromski NJ, House MG, Ellsworth S, El Hajj I, O'Neil BH, Nakeeb A, Sherman S. A Multidisciplinary Approach to Pancreas Cancer in 2016: A Review. Am J Gastroenterol. 2017;112:537-554. [PMID: 28139655 DOI: 10.1038/ajg.2016.610] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 11.6] [Reference Citation Analysis]
7 Liu D, Zhang J, Wu Y, Shi G, Yuan H, Lu Z, Zhu Q, Wu P, Lu C, Guo F, Chen J, Jiang K, Miao Y. YY1 suppresses proliferation and migration of pancreatic ductal adenocarcinoma by regulating the CDKN3/MdM2/P53/P21 signaling pathway. Int J Cancer 2018;142:1392-404. [PMID: 29168185 DOI: 10.1002/ijc.31173] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 6.0] [Reference Citation Analysis]
8 Fang K, Wang L, Chen L, Liu T, Fang Z. Antiproliferative Effects of Matricine in Gemcitabine-Resistant Human Pancreatic Carcinoma Cells Are Mediated via Mitochondrial-Mediated Apoptosis, Inhibition of Cell Migration, Invasion Suppression, and Mammalian Target of Rapamycin (mTOR)-TOR/PI3K/AKT Signalling Pathway. Med Sci Monit 2019;25:2943-9. [PMID: 31005960 DOI: 10.12659/MSM.914244] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Kuwatani M, Kawakubo K, Sugimori K, Inoue H, Kamada H, Ishiwatari H, Kato S, Iwashita T, Yoshida M, Hashimoto S, Itonaga M, Mizukami Y, Nomura Y, Katanuma A, Sakamoto N. Trial protocol: a randomised controlled trial to verify the non-inferiority of a partially covered self-expandable metal stent to an uncovered self-expandable metal stent for biliary drainage during neoadjuvant therapy in patients with pancreatic cancer with obstructive jaundice (PUN-NAC trial). BMJ Open 2021;11:e045698. [PMID: 34244257 DOI: 10.1136/bmjopen-2020-045698] [Reference Citation Analysis]
10 Wysocka O, Kulbacka J, Saczko J. Adjuvant, neoadjuvant, and experimental regimens in overcoming pancreatic ductal adenocarcinoma. Prz Gastroenterol 2016;11:155-62. [PMID: 27713776 DOI: 10.5114/pg.2016.61438] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
11 Petrelli F, Inno A, Barni S, Ghidini A, Labianca R, Falconi M, Reni M, Cascinu S; GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digerente) and San Raffaele Hospital. Borderline resectable pancreatic cancer: More than an anatomical concept. Dig Liver Dis 2017;49:223-6. [PMID: 27931968 DOI: 10.1016/j.dld.2016.11.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
12 Kamyabi N, Abbasgholizadeh R, Maitra A, Ardekani A, Biswal SL, Grande-Allen KJ. Isolation and mutational assessment of pancreatic cancer extracellular vesicles using a microfluidic platform. Biomed Microdevices 2020;22:23. [PMID: 32162067 DOI: 10.1007/s10544-020-00483-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
13 Weber GF, Kersting S, Haller F, Grützmann R. R1-Resektion beim Pankreaskarzinom. Chirurg 2017;88:764-70. [DOI: 10.1007/s00104-017-0462-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
14 Scott J, Dundas K, Surjan Y, King O, Arumugam S, Deshpande S, Udovitch M, Lee M. Quantifying and Assessing the Dosimetric Impact of Changing Gas Volumes Throughout the Course of VMAT Radiation Therapy of Upper Gastrointestinal Tumors. Adv Radiat Oncol 2021;6:100650. [PMID: 34195488 DOI: 10.1016/j.adro.2021.100650] [Reference Citation Analysis]
15 Kanji ZS, Gallinger S. Diagnosis and management of pancreatic cancer. CMAJ. 2013;185:1219-1226. [PMID: 23610017 DOI: 10.1503/cmaj.121368] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
16 Strobel O, Neoptolemos J, Jäger D, Büchler MW. Optimizing the outcomes of pancreatic cancer surgery. Nat Rev Clin Oncol 2019;16:11-26. [PMID: 30341417 DOI: 10.1038/s41571-018-0112-1] [Cited by in Crossref: 165] [Cited by in F6Publishing: 160] [Article Influence: 55.0] [Reference Citation Analysis]
17 Zhang Y, Frampton AE, Kyriakides C, Bong JJ, Habib N, Ahmad R, Jiao LR. Loco-recurrence after resection for ductal adenocarcinoma of the pancreas: predictors and implications for adjuvant chemoradiotherapy. J Cancer Res Clin Oncol 2012;138:1063-71. [PMID: 22392075 DOI: 10.1007/s00432-012-1165-7] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 3.6] [Reference Citation Analysis]
18 Pipas JM, Zaki BI, McGowan MM, Tsapakos MJ, Ripple GH, Suriawinata AA, Tsongalis GJ, Colacchio TA, Gordon SR, Sutton JE. Neoadjuvant cetuximab, twice-weekly gemcitabine, and intensity-modulated radiotherapy (IMRT) in patients with pancreatic adenocarcinoma. Ann Oncol. 2012;23:2820-2827. [PMID: 22571859 DOI: 10.1093/annonc/mds109] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 3.5] [Reference Citation Analysis]
19 Lombardi P, Silvestri S, Marino D, Santarelli M, Campra D, De Paolis P, Aglietta M, Leone F. “Shades of Gray” in pancreatic ductal adenocarcinoma: Reappraisals on resectability criteria. Critical Reviews in Oncology/Hematology 2019;133:17-24. [DOI: 10.1016/j.critrevonc.2018.10.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
20 Turpin A, El Amrani M, Bachet JB, Pietrasz D, Schwarz L, Hammel P. Adjuvant Pancreatic Cancer Management: Towards New Perspectives in 2021. Cancers (Basel) 2020;12:E3866. [PMID: 33371464 DOI: 10.3390/cancers12123866] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
21 Azab B, Macedo FI, Chang D, Ripat C, Franceschi D, Livingstone AS, Yakoub D. The Impact of Prolonged Chemotherapy to Surgery Interval and Neoadjuvant Radiotherapy on Pathological Complete Response and Overall Survival in Pancreatic Cancer Patients. Clin Med Insights Oncol 2020;14:1179554920919402. [PMID: 32669884 DOI: 10.1177/1179554920919402] [Reference Citation Analysis]
22 Baekelandt BM, Hjermstad MJ, Nordby T, Fagerland MW, Kure EH, Heiberg T, Buanes T, Labori KJ. Preoperative cognitive function predicts survival in patients with resectable pancreatic ductal adenocarcinoma. HPB (Oxford) 2016;18:247-54. [PMID: 27017164 DOI: 10.1016/j.hpb.2015.09.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
23 Yu C, Wang M, Li Z, Xiao J, Peng F, Guo X, Deng Y, Jiang J, Sun C. MicroRNA-138-5p regulates pancreatic cancer cell growth through targeting FOXC1. Cell Oncol (Dordr). 2015;38:173-181. [PMID: 25875420 DOI: 10.1007/s13402-014-0200-x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 59] [Article Influence: 7.4] [Reference Citation Analysis]
24 Lambert A, Schwarz L, Borbath I, Henry A, Van Laethem JL, Malka D, Ducreux M, Conroy T. An update on treatment options for pancreatic adenocarcinoma. Ther Adv Med Oncol 2019;11:1758835919875568. [PMID: 31598142 DOI: 10.1177/1758835919875568] [Cited by in Crossref: 46] [Cited by in F6Publishing: 51] [Article Influence: 15.3] [Reference Citation Analysis]
25 Segelov E, Lordick F, Goldstein D, Chantrill LA, Croagh D, Lawrence B, Arnold D, Chau I, Obermannova R, Price TJ. Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. Expert Rev Anticancer Ther 2017;17:951-64. [PMID: 28817982 DOI: 10.1080/14737140.2017.1369882] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
26 Bjerregaard JK, Mortensen MB, Jensen HA, Nielsen M, Pfeiffer P. Prognostic Factors for Survival and Resection in Patients With Initial Nonresectable Locally Advanced Pancreatic Cancer Treated With Chemoradiotherapy. International Journal of Radiation Oncology*Biology*Physics 2012;83:909-15. [DOI: 10.1016/j.ijrobp.2011.09.008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
27 Pigula M, Mai Z, Anbil S, Choi MG, Wang K, Maytin E, Pogue B, Hasan T. Dramatic Reduction of Distant Pancreatic Metastases Using Local Light Activation of Verteporfin with Nab-Paclitaxel. Cancers (Basel) 2021;13:5781. [PMID: 34830934 DOI: 10.3390/cancers13225781] [Reference Citation Analysis]
28 Lee JL, Kim SC, Kim JH, Lee SS, Kim TW, Park DH, Seo DW, Lee SK, Kim MH, Park JH, Shin SH, Han DJ. Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma. Surgery. 2012;152:851-862. [PMID: 22682078 DOI: 10.1016/j.surg.2012.03.010] [Cited by in Crossref: 80] [Cited by in F6Publishing: 66] [Article Influence: 8.0] [Reference Citation Analysis]
29 Sharma G, Whang EE, Ruan DT, Ito H. Efficacy of Neoadjuvant Versus Adjuvant Therapy for Resectable Pancreatic Adenocarcinoma: A Decision Analysis. Ann Surg Oncol. 2015;22 Suppl 3:S1229-S1237. [PMID: 26152276 DOI: 10.1245/s10434-015-4711-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
30 Ashida R, Fukutake N, Takada R, Ioka T, Ohkawa K, Katayama K, Akita H, Takahashi H, Ohira S, Teshima T. Endoscopic ultrasound-guided fiducial marker placement for neoadjuvant chemoradiation therapy for resectable pancreatic cancer. World J Gastrointest Oncol 2020; 12(7): 768-781 [PMID: 32864044 DOI: 10.4251/wjgo.v12.i7.768] [Reference Citation Analysis]
31 Velez-Serrano JF, Velez-Serrano D, Hernandez-Barrera V, Jimenez-Garcia R, Lopez de Andres A, Garrido PC, Álvaro-Meca A. Prediction of in-hospital mortality after pancreatic resection in pancreatic cancer patients: A boosting approach via a population-based study using health administrative data. PLoS One 2017;12:e0178757. [PMID: 28591154 DOI: 10.1371/journal.pone.0178757] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
32 Damm M, Weniger M, Kölsch A, Lampert C, Ceyhan GO, Beer S, Schorn S, Moir J, Michl P, Rosendahl J. The quality of pain management in pancreatic cancer: A prospective multi-center study. Pancreatology 2020;20:1511-8. [DOI: 10.1016/j.pan.2020.08.017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
33 van Tienhoven G, Gouma DJ, Richel DJ. Neoadjuvant chemoradiotherapy has a potential role in pancreatic carcinoma. Ther Adv Med Oncol 2011;3:27-33. [PMID: 21789153 DOI: 10.1177/1758834010383150] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
34 Loehrer AP, Kinnier CV, Ferrone CR. Treatment of Locally Advanced Pancreatic Ductal Adenocarcinoma. Adv Surg 2016;50:115-28. [PMID: 27520867 DOI: 10.1016/j.yasu.2016.03.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
35 Windisch O, Frossard J, Schiffer E, Harbarth S, Morel P, Bühler L. Microbiologic Changes Induced by Biliary Drainage Require Adapted Antibiotic Prophylaxis during Duodenopancreatectomy. Surgical Infections 2019;20:677-82. [DOI: 10.1089/sur.2019.088] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
36 Okano K, Suto H, Oshima M, Maeda E, Yamamoto N, Kakinoki K, Kamada H, Masaki T, Takahashi S, Shibata T, Suzuki Y. A Prospective Phase II Trial of Neoadjuvant S-1 with Concurrent Hypofractionated Radiotherapy in Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol. 2017;24:2777-2784. [PMID: 28608121 DOI: 10.1245/s10434-017-5921-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
37 Awasthi N, Monahan S, Stefaniak A, Schwarz MA, Schwarz RE. Inhibition of the MEK/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancer. Oncotarget 2018;9:5274-86. [PMID: 29435178 DOI: 10.18632/oncotarget.23684] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
38 Goess R, Friess H. A look at the progress of treating pancreatic cancer over the past 20 years. Expert Rev Anticancer Ther. 2018;18:295-304. [PMID: 29334794 DOI: 10.1080/14737140.2018.1428093] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
39 Coppola R. Pancreas cancer treatment: A surgeon's perspective today. International Journal of Surgery 2012;10:187-9. [DOI: 10.1016/j.ijsu.2012.03.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
40 Tran NH, Sahai V, Griffith KA, Nathan H, Kaza R, Cuneo KC, Shi J, Kim E, Sonnenday CJ, Cho CS, Lawrence TS, Zalupski MM. Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemcitabine in Patients With Borderline Resectable Pancreatic Cancer. Int J Radiat Oncol Biol Phys 2020;106:124-33. [PMID: 31494181 DOI: 10.1016/j.ijrobp.2019.08.057] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
41 Hua YQ, Zhang K, Sheng J, Ning ZY, Li Y, Shi WD, Liu LM. NUCB1 Suppresses Growth and Shows Additive Effects With Gemcitabine in Pancreatic Ductal Adenocarcinoma via the Unfolded Protein Response. Front Cell Dev Biol 2021;9:641836. [PMID: 33855021 DOI: 10.3389/fcell.2021.641836] [Reference Citation Analysis]
42 Gantois D, Guilbaud T, Scemama U, Girard E, Picaud O, Lefevre M, Elgani M, Hamidou Z, Moutardier V, Balandraud P, Chirica M, Barbier L, Fuks D, Birnbaum DJ. Prognostic impact of splenic vessel involvement and tumor size in distal pancreatectomy for adenocarcinoma: a retrospective multicentric cohort study. Langenbecks Arch Surg 2021. [PMID: 34373941 DOI: 10.1007/s00423-021-02291-w] [Reference Citation Analysis]
43 Cloyd JM, Wang H, Egger ME, Tzeng CD, Prakash LR, Maitra A, Varadhachary GR, Shroff R, Javle M, Fogelman D, Wolff RA, Overman MJ, Koay EJ, Das P, Herman JM, Kim MP, Vauthey JN, Aloia TA, Fleming JB, Lee JE, Katz MHG. Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. JAMA Surg. 2017;152:1048-1056. [PMID: 28700784 DOI: 10.1001/jamasurg.2017.2227] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 11.0] [Reference Citation Analysis]
44 Laurence JM, Tran PD, Morarji K, Eslick GD, Lam VW, Sandroussi C. A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer. J Gastrointest Surg. 2011;15:2059-2069. [PMID: 21913045 DOI: 10.1007/s11605-011-1659-7] [Cited by in Crossref: 98] [Cited by in F6Publishing: 81] [Article Influence: 8.9] [Reference Citation Analysis]
45 Yang YH, Liu JB, Gui Y, Lei LL, Zhang SJ. Relationship between autophagy and perineural invasion, clinicopathological features, and prognosis in pancreatic cancer. World J Gastroenterol 2017; 23(40): 7232-7241 [PMID: 29142470 DOI: 10.3748/wjg.v23.i40.7232] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
46 Qiu C, Yang L, Wang B, Cui L, Li C, Zhuo Y, Zhang L, Zhang S, Zhang Q, Wang X. The role of 2-arachidonoylglycerol in the regulation of the tumor-immune microenvironment in murine models of pancreatic cancer. Biomedicine & Pharmacotherapy 2019;115:108952. [DOI: 10.1016/j.biopha.2019.108952] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
47 Delpero JR, Boher JM, Sauvanet A, Le Treut YP, Sa-Cunha A, Mabrut JY, Chiche L, Turrini O, Bachellier P, Paye F. Pancreatic adenocarcinoma with venous involvement: is up-front synchronous portal-superior mesenteric vein resection still justified? Ann Surg Oncol. 2015;22:1874-1883. [PMID: 25665947 DOI: 10.1245/s10434-014-4304-3] [Cited by in Crossref: 64] [Cited by in F6Publishing: 61] [Article Influence: 9.1] [Reference Citation Analysis]
48 Wang S, You L, Dai M, Zhao Y. Quantitative assessment of the diagnostic role of mucin family members in pancreatic cancer: a meta-analysis. Ann Transl Med. 2021;9:192. [PMID: 33708819 DOI: 10.21037/atm-20-5606] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
49 Kirkegård J, Mortensen FV, Hansen CP, Mortensen MB, Sall M, Fristrup C. Waiting time to surgery and pancreatic cancer survival: A nationwide population-based cohort study. Eur J Surg Oncol 2019;45:1901-5. [PMID: 31160135 DOI: 10.1016/j.ejso.2019.05.029] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
50 Kunzmann V, Siveke JT, Algül H, Goekkurt E, Siegler G, Martens U, Waldschmidt D, Pelzer U, Fuchs M, Kullmann F, Boeck S, Ettrich TJ, Held S, Keller R, Klein I, Germer CT, Stein H, Friess H, Bahra M, Jakobs R, Hartlapp I, Heinemann V; German Pancreatic Cancer Working Group (AIO-PAK) and NEOLAP investigators. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol 2021;6:128-38. [PMID: 33338442 DOI: 10.1016/S2468-1253(20)30330-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
51 Peng JS, Mino J, Monteiro R, Morris-Stiff G, Ali NS, Wey J, El-Hayek KM, Walsh RM, Chalikonda S. Diagnostic Laparoscopy Prior to Neoadjuvant Therapy in Pancreatic Cancer Is High Yield: an Analysis of Outcomes and Costs. J Gastrointest Surg 2017;21:1420-7. [PMID: 28597320 DOI: 10.1007/s11605-017-3470-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
52 Lutfi W, Talamonti MS, Kantor O, Wang C, Stocker SJ, Bentrem DJ, Roggin KK, Winchester DJ, Marsh R, Prinz RA, Baker MS. Neoadjuvant external beam radiation is associated with No benefit in overall survival for early stage pancreatic cancer. The American Journal of Surgery 2017;213:521-5. [DOI: 10.1016/j.amjsurg.2016.11.039] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
53 Jun E, Koo B, Kim EJ, Hwang DW, Lee JH, Song KB, Lee W, Park Y, Hong S, Shin Y, Kim SC. Analysis of KRAS Mutation Subtype in Tissue DNA and Cell-Free DNA Using Droplet Digital PCR and the Function of Cell-Free DNA as a Recurrence Predictive Marker in Pancreatic Cancer. Biomedicines 2021;9:1599. [PMID: 34829828 DOI: 10.3390/biomedicines9111599] [Reference Citation Analysis]
54 Kumar R, Herman JM, Wolfgang CL, Zheng L. Multidisciplinary management of pancreatic cancer. Surg Oncol Clin N Am. 2013;22:265-287. [PMID: 23453334 DOI: 10.1016/j.soc.2012.12.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
55 Li L, Zhang GQ, Chen H, Zhao ZJ, Chen HZ, Liu H, Wang G, Jia YH, Pan SH, Kong R, Wang YW, Sun B. Plasma and tumor levels of Linc-pint are diagnostic and prognostic biomarkers for pancreatic cancer. Oncotarget. 2016;7:71773-71781. [PMID: 27708234 DOI: 10.18632/oncotarget.12365] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 10.3] [Reference Citation Analysis]
56 Hayasaki A, Murata Y, Usui M, Hibi T, Ito T, Iizawa Y, Kato H, Tanemura A, Azumi Y, Kuriyama N. Clinical Significance of Histological Effect and Intratumor Stromal Expression of Tenascin-C in Resected Specimens After Chemoradiotherapy for Initially Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma. Pancreas. 2018;47:390-399. [PMID: 29517632 DOI: 10.1097/mpa.0000000000001022] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
57 Venkat S, Hosein PJ, Narayanan G. Percutaneous Approach to Irreversible Electroporation of the Pancreas: Miami Protocol. Techniques in Vascular and Interventional Radiology 2015;18:153-8. [DOI: 10.1053/j.tvir.2015.06.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
58 Takahashi C, Shridhar R, Huston J, Meredith K. Adjuvant therapy for margin positive pancreatic cancer: A propensity score matched analysis. Pancreatology 2022. [DOI: 10.1016/j.pan.2022.03.008] [Reference Citation Analysis]
59 Bradley A, Van Der Meer R. Neoadjuvant therapy versus upfront surgery for potentially resectable pancreatic cancer: A Markov decision analysis. PLoS One 2019;14:e0212805. [PMID: 30817807 DOI: 10.1371/journal.pone.0212805] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
60 Wo JY, Childs SK, Szymonifka J, Mamon HJ, Ryan DP, Blaszkowsky LS, Kwak EL, Ferrone CR, Allen JN, Zhu AX, Wolpin BM, Chan JA, Abrams TA, McCleary NJ, Fernandez-Del Castillo C, Hong TS. Delaying chemoradiation until after completion of adjuvant chemotherapy for pancreatic cancer may not impact local control. Pract Radiat Oncol 2014;4:e117-23. [PMID: 24890357 DOI: 10.1016/j.prro.2013.07.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
61 Calvo F, Guillen Ponce C, Muñoz Beltran M, Sanjuanbenito Dehesa A. Multidisciplinary management of locally advanced–borderline resectable adenocarcinoma of the head of the pancreas. Clin Transl Oncol 2013;15:173-81. [DOI: 10.1007/s12094-012-0962-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
62 Lim KH, Chung E, Khan A, Cao D, Linehan D, Ben-Josef E, Wang-Gillam A. Neoadjuvant therapy of pancreatic cancer: the emerging paradigm? Oncologist. 2012;17:192-200. [PMID: 22250057 DOI: 10.1634/theoncologist.2011-0268] [Cited by in Crossref: 54] [Cited by in F6Publishing: 57] [Article Influence: 5.4] [Reference Citation Analysis]
63 Kim H, Kang KN, Shin YS, Byun Y, Han Y, Kwon W, Kim CW, Jang JY. Biomarker Panel for the Diagnosis of Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2020;12:E1443. [PMID: 32492943 DOI: 10.3390/cancers12061443] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Pouypoudat C, Buscail E, Cossin S, Cassinotto C, Terrebonne E, Blanc JF, Smith D, Marty M, Dupin C, Laurent C, Dabernat S, Chiche L, Vendrely V. FOLFIRINOX-based neoadjuvant chemoradiotherapy for borderline and locally advanced pancreatic cancer: A pilot study from a tertiary centre. Dig Liver Dis 2019;51:1043-9. [PMID: 31000479 DOI: 10.1016/j.dld.2019.03.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
65 Elberm H, Ravikumar R, Sabin C, Abu Hilal M, Al-Hilli A, Aroori S, Bond-Smith G, Bramhall S, Coldham C, Hammond J. Outcome after pancreaticoduodenectomy for T3 adenocarcinoma: A multivariable analysis from the UK Vascular Resection for Pancreatic Cancer Study Group. Eur J Surg Oncol. 2015;41:1500-1507. [PMID: 26346183 DOI: 10.1016/j.ejso.2015.08.158] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
66 Rangarajan K, Pucher PH, Armstrong T, Bateman A, Hamady Z. Systemic neoadjuvant chemotherapy in modern pancreatic cancer treatment: a systematic review and meta-analysis. Ann R Coll Surg Engl. 2019;101:453-462. [PMID: 31304767 DOI: 10.1308/rcsann.2019.0060] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
67 Ramachandran S, Kaushik IS, Srivastava SK. Pimavanserin: A Novel Autophagy Modulator for Pancreatic Cancer Treatment. Cancers (Basel) 2021;13:5661. [PMID: 34830816 DOI: 10.3390/cancers13225661] [Reference Citation Analysis]
68 Strobel O, Hank T, Hinz U, Bergmann F, Schneider L, Springfeld C, Jäger D, Schirmacher P, Hackert T, Büchler MW. Pancreatic Cancer Surgery: The New R-status Counts. Ann Surg 2017;265:565-73. [PMID: 27918310 DOI: 10.1097/SLA.0000000000001731] [Cited by in Crossref: 148] [Cited by in F6Publishing: 54] [Article Influence: 29.6] [Reference Citation Analysis]
69 Moutinho-Ribeiro P, Liberal R, Macedo G. Endoscopic ultrasound in pancreatic cancer treatment: Facts and hopes. Clin Res Hepatol Gastroenterol 2019;43:513-21. [PMID: 30935904 DOI: 10.1016/j.clinre.2019.02.014] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
70 Kameyama A, Ye J, Shimomura A, Yokohira M, Nakano-Narusawa Y, Yamakawa K, Mukai Y, Sanomura T, Okuyama H, Miyatake N, Furihata M, Tanaka C, Kitazawa R, Bando Y, Suemitsu Y, Kojima M, Mino-Kenudson M, Suzuki Y, Okano K, Matsuda Y. Reproducibility and prognostic significance of area of residual tumor (ART) in post-neoadjuvant resections of pancreatic ductal adenocarcinoma. Pancreatology 2021:S1424-3903(21)00570-6. [PMID: 34563448 DOI: 10.1016/j.pan.2021.09.006] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
71 Bisht S, Brossart P, Feldmann G. Current Therapeutic Options for Pancreatic Ductal Adenocarcinoma. Oncol Res Treat 2018;41:590-4. [PMID: 30286472 DOI: 10.1159/000493868] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
72 Elbanna KY, Jang HJ, Kim TK. Imaging diagnosis and staging of pancreatic ductal adenocarcinoma: a comprehensive review. Insights Imaging. 2020;11:58. [PMID: 32335790 DOI: 10.1186/s13244-020-00861-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
73 Glazer ES, Hornbrook MC, Krouse RS. A meta-analysis of randomized trials: immediate stent placement vs. surgical bypass in the palliative management of malignant biliary obstruction. J Pain Symptom Manage. 2014;47:307-314. [PMID: 23830531 DOI: 10.1016/j.jpainsymman.2013.03.013] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 5.0] [Reference Citation Analysis]
74 Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378:607-620. [PMID: 21620466 DOI: 10.1016/so140-6736(10)62307-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
75 N. Kalimuthu S, Chetty R. Regression grading in post neoadjuvant treated pancreatic cancer. Diagnostic Histopathology 2016;22:219-25. [DOI: 10.1016/j.mpdhp.2016.05.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
76 Bauer TM, Dhir T, Strickland A, Thomsett H, Goetz AB, Cannaday S, Brody JR, Pishvaian MJ, Yeo CJ. Genetic Drivers of Pancreatic Cancer Are Identical Between the Primary Tumor and a Secondary Lesion in a Long-Term (>5 Years) Survivor After a Whipple Procedure. J Pancreat Cancer 2018;4:81-7. [PMID: 30788462 DOI: 10.1089/pancan.2018.0015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
77 Datta J, Willobee BA, Ryon EL, Shah MM, Drebin JA, Kooby DA, Merchant NB. Contemporary Reappraisal of Intraoperative Neck Margin Assessment During Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: A Review. JAMA Surg 2021;156:489-95. [PMID: 33533898 DOI: 10.1001/jamasurg.2020.5676] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
78 Shimomura H, Okada R, Tanaka T, Hozaka Y, Wada M, Moriya S, Idichi T, Kita Y, Kurahara H, Ohtsuka T, Seki N. Role of miR-30a-3p Regulation of Oncogenic Targets in Pancreatic Ductal Adenocarcinoma Pathogenesis. Int J Mol Sci 2020;21:E6459. [PMID: 32899691 DOI: 10.3390/ijms21186459] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
79 Kim SS, Lee S, Lee HS, Bang S, Park MS. Prognostic factors in patients with locally advanced or borderline resectable pancreatic ductal adenocarcinoma: chemotherapy vs. chemoradiotherapy. Abdom Radiol (NY) 2021;46:655-66. [PMID: 32748250 DOI: 10.1007/s00261-020-02661-w] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
80 Hartwig W, Werner J, Jäger D, Debus J, Büchler MW. Improvement of surgical results for pancreatic cancer. The Lancet Oncology 2013;14:e476-85. [DOI: 10.1016/s1470-2045(13)70172-4] [Cited by in Crossref: 193] [Cited by in F6Publishing: 85] [Article Influence: 21.4] [Reference Citation Analysis]
81 Einama T, Kamachi H, Tsuruga Y, Sakata T, Shibuya K, Sakamoto Y, Shimada S, Wakayama K, Orimo T, Yokoo H, Kamiyama T, Katoh N, Uchinami Y, Mitsuhashi T, Taketomi A. Optimal resection area for superior mesenteric artery nerve plexuses after neoadjuvant chemoradiotherapy for locally advanced pancreatic carcinoma. Medicine (Baltimore) 2018;97:e11309. [PMID: 30075497 DOI: 10.1097/MD.0000000000011309] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
82 Eskander MF, Bliss LA, Tseng JF. Pancreatic adenocarcinoma. Current Problems in Surgery 2016;53:107-54. [DOI: 10.1067/j.cpsurg.2016.01.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
83 Levy J, Zuckerman J, Garfinkle R, Acuna SA, Touchette J, Vanounou T, Pelletier JS. Intra-arterial therapies for unresectable and chemorefractory colorectal cancer liver metastases: a systematic review and meta-analysis. HPB (Oxford). 2018;20:905-915. [PMID: 29887263 DOI: 10.1016/j.hpb.2018.04.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
84 Eilaghi A, Baig S, Zhang Y, Zhang J, Karanicolas P, Gallinger S, Khalvati F, Haider MA. CT texture features are associated with overall survival in pancreatic ductal adenocarcinoma - a quantitative analysis. BMC Med Imaging. 2017;17:38. [PMID: 28629416 DOI: 10.1186/s12880-017-0209-5] [Cited by in Crossref: 67] [Cited by in F6Publishing: 64] [Article Influence: 13.4] [Reference Citation Analysis]
85 Girelli R, Prejanò S, Cataldo I, Corbo V, Martini L, Scarpa A, Claudio B. Feasibility and safety of electrochemotherapy (ECT) in the pancreas: a pre-clinical investigation. Radiol Oncol 2015;49:147-54. [PMID: 26029026 DOI: 10.1515/raon-2015-0013] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 4.6] [Reference Citation Analysis]
86 Janssen QP, van Dam JL, Kivits IG, Besselink MG, van Eijck CHJ, Homs MYV, Nuyttens JJME, Qi H, van Santvoort HJ, Wei AC, de Wilde RF, Wilmink JW, van Tienhoven G, Groot Koerkamp B. Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis. Ann Surg Oncol 2021. [PMID: 34142290 DOI: 10.1245/s10434-021-10276-8] [Reference Citation Analysis]
87 Naumann P, Habermehl D, Welzel T, Debus J, Combs SE. Outcome after neoadjuvant chemoradiation and correlation with nutritional status in patients with locally advanced pancreatic cancer. Strahlenther Onkol 2013;189:745-52. [PMID: 23896631 DOI: 10.1007/s00066-013-0393-3] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
88 Eyff TF, Bosi HR, Toni MS, Zilio MB, Corso CO, Bersch VP, Osvaldt AB. THE ROLE OF IMMUNOINFLAMMATORY MARKERS IN THE PROGNOSIS AND RESECTABILITY OF PANCREATIC ADENOCARCINOMA. Arq Bras Cir Dig 2018;31:e1366. [PMID: 29972394 DOI: 10.1590/0102-672020180001e1366] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
89 Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK, Hruban RH. Recent progress in pancreatic cancer. CA Cancer J Clin. 2013;63:318-348. [PMID: 23856911 DOI: 10.3322/caac.21190] [Cited by in Crossref: 479] [Cited by in F6Publishing: 473] [Article Influence: 53.2] [Reference Citation Analysis]
90 Zhao Z, Liu W. Pancreatic Cancer: A Review of Risk Factors, Diagnosis, and Treatment. Technol Cancer Res Treat 2020;19:1533033820962117. [PMID: 33357065 DOI: 10.1177/1533033820962117] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
91 Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, Neale RE, Tempero M, Tuveson DA, Hruban RH, Neoptolemos JP. Pancreatic cancer. Nat Rev Dis Primers. 2016;2:16022. [PMID: 27158978 DOI: 10.1038/nrdp.2016.22] [Cited by in Crossref: 657] [Cited by in F6Publishing: 617] [Article Influence: 109.5] [Reference Citation Analysis]
92 Verma V, Li J, Lin C. Neoadjuvant Therapy for Pancreatic Cancer: Systematic Review of Postoperative Morbidity, Mortality, and Complications. Am J Clin Oncol. 2016;39:302-313. [PMID: 26950464 DOI: 10.1097/coc.0000000000000278] [Cited by in Crossref: 52] [Cited by in F6Publishing: 33] [Article Influence: 10.4] [Reference Citation Analysis]
93 de Leede E, Sibinga Mulder B, Bastiaannet E, Poston G, Sahora K, Van Eycken E, Valerianova Z, Mortensen M, Dralle H, Primic-žakelj M, Borràs J, Gasslander T, Ryzhov A, Lemmens V, Mieog J, Boelens P, van de Velde C, Bonsing B. Common variables in European pancreatic cancer registries: The introduction of the EURECCA pancreatic cancer project. European Journal of Surgical Oncology (EJSO) 2016;42:1414-9. [DOI: 10.1016/j.ejso.2016.03.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
94 Suto H, Okano K, Oshima M, Ando Y, Matsukawa H, Takahashi S, Shibata T, Kamada H, Masaki T, Suzuki Y. Prediction of local tumor control and recurrence-free survival in patients with pancreatic cancer undergoing curative resection after neoadjuvant chemoradiotherapy. J Surg Oncol 2022. [PMID: 35289928 DOI: 10.1002/jso.26854] [Reference Citation Analysis]
95 Wang G, Zhou D. Preoperative ultrasound ablation for borderline resectable pancreatic cancer: A report of 30 cases. Ultrason Sonochem. 2015;27:694-702. [PMID: 26113389 DOI: 10.1016/j.ultsonch.2015.05.029] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
96 Pompa TA, Morano WF, Jeurkar C, Li H, Soundararajan S, Poli J, Bowne WB, Styler M. Complete Response after Treatment with Neoadjuvant Chemoradiation with Prolonged Chemotherapy for Locally Advanced, Unresectable Adenocarcinoma of the Pancreas. Case Rep Oncol Med 2017;2017:7834702. [PMID: 28373919 DOI: 10.1155/2017/7834702] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
97 Groen JV, Sibinga Mulder BG, van Eycken E, Valerianova Z, Borras JM, van der Geest LGM, Capretti G, Schlesinger-Raab A, Primic-Zakelj M, Ryzhov A, van de Velde CJH, Bonsing BA, Bastiaannet E, Mieog JSD. Differences in Treatment and Outcome of Pancreatic Adenocarcinoma Stage I and II in the EURECCA Pancreas Consortium. Ann Surg Oncol 2018;25:3492-501. [PMID: 30151560 DOI: 10.1245/s10434-018-6705-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
98 Du X, Zhao YP, Zhang TP, Zhou L, Chen G, Wang TX, You L, Shu H. Alteration of the intrinsic apoptosis pathway is involved in Notch-induced chemoresistance to gemcitabine in pancreatic cancer. Arch Med Res 2014;45:15-20. [PMID: 24316112 DOI: 10.1016/j.arcmed.2013.10.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
99 Zhang Z, Chen H, Lu Y, Feng T, Sun W. LncRNA BC032020 suppresses the survival of human pancreatic ductal adenocarcinoma cells by targeting ZNF451. Int J Oncol 2018;52:1224-34. [PMID: 29532883 DOI: 10.3892/ijo.2018.4289] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
100 Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. The Lancet 2004;363:1049-57. [DOI: 10.1016/s0140-6736(04)15841-8] [Cited by in Crossref: 1360] [Cited by in F6Publishing: 672] [Article Influence: 75.6] [Reference Citation Analysis]
101 Liu Q, Liao Q, Zhao Y. Chemotherapy and tumor microenvironment of pancreatic cancer. Cancer Cell Int 2017;17:68. [PMID: 28694739 DOI: 10.1186/s12935-017-0437-3] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 8.8] [Reference Citation Analysis]
102 Leal AD, Messersmith WA, Lieu CH. Neoadjuvant treatment of localized pancreatic adenocarcinoma. J Gastrointest Oncol 2021;12:2461-74. [PMID: 34790407 DOI: 10.21037/jgo-20-250] [Reference Citation Analysis]
103 Masui T, Doi R, Kawaguchi Y, Sato A, Nakano K, Ito T, Anazawa T, Takaori K, Uemoto S. Concurrent gemcitabine+S-1 neoadjuvant chemotherapy contributes to the improved survival of patients with small borderline-resectable pancreatic cancer tumors. Surg Today 2016;46:1282-9. [PMID: 26860274 DOI: 10.1007/s00595-016-1310-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
104 Sahora K, Schindl M, Kuehrer I, Werba G, Fitzal F, Goetzinger P, Gnant M. Gemcitabine-based neoadjuvant chemotherapy for locally advanced pancreatic cancer does not affect mortality and morbidity after pancreatic resection. Eur Surg 2013;45:169-78. [DOI: 10.1007/s10353-013-0213-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
105 Pan H, Diao H, Zhong W, Wang T, Wen P, Wu C. A Cancer Cell Cluster Marked by LincRNA MEG3 Leads Pancreatic Ductal Adenocarcinoma Metastasis. Front Oncol 2021;11:656564. [PMID: 34055623 DOI: 10.3389/fonc.2021.656564] [Reference Citation Analysis]
106 Fokas E, Eccles C, Patel N, Chu KY, Warren S, Gillies McKenna W, Brunner TB. Comparison of four target volume definitions for pancreatic cancer. Guidelines for treatment of the lymphatics and the primary tumor. Strahlenther Onkol 2013;189:407-16. [PMID: 23553047 DOI: 10.1007/s00066-013-0332-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
107 Puleo F, Maréchal R, Demetter P, Bali MA, Calomme A, Closset J, Bachet JB, Deviere J, Laethem JLV. New challenges in perioperative management of pancreatic cancer. World J Gastroenterol 2015; 21(8): 2281-2293 [PMID: 25741134 DOI: 10.3748/wjg.v21.i8.2281] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 37] [Article Influence: 5.4] [Reference Citation Analysis]
108 Blair AB, Yin LD, Pu N, Yu J, Groot VP, Rozich NS, Javed AA, Zheng L, Cameron JL, Burkhart RA, Weiss MJ, Wolfgang CL, He J. Recurrence in Patients Achieving Pathological Complete Response After Neoadjuvant Treatment for Advanced Pancreatic Cancer. Ann Surg 2021;274:162-9. [PMID: 32304375 DOI: 10.1097/SLA.0000000000003570] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
109 Sun C, Wang P, Dong W, Liu H, Sun J, Zhao L. LncRNA PVT1 promotes exosome secretion through YKT6, RAB7, and VAMP3 in pancreatic cancer. Aging (Albany NY) 2020;12:10427-40. [PMID: 32499447 DOI: 10.18632/aging.103268] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
110 Zhu Y, Tian J, Peng X, Wang X, Yang N, Ying P, Wang H, Li B, Li Y, Zhang M, Cai Y, Lu Z, Niu S, Li Y, Zhong R, Chang J, Miao X. A genetic variant conferred high expression of CAV2 promotes pancreatic cancer progression and associates with poor prognosis. Eur J Cancer 2021;151:94-105. [PMID: 33975060 DOI: 10.1016/j.ejca.2021.04.008] [Reference Citation Analysis]
111 Yamamoto KN, Nakamura A, Liu LL, Stein S, Tramontano AC, Kartoun U, Shimizu T, Inoue Y, Asakuma M, Haeno H, Kong CY, Uchiyama K, Gonen M, Hur C, Michor F. Computational modeling of pancreatic cancer patients receiving FOLFIRINOX and gemcitabine-based therapies identifies optimum intervention strategies. PLoS One 2019;14:e0215409. [PMID: 31026288 DOI: 10.1371/journal.pone.0215409] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
112 Kamisawa T, Wood LD, Itoi T, Takaori K. Pancreatic cancer. Lancet. 2016;388:73-85. [PMID: 26830752 DOI: 10.1016/s0140-6736(16)00141-0] [Cited by in Crossref: 995] [Cited by in F6Publishing: 643] [Article Influence: 165.8] [Reference Citation Analysis]
113 Reni M, Balzano G, Zanon S, Zerbi A, Rimassa L, Castoldi R, Pinelli D, Mosconi S, Doglioni C, Chiaravalli M, Pircher C, Arcidiacono PG, Torri V, Maggiora P, Ceraulo D, Falconi M, Gianni L. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2–3 trial. The Lancet Gastroenterology & Hepatology 2018;3:413-23. [DOI: 10.1016/s2468-1253(18)30081-5] [Cited by in Crossref: 68] [Cited by in F6Publishing: 30] [Article Influence: 17.0] [Reference Citation Analysis]
114 Neuzillet C, Tijeras-Raballand A, Bourget P, Cros J, Couvelard A, Sauvanet A, Vullierme MP, Tournigand C, Hammel P. State of the art and future directions of pancreatic ductal adenocarcinoma therapy. Pharmacol Ther. 2015;155:80-104. [PMID: 26299994 DOI: 10.1016/j.pharmthera.2015.08.006] [Cited by in Crossref: 58] [Cited by in F6Publishing: 57] [Article Influence: 8.3] [Reference Citation Analysis]
115 Gao S, Zhu X, Shi X, Cao K, Bian Y, Jiang H, Wang K, Guo S, Zhang H, Jin G. Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1). Radiat Oncol 2019;14:52. [PMID: 30917842 DOI: 10.1186/s13014-019-1254-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
116 van der Geest LGM, van Eijck CHJ, Groot Koerkamp B, Lemmens VEPP, Busch OR, Vissers PAJ, Wilmink JW, Besselink MG; Dutch Pancreatic Cancer Group. Trends in treatment and survival of patients with nonresected, nonmetastatic pancreatic cancer: A population-based study. Cancer Med 2018;7:4943-51. [PMID: 30188015 DOI: 10.1002/cam4.1750] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
117 Müller SA, Tarantino I, Martin DJ, Schmied BM. Pancreatic surgery: beyond the traditional limits. Recent Results Cancer Res 2012;196:53-64. [PMID: 23129366 DOI: 10.1007/978-3-642-31629-6_4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
118 Pandé R, Roberts KJ. Determining Optimal Routes to Surgery for Borderline Resectable Venous Pancreatic Cancer-Where Is the Least Harm and Most Benefit? Front Oncol 2019;9:1060. [PMID: 31681596 DOI: 10.3389/fonc.2019.01060] [Reference Citation Analysis]
119 Byrne JD, Yeh JJ, DeSimone JM. Use of iontophoresis for the treatment of cancer. J Control Release 2018;284:144-51. [PMID: 29908892 DOI: 10.1016/j.jconrel.2018.06.020] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 8.3] [Reference Citation Analysis]
120 Desai NV, Sliesoraitis S, Hughes SJ, Trevino JG, Zlotecki RA, Ivey AM, George TJ Jr. Multidisciplinary neoadjuvant management for potentially curable pancreatic cancer. Cancer Med 2015;4:1224-39. [PMID: 25766842 DOI: 10.1002/cam4.444] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
121 Thanikachalam K, Damarla V, Seixas T, Dobrosotskaya I, Wollner I, Kwon D, Winters K, Raoufi M, Li J, Siddiqui F, Khan G. Neoadjuvant Phase II Trial of Chemoradiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer. Am J Clin Oncol 2020;43:435-41. [PMID: 32251119 DOI: 10.1097/COC.0000000000000688] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
122 Nguyen L, Schilling D, Dobiasch S, Raulefs S, Santiago Franco M, Buschmann D, Pfaffl MW, Schmid TE, Combs SE. The Emerging Role of miRNAs for the Radiation Treatment of Pancreatic Cancer. Cancers (Basel) 2020;12:E3703. [PMID: 33317198 DOI: 10.3390/cancers12123703] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
123 Giovinazzo F, Soggiu F, Jang JY, Versteijne E, van Tienhoven G, van Eijck CH, Han Y, Choi SH, Kang CM, Zalupski M, Ahmad H, Yentz S, Helton S, Rose JB, Takishita C, Nagakawa Y, Abu Hilal M. Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data.Front Oncol. 2020;10:1112. [PMID: 32850319 DOI: 10.3389/fonc.2020.01112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
124 Arrington AK, Hsu CH, Schaefer KL, O'Grady CL, Khreiss M, Riall TS. Survival after Margin-Positive Resection in the Era of Modern Chemotherapy for Pancreatic Cancer: Do Patients Still Benefit? J Am Coll Surg 2021;233:100-9. [PMID: 33781861 DOI: 10.1016/j.jamcollsurg.2021.02.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
125 Lekka K, Tzitzi E, Giakoustidis A, Papadopoulos V, Giakoustidis D. Contemporary management of borderline resectable pancreatic ductal adenocarcinoma. Ann Hepatobiliary Pancreat Surg 2019;23:97-108. [PMID: 31225409 DOI: 10.14701/ahbps.2019.23.2.97] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
126 Sugumar K, Hue JJ, Hardacre JM, Ammori JB, Rothermel LD, Dorth J, Saltzman J, Mohamed A, Selfridge JE, Bajor D, Winter JM, Ocuin LM. Combined multiagent chemotherapy and radiotherapy is associated with prolonged overall survival in patients with non-operatively managed stage II-III pancreatic adenocarcinoma. HPB (Oxford) 2021:S1365-182X(21)01582-3. [PMID: 34465529 DOI: 10.1016/j.hpb.2021.08.938] [Reference Citation Analysis]
127 Liu S, Qin Z, Xu J, Zeng J, Chen J, Niu L, Xu M. Irreversible electroporation combined with chemotherapy for unresectable pancreatic carcinoma: a prospective cohort study. Onco Targets Ther. 2019;12:1341-1350. [PMID: 30863100 DOI: 10.2147/ott.s186721] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
128 Clancy TE. Surgery for Pancreatic Cancer. Hematol Oncol Clin North Am 2015;29:701-16. [PMID: 26226905 DOI: 10.1016/j.hoc.2015.04.001] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
129 Li Z, Li X, Yu C, Wang M, Peng F, Xiao J, Tian R, Jiang J, Sun C. MicroRNA-100 regulates pancreatic cancer cells growth and sensitivity to chemotherapy through targeting FGFR3. Tumour Biol. 2014;35:11751-11759. [PMID: 25344675 DOI: 10.1007/s13277- 014-2271-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
130 Idichi T, Seki N, Kurahara H, Fukuhisa H, Toda H, Shimonosono M, Yamada Y, Arai T, Kita Y, Kijima Y, Mataki Y, Maemura K, Natsugoe S. Involvement of anti-tumor miR-124-3p and its targets in the pathogenesis of pancreatic ductal adenocarcinoma: direct regulation of ITGA3 and ITGB1 by miR-124-3p. Oncotarget 2018;9:28849-65. [PMID: 29988949 DOI: 10.18632/oncotarget.25599] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
131 Rose JB, Rocha FG, Alseidi A, Biehl T, Moonka R, Ryan JA, Lin B, Picozzi V, Helton S. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival. Ann Surg Oncol. 2014;21:1530-1537. [PMID: 24473642 DOI: 10.1245/s10434-014-3486-z] [Cited by in Crossref: 92] [Cited by in F6Publishing: 82] [Article Influence: 11.5] [Reference Citation Analysis]
132 Meng X, Deng Y, He S, Niu L, Zhu H. m6A-Mediated Upregulation of LINC00857 Promotes Pancreatic Cancer Tumorigenesis by Regulating the miR-150-5p/E2F3 Axis. Front Oncol 2021;11:629947. [PMID: 33680969 DOI: 10.3389/fonc.2021.629947] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
133 Isherwood J, Arshad A, Chung WY, Runau F, Cooke J, Pollard C, Howells L, Fishwick J, Thompson J, Metcalfe M, Steward W, Dennison A. Myeloid derived suppressor cells are reduced and T regulatory cells stabilised in patients with advanced pancreatic cancer treated with gemcitabine and intravenous omega 3. Ann Transl Med 2020;8:172. [PMID: 32309319 DOI: 10.21037/atm.2020.02.02] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
134 Yu C, Jiang JX, Sun CY. Effect of siRNA-mediated FOXC1 gene silencing on proliferation of pancreatic cancer cells. Shijie Huaren Xiaohua Zazhi 2015; 23(11): 1712-1720 [DOI: 10.11569/wcjd.v23.i11.1712] [Reference Citation Analysis]
135 Strobel O, Berens V, Hinz U, Hartwig W, Hackert T, Bergmann F, Debus J, Jäger D, Büchler MW, Werner J. Resection after neoadjuvant therapy for locally advanced, "unresectable" pancreatic cancer. Surgery 2012;152:S33-42. [PMID: 22770956 DOI: 10.1016/j.surg.2012.05.029] [Cited by in Crossref: 75] [Cited by in F6Publishing: 65] [Article Influence: 7.5] [Reference Citation Analysis]
136 Liu Y, Feng M, Chen H, Yang G, Qiu J, Zhao F, Cao Z, Luo W, Xiao J, You L, Zheng L, Zhang T. Mechanistic target of rapamycin in the tumor microenvironment and its potential as a therapeutic target for pancreatic cancer. Cancer Lett 2020;485:1-13. [PMID: 32428662 DOI: 10.1016/j.canlet.2020.05.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
137 Luu AM, Hoehn P, Vogel SR, Reinacher-Schick A, Munding J, Uhl W, Braumann C. Pathologic Complete Response of Pancreatic Cancer following Neoadjuvant FOLFIRINOX Treatment in Hepatic Metastasized Pancreatic Cancer. Visc Med 2019;35:387-91. [PMID: 31934588 DOI: 10.1159/000497827] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
138 Loi M, Magallon-Baro A, Suker M, van Eijck C, Sharma A, Hoogeman M, Nuyttens J. Pancreatic cancer treated with SBRT: Effect of anatomical interfraction variations on dose to organs at risk. Radiother Oncol 2019;134:67-73. [PMID: 31005226 DOI: 10.1016/j.radonc.2019.01.020] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
139 Macarulla T, Hendifar AE, Li CP, Reni M, Riess H, Tempero MA, Dueck AC, Botteman MF, Deshpande CG, Lucas EJ, Oh DY. Landscape of Health-Related Quality of Life in Patients With Early-Stage Pancreatic Cancer Receiving Adjuvant or Neoadjuvant Chemotherapy: A Systematic Literature Review. Pancreas 2020;49:393-407. [PMID: 32132518 DOI: 10.1097/MPA.0000000000001507] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
140 Emelyanova M, Pokataev I, Shashkov I, Kopantseva E, Lyadov V, Heydarov R, Mikhailovich V. TYMS 3'-UTR Polymorphism: A Novel Association with FOLFIRINOX-Induced Neurotoxicity in Pancreatic Cancer Patients. Pharmaceutics 2021;14:77. [PMID: 35056973 DOI: 10.3390/pharmaceutics14010077] [Reference Citation Analysis]
141 Ren L, Mota Reyes C, Friess H, Demir IE. Neoadjuvant therapy in pancreatic cancer: what is the true oncological benefit? Langenbecks Arch Surg 2020;405:879-87. [PMID: 32776259 DOI: 10.1007/s00423-020-01946-4] [Reference Citation Analysis]
142 Court CM, Ankeny JS, Sho S, Winograd P, Hou S, Song M, Wainberg ZA, Girgis MD, Graeber TG, Agopian VG, Tseng HR, Tomlinson JS. Circulating Tumor Cells Predict Occult Metastatic Disease and Prognosis in Pancreatic Cancer. Ann Surg Oncol. 2018;25:1000-1008. [PMID: 29442211 DOI: 10.1245/s10434-017-6290-8] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 9.5] [Reference Citation Analysis]
143 Zhang L, Tan S, Huang S, Zhong C, Lü M, Peng Y, Tang X. The safety and efficacy of endoscopic ultrasound-guided ablation therapy for solid pancreatic tumors: a systematic review. Scandinavian Journal of Gastroenterology 2020;55:1121-31. [DOI: 10.1080/00365521.2020.1797870] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
144 Venkatesulu BP, Hsieh CE, Sanders KL, Krishnan S. Recent advances in radiation therapy of pancreatic cancer. F1000Res 2018;7:F1000 Faculty Rev-1931. [PMID: 30613390 DOI: 10.12688/f1000research.16272.1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
145 Barugola G, Partelli S, Crippa S, Capelli P, D’Onofrio M, Pederzoli P, Falconi M. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy. Am J Surg. 2012;203:132-139. [PMID: 21824596 DOI: 10.1016/j.amjsurg.2011.03.008] [Cited by in Crossref: 68] [Cited by in F6Publishing: 65] [Article Influence: 6.2] [Reference Citation Analysis]
146 Heller A, Angelova AL, Bauer S, Grekova SP, Aprahamian M, Rommelaere J, Volkmar M, Janssen JW, Bauer N, Herr I, Giese T, Gaida MM, Bergmann F, Hackert T, Fritz S, Giese NA. Establishment and Characterization of a Novel Cell Line, ASAN-PaCa, Derived From Human Adenocarcinoma Arising in Intraductal Papillary Mucinous Neoplasm of the Pancreas. Pancreas 2016;45:1452-60. [PMID: 27518460 DOI: 10.1097/MPA.0000000000000673] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
147 Loizou L, Albiin N, Leidner B, Axelsson E, Fischer MA, Grigoriadis A, Del Chiaro M, Segersvärd R, Verbeke C, Sundin A, Kartalis N. Multidetector CT of pancreatic ductal adenocarcinoma: Effect of tube voltage and iodine load on tumour conspicuity and image quality. Eur Radiol 2016;26:4021-9. [PMID: 26965503 DOI: 10.1007/s00330-016-4273-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
148 Kurahara H, Maemura K, Mataki Y, Sakoda M, Iino S, Kawasaki Y, Arigami T, Mori S, Kijima Y, Ueno S, Shinchi H, Natsugoe S. A Therapeutic Strategy for Resectable Pancreatic Cancer Based on Risk Factors of Early Recurrence. Pancreas 2018;47:753-8. [PMID: 29771771 DOI: 10.1097/MPA.0000000000001066] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
149 Ballehaninna UK, Chamberlain RS. Serum CA 19-9 as a Biomarker for Pancreatic Cancer-A Comprehensive Review. Indian J Surg Oncol. 2011;2:88-100. [PMID: 22693400 DOI: 10.1007/s13193-011-0042-1] [Cited by in Crossref: 122] [Cited by in F6Publishing: 107] [Article Influence: 11.1] [Reference Citation Analysis]
150 Haeri HH, Tomaszewski J, Phytides B, Schimm H, Möslein G, Niedergethmann M, Hinderberger D, Gelos M. Identification of Patients with Pancreatic Cancer by Electron Paramagnetic Resonance Spectroscopy of Fatty Acid Binding to Human Serum Albumin. ACS Pharmacol Transl Sci 2020;3:1188-98. [PMID: 33344896 DOI: 10.1021/acsptsci.0c00116] [Reference Citation Analysis]
151 Casadei R, Di Marco M, Ricci C, Santini D, Serra C, Calculli L, D'Ambra M, Guido A, Morselli-Labate AM, Minni F. Neoadjuvant Chemoradiotherapy and Surgery Versus Surgery Alone in Resectable Pancreatic Cancer: A Single-Center Prospective, Randomized, Controlled Trial Which Failed to Achieve Accrual Targets. J Gastrointest Surg. 2015;19:1802-1812. [PMID: 26224039 DOI: 10.1007/s11605-015-2890-4] [Cited by in Crossref: 95] [Cited by in F6Publishing: 81] [Article Influence: 13.6] [Reference Citation Analysis]
152 Goodman KA. Stereotactic Body Radiation Therapy for Pancreatic Cancer. Cancer J 2016;22:290-5. [PMID: 27441749 DOI: 10.1097/PPO.0000000000000206] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
153 Hank T, Strobel O. Conversion Surgery for Advanced Pancreatic Cancer. J Clin Med 2019;8:E1945. [PMID: 31718103 DOI: 10.3390/jcm8111945] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
154 Luu AM, Herzog T, Hoehn P, Reinacher-Schick A, Munding J, Uhl W, Braumann C. FOLFIRINOX treatment leading to pathologic complete response of a locally advanced pancreatic cancer. J Gastrointest Oncol 2018;9:E9-E12. [PMID: 29755782 DOI: 10.21037/jgo.2018.01.07] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
155 Majmudar JD, Morrison-logue A, Song J, Hrycyna CA, Gibbs RA. Identification of a novel nanomolar inhibitor of hIcmt via a carboxylate replacement approach. Med Chem Commun 2012;3:1125. [DOI: 10.1039/c2md20108a] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
156 Maire F, Cibot JO, Compagne C, Hentic O, Hammel P, Muller N, Ponsot P, Levy P, Ruszniewski P. Epidemiology of pancreatic cancer in France: descriptive study from the French national hospital database. Eur J Gastroenterol Hepatol 2017;29:904-8. [PMID: 28471829 DOI: 10.1097/MEG.0000000000000901] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
157 Kirkegård J, Mortensen FV, Cronin-Fenton D. Comment on "Surgery Improves Survival After Neoadjuvant Therapy for Borderline and Locally Advanced Pancreatic Cancer". Ann Surg 2019;270:e138-9. [PMID: 31356282 DOI: 10.1097/SLA.0000000000003422] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
158 Russo S, Saif MW. Neoadjuvant therapy for pancreatic cancer: an ongoing debate. Therap Adv Gastroenterol 2016;9:429-36. [PMID: 27366211 DOI: 10.1177/1756283X16646524] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
159 Hyun JJ, Rose JB, Alseidi AA, Biehl TR, Helton S, Coy DL, Kozarek RA, Rocha FG. Significance of radiographic splenic vessel involvement in the pancreatic ductal adenocarcinoma of the body and tail of the gland. J Surg Oncol 2019;120:262-9. [PMID: 31093997 DOI: 10.1002/jso.25498] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
160 Jeong JY, Kim TB, Kim J, Choi HW, Kim EJ, Yoo HJ, Lee S, Jun HR, Yoo W, Kim S, Kim SC, Jun E. Diversity in the Extracellular Vesicle-Derived Microbiome of Tissues According to Tumor Progression in Pancreatic Cancer. Cancers (Basel) 2020;12:E2346. [PMID: 32825137 DOI: 10.3390/cancers12092346] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
161 Kleeff J, Stöß C, Yip V, Knoefel WT. [Resection for advanced pancreatic cancer following multimodal therapy]. Chirurg 2016;87:406-12. [PMID: 27138271 DOI: 10.1007/s00104-016-0184-3] [Reference Citation Analysis]
162 di Sebastiano P, Grottola T, di Mola FF. Borderline resectable pancreatic cancer and the role of neoadjuvant chemoradiotherapy. Updates Surg. 2016;68:235-239. [PMID: 27629483 DOI: 10.1007/s13304-016-0392-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
163 Martin-Perez E, Domínguez-Muñoz JE, Botella-Romero F, Cerezo L, Matute Teresa F, Serrano T, Vera R. Multidisciplinary consensus statement on the clinical management of patients with pancreatic cancer. Clin Transl Oncol 2020;22:1963-75. [PMID: 32318964 DOI: 10.1007/s12094-020-02350-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
164 Kato Y, Ohishi T, Sano M, Asano T, Sayama Y, Takei J, Kawada M, Kaneko MK. H2Mab-19 Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody Therapy Exerts Antitumor Activity in Pancreatic Cancer Xenograft Models. Monoclon Antib Immunodiagn Immunother 2020;39:61-5. [PMID: 32423281 DOI: 10.1089/mab.2020.0011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
165 Golcher H, Brunner TB, Witzigmann H, Marti L, Bechstein WO, Bruns C, Jungnickel H, Schreiber S, Grabenbauer GG, Meyer T, Merkel S, Fietkau R, Hohenberger W. Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial. Strahlenther Onkol. 2015;191:7-16. [PMID: 25252602 DOI: 10.1007/s00066-014-0737-7] [Cited by in Crossref: 167] [Cited by in F6Publishing: 138] [Article Influence: 20.9] [Reference Citation Analysis]
166 Guseva LN. [Nitritometric determination of allacyl]. Farmatsiia. 1969;18:43-45. [PMID: 5793409 DOI: 10.1186/s13045-017-0551-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 0.3] [Reference Citation Analysis]
167 Leone F, Gatti M, Massucco P, Colombi F, Sperti E, Campanella D, Regge D, Gabriele P, Capussotti L, Aglietta M. Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: A single institutional experience. Cancer 2013;119:277-84. [DOI: 10.1002/cncr.27736] [Cited by in Crossref: 56] [Cited by in F6Publishing: 50] [Article Influence: 5.6] [Reference Citation Analysis]
168 Wellner UF, Makowiec F, Bausch D, Höppner J, Sick O, Hopt UT, Keck T. Locally advanced pancreatic head cancer: margin-positive resection or bypass? ISRN Surg 2012;2012:513241. [PMID: 22779001 DOI: 10.5402/2012/513241] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
169 Zins M, Matos C, Cassinotto C. Pancreatic Adenocarcinoma Staging in the Era of Preoperative Chemotherapy and Radiation Therapy. Radiology. 2018;287:374-390. [PMID: 29668413 DOI: 10.1148/radiol.2018171670] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 13.8] [Reference Citation Analysis]
170 Mellon EA, Jin WH, Frakes JM, Centeno BA, Strom TJ, Springett GM, Malafa MP, Shridhar R, Hodul PJ, Hoffe SE. Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy. Acta Oncologica 2017;56:391-7. [DOI: 10.1080/0284186x.2016.1256497] [Cited by in Crossref: 47] [Cited by in F6Publishing: 21] [Article Influence: 7.8] [Reference Citation Analysis]
171 Mikulic D, Mrzljak A. Borderline resectable pancreatic cancer and vascular resections in the era of neoadjuvant therapy. World J Clin Cases 2021; 9(20): 5398-5407 [PMID: 34307593 DOI: 10.12998/wjcc.v9.i20.5398] [Reference Citation Analysis]
172 O'Reilly EM. Adjuvant therapy for pancreas adenocarcinoma: where are we going? Expert Rev Anticancer Ther 2011;11:173-7. [PMID: 21342036 DOI: 10.1586/era.10.232] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
173 Castillo Tuñón JM, Valle Rodas ME, Botello Martínez F, Rojas Holguín A, López Guerra D, Santos Naharro J, Jaén Torrejímeno I, Blanco Fernández G. Implementation of a regional reference center in pancreatic surgery. Experience after 631 procedures. Cir Esp (Engl Ed) 2020:S0009-739X(20)30313-4. [PMID: 33342520 DOI: 10.1016/j.ciresp.2020.09.013] [Reference Citation Analysis]
174 Poruk KE, Valero V 3rd, Saunders T, Blackford AL, Griffin JF, Poling J, Hruban RH, Anders RA, Herman J, Zheng L, Rasheed ZA, Laheru DA, Ahuja N, Weiss MJ, Cameron JL, Goggins M, Iacobuzio-Donahue CA, Wood LD, Wolfgang CL. Circulating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma. Ann Surg 2016;264:1073-81. [PMID: 26756760 DOI: 10.1097/SLA.0000000000001600] [Cited by in Crossref: 73] [Cited by in F6Publishing: 50] [Article Influence: 14.6] [Reference Citation Analysis]
175 Zhu H, Wei M, Xu J, Hua J, Liang C, Meng Q, Zhang Y, Liu J, Zhang B, Yu X, Shi S. PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications. Mol Cancer 2020;19:49. [PMID: 32122376 DOI: 10.1186/s12943-020-01167-9] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 20.0] [Reference Citation Analysis]
176 Kang CM, Hwang HK, Choi SH, Lee WJ. Controversial issues of neoadjuvant treatment in borderline resectable pancreatic cancer. Surg Oncol. 2013;22:123-131. [PMID: 23518243 DOI: 10.1016/j.suronc.2013.02.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
177 Ueda A, Sakai N, Yoshitomi H, Furukawa K, Takayashiki T, Kuboki S, Takano S, Suzuki D, Kagawa S, Mishima T, Nakadai E, Miyazaki M, Ohtsuka M. Is hepatic artery coil embolization useful in distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic cancer? World J Surg Oncol 2019;17:124. [PMID: 31315628 DOI: 10.1186/s12957-019-1667-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
178 Winner M, Goff SL, Chabot JA. Neoadjuvant therapy for non-metastatic pancreatic ductal adenocarcinoma. Semin Oncol 2015;42:86-97. [PMID: 25726054 DOI: 10.1053/j.seminoncol.2014.12.008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
179 Wang H, Mao C, Li N, Sun L, Zheng Y, Xu N. A case report of a dramatic response to olaparib in a patient with metastatic pancreatic cancer harboring a germline BRCA2 mutation. Medicine (Baltimore) 2019;98:e17443. [PMID: 31577767 DOI: 10.1097/MD.0000000000017443] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
180 Papalezova KT, Tyler DS, Blazer DG, Clary BM, Czito BG, Hurwitz HI, Uronis HE, Pappas TN, Willett CG, White RR. Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer? J Surg Oncol. 2012;106:111-118. [PMID: 22311829 DOI: 10.1002/jso.23044] [Cited by in Crossref: 57] [Cited by in F6Publishing: 55] [Article Influence: 5.7] [Reference Citation Analysis]
181 Oneda E, Zaniboni A. Are We Sure that Adjuvant Chemotherapy is the Best Approach for Resectable Pancreatic Cancer? Are We in the Era of Neoadjuvant Treatment? A Review of Current Literature. J Clin Med 2019;8:E1922. [PMID: 31717439 DOI: 10.3390/jcm8111922] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
182 Li TH, Zhao BB, Qin C, Wang YY, Li ZR, Cao HT, Yang XY, Zhou XT, Wang WB. IFIT1 modulates the proliferation, migration and invasion of pancreatic cancer cells via Wnt/β-catenin signaling. Cell Oncol (Dordr) 2021;44:1425-37. [PMID: 34791638 DOI: 10.1007/s13402-021-00651-8] [Reference Citation Analysis]
183 Versteijne E, Suker M, Groothuis K, Akkermans-Vogelaar JM, Besselink MG, Bonsing BA, Buijsen J, Busch OR, Creemers GM, van Dam RM, Eskens FALM, Festen S, de Groot JWB, Groot Koerkamp B, de Hingh IH, Homs MYV, van Hooft JE, Kerver ED, Luelmo SAC, Neelis KJ, Nuyttens J, Paardekooper GMRM, Patijn GA, van der Sangen MJC, de Vos-Geelen J, Wilmink JW, Zwinderman AH, Punt CJ, van Eijck CH, van Tienhoven G;  Dutch Pancreatic Cancer Group. Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. J Clin Oncol. 2020;38:1763-1773. [PMID: 32105518 DOI: 10.1200/jco.19.02274] [Cited by in Crossref: 174] [Cited by in F6Publishing: 89] [Article Influence: 87.0] [Reference Citation Analysis]
184 Artioli G, Besutti G, Cassetti T, Sereni G, Zizzo M, Bonacini S, Carlinfante G, Panebianco M, Cavazza A, Pinto C, Sassatelli R, Pattacini P, Giorgi Rossi P. Impact of multidisciplinary approach and radiologic review on surgical outcome and overall survival of patients with pancreatic cancer: a retrospective cohort study. Tumori 2021;:300891621999092. [PMID: 33719770 DOI: 10.1177/0300891621999092] [Reference Citation Analysis]
185 Kimura J, Ono HA, Kosaka T, Nagashima Y, Hirai S, Ohno S, Aoki K, Julia D, Yamamoto M, Kunisaki C, Endo I. Conditionally replicative adenoviral vectors for imaging the effect of chemotherapy on pancreatic cancer cells. Cancer Sci 2013;104:1083-90. [PMID: 23679574 DOI: 10.1111/cas.12196] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
186 Park KW, Kang SH, Velders MA, Shin DH, Hahn S, Lim WH, Yang HM, Lee HY, Van Boven AJ, Hofma SH. Safety and efficacy of everolimus- versus sirolimus-eluting stents: a systematic review and meta-analysis of 11 randomized trials. Am Heart J. 2013;165:241-50.e4. [PMID: 23351828 DOI: 10.1016/j.ahj.2012.08.007] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 5.0] [Reference Citation Analysis]
187 Lee M, Kang JS, Kim H, Kwon W, Lee SH, Ryu JK, Kim YT, Oh DY, Chie EK, Jang JY. Impact of conversion surgery on survival in locally advanced pancreatic cancer patients treated with FOLFIRINOX chemotherapy. J Hepatobiliary Pancreat Sci 2021. [PMID: 34581022 DOI: 10.1002/jhbp.1050] [Reference Citation Analysis]
188 Ansari D, Kristoffersson S, Andersson R, Bergenfeldt M. The role of irreversible electroporation (IRE) for locally advanced pancreatic cancer: a systematic review of safety and efficacy. Scand J Gastroenterol. 2017;52:1165-1171. [PMID: 28687047 DOI: 10.1080/00365521.2017.1346705] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 7.2] [Reference Citation Analysis]
189 Katz MH, Fleming JB, Bhosale P, Varadhachary G, Lee JE, Wolff R, Wang H, Abbruzzese J, Pisters PW, Vauthey JN, Charnsangavej C, Tamm E, Crane CH, Balachandran A. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 2012;118:5749-5756. [PMID: 22605518 DOI: 10.1002/cncr.27636] [Cited by in Crossref: 334] [Cited by in F6Publishing: 288] [Article Influence: 33.4] [Reference Citation Analysis]
190 Schorn S, Demir IE, Samm N, Scheufele F, Calavrezos L, Sargut M, Schirren RM, Friess H, Ceyhan GO. Meta-analysis of the impact of neoadjuvant therapy on patterns of recurrence in pancreatic ductal adenocarcinoma. BJS Open 2018;2:52-61. [PMID: 29951629 DOI: 10.1002/bjs5.46] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
191 Haller SD, Monaco ML, Essani K. The Present Status of Immuno-Oncolytic Viruses in the Treatment of Pancreatic Cancer. Viruses. 2020;12. [PMID: 33213031 DOI: 10.3390/v12111318] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
192 Bittoni A, Santoni M, Lanese A, Pellei C, Andrikou K, Stefano C. Neoadjuvant therapy in pancreatic cancer: an emerging strategy. Gastroenterol Res Pract 2014;2014:183852. [PMID: 25101123 DOI: 10.1155/2014/183852] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
193 Brunner TB, Seufferlein T. Pancreatic cancer chemoradiotherapy. Best Pract Res Clin Gastroenterol. 2016;30:617-628. [PMID: 27644909 DOI: 10.1016/j.bpg.2016.08.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
194 Watanabe F, Suzuki K, Tamaki S, Abe I, Endo Y, Takayama Y, Ishikawa H, Kakizawa N, Saito M, Futsuhara K, Noda H, Konishi F, Rikiyama T. Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer. PLoS One 2019;14:e0227366. [PMID: 31891652 DOI: 10.1371/journal.pone.0227366] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
195 Di Caro G, Castino GF, Bergomas F, Cortese N, Chiriva-Internati M, Grizzi F, Marchesi F. Immune-based therapies in pancreatic and colorectal cancers and biomarkers of responsiveness. Expert Rev Anticancer Ther 2014;14:1219-28. [PMID: 25222571 DOI: 10.1586/14737140.2014.947277] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
196 Attiyeh MA, Amini A, Chung V, Melstrom LG. Multidisciplinary management of locally advanced pancreatic adenocarcinoma: Biology is King. J Surg Oncol 2021;123:1395-404. [PMID: 33831247 DOI: 10.1002/jso.26415] [Reference Citation Analysis]
197 Tajima H, Ohta T, Okazaki M, Yamaguchi T, Ohbatake Y, Okamoto K, Nakanuma S, Kinoshita J, Makino I, Nakamura K, Miyashita T, Takamura H, Ninomiya I, Fushida S, Nakamura H. Neoadjuvant chemotherapy with gemcitabine-based regimens improves the prognosis of node positive resectable pancreatic head cancer. Mol Clin Oncol 2019;11:157-66. [PMID: 31281650 DOI: 10.3892/mco.2019.1867] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
198 Ouaïssi M, Turrini O, Hubert C, Louis G, Gigot JF, Mabrut JY. Vascular resection during radical resection of pancreatic adenocarcinomas: evolution over the past 15 years. J Hepatobiliary Pancreat Sci 2014;21:623-38. [PMID: 24890182 DOI: 10.1002/jhbp.122] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
199 N Kalimuthu S, Serra S, Dhani N, Hafezi-Bakhtiari S, Szentgyorgyi E, Vajpeyi R, Chetty R. Regression grading in neoadjuvant treated pancreatic cancer: an interobserver study. J Clin Pathol 2017;70:237-43. [PMID: 27681847 DOI: 10.1136/jclinpath-2016-203947] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
200 Van Laethem JL, Verslype C, Iovanna JL, Michl P, Conroy T, Louvet C, Hammel P, Mitry E, Ducreux M, Maraculla T. New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel. Ann Oncol. 2012;23:570-576. [PMID: 21810728 DOI: 10.1093/annonc/mdr351] [Cited by in Crossref: 54] [Cited by in F6Publishing: 45] [Article Influence: 4.9] [Reference Citation Analysis]
201 Mazzola R, Fersino S, Aiello D, Gregucci F, Tebano U, Corradini S, Di Paola G, Cirillo M, Tondulli L, Ruffo G, Ruggieri R, Alongi F. Linac-based stereotactic body radiation therapy for unresectable locally advanced pancreatic cancer: risk-adapted dose prescription and image-guided delivery. Strahlenther Onkol 2018;194:835-42. [PMID: 29696321 DOI: 10.1007/s00066-018-1306-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
202 Estrella JS, Rashid A, Fleming JB, Katz MH, Lee JE, Wolf RA, Varadhachary GR, Pisters PW, Abdalla EK, Vauthey JN, Wang H, Gomez HF, Evans DB, Abbruzzese JL, Wang H. Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation. Cancer 2012;118:268-77. [PMID: 21735446 DOI: 10.1002/cncr.26243] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 4.9] [Reference Citation Analysis]
203 Blouhos K, Boulas K, Tsalis K, Hatzigeorgiadis A. The isoattenuating pancreatic adenocarcinoma: Review of the literature and critical analysis. Surgical Oncology 2015;24:322-8. [DOI: 10.1016/j.suronc.2015.09.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
204 Kimple RJ, Russo S, Monjazeb A, Blackstock AW. The role of chemoradiation for patients with resectable or potentially resectable pancreatic cancer. Expert Rev Anticancer Ther 2012;12:469-80. [PMID: 22500684 DOI: 10.1586/era.12.18] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
205 Huang X, Fan C, Zhu H, Le W, Cui S, Chen X, Li W, Zhang F, Huang Y, Sh D, Cui Z, Shao C, Chen B. Glypican-1-antibody-conjugated Gd-Au nanoclusters for FI/MRI dual-modal targeted detection of pancreatic cancer. Int J Nanomedicine 2018;13:2585-99. [PMID: 29750031 DOI: 10.2147/IJN.S158559] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
206 Girelli R, Frigerio I, Giardino A, Regi P, Gobbo S, Malleo G, Salvia R, Bassi C. Results of 100 pancreatic radiofrequency ablations in the context of a multimodal strategy for stage III ductal adenocarcinoma. Langenbecks Arch Surg 2013;398:63-9. [DOI: 10.1007/s00423-012-1011-z] [Cited by in Crossref: 56] [Cited by in F6Publishing: 48] [Article Influence: 5.6] [Reference Citation Analysis]
207 Okasha HH, Naga YM, El Sherbiny M. EUS-guided radiofrequency ablation: Where we are? Endosc Ultrasound. 2020;9:277-279. [PMID: 32655083 DOI: 10.4103/eus.eus_33_20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
208 Meng Z, Cao M, Zhang Y, Liu Z, Wu S, Wu H. Tumor location as an indicator of survival in T1 resectable pancreatic ductal adenocarcinoma: a propensity score-matched analysis. BMC Gastroenterol 2019;19:59. [PMID: 31014264 DOI: 10.1186/s12876-019-0975-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
209 Maggino L, Malleo G, Marchegiani G, Viviani E, Nessi C, Ciprani D, Esposito A, Landoni L, Casetti L, Tuveri M, Paiella S, Casciani F, Sereni E, Binco A, Bonamini D, Secchettin E, Auriemma A, Merz V, Simionato F, Zecchetto C, D'Onofrio M, Melisi D, Bassi C, Salvia R. Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma. JAMA Surg 2019;154:932-42. [PMID: 31339530 DOI: 10.1001/jamasurg.2019.2277] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 18.0] [Reference Citation Analysis]
210 Casadei R, Ricci C, Minni F. Locally advanced pancreatic cancer: open questions on terminology, diagnosis and management. Updates Surg 2014;66:227-8. [PMID: 24965064 DOI: 10.1007/s13304-014-0258-z] [Reference Citation Analysis]
211 Zhou Q, Xia S, Guo F, Hu F, Wang Z, Ni Y, Wei T, Xiang H, Shang D. Transforming growth factor-β in pancreatic diseases: Mechanisms and therapeutic potential. Pharmacol Res 2019;142:58-69. [PMID: 30682425 DOI: 10.1016/j.phrs.2019.01.038] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
212 Michelakos T, Pergolini I, Castillo CF, Honselmann KC, Cai L, Deshpande V, Wo JY, Ryan DP, Allen JN, Blaszkowsky LS, Clark JW, Murphy JE, Nipp RD, Parikh A, Qadan M, Warshaw AL, Hong TS, Lillemoe KD, Ferrone CR. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX. Ann Surg. 2019;269:733-740. [PMID: 29227344 DOI: 10.1097/sla.0000000000002600] [Cited by in Crossref: 113] [Cited by in F6Publishing: 45] [Article Influence: 56.5] [Reference Citation Analysis]
213 Isaji S, Murata Y, Kishiwada M. New Japanese Classification of Pancreatic Cancer. In: Neoptolemos JP, Urrutia R, Abbruzzese JL, Büchler MW, editors. Pancreatic Cancer. New York: Springer; 2018. pp. 1021-37. [DOI: 10.1007/978-1-4939-7193-0_84] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
214 Krieger TG, Le Blanc S, Jabs J, Ten FW, Ishaque N, Jechow K, Debnath O, Leonhardt CS, Giri A, Eils R, Strobel O, Conrad C. Single-cell analysis of patient-derived PDAC organoids reveals cell state heterogeneity and a conserved developmental hierarchy. Nat Commun 2021;12:5826. [PMID: 34611171 DOI: 10.1038/s41467-021-26059-4] [Reference Citation Analysis]
215 Sabater L, Muñoz E, Roselló S, Dorcaratto D, Garcés-Albir M, Huerta M, Roda D, Gómez-Mateo MC, Ferrández-Izquierdo A, Darder A, Cervantes A. Borderline resectable pancreatic cancer. Challenges and controversies. Cancer Treat Rev 2018;68:124-35. [PMID: 29957372 DOI: 10.1016/j.ctrv.2018.06.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
216 Zhu JH, De Mello RA, Yan QL, Wang JW, Chen Y, Ye QH, Wang ZJ, Tang HJ, Huang T. MiR-139-5p/SLC7A11 inhibits the proliferation, invasion and metastasis of pancreatic carcinoma via PI3K/Akt signaling pathway. Biochim Biophys Acta Mol Basis Dis 2020;1866:165747. [PMID: 32109492 DOI: 10.1016/j.bbadis.2020.165747] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
217 Kumar N, Perez-Novo C, Shaw P, Logie E, Privat-Maldonado A, Dewilde S, Smits E, Berghe WV, Bogaerts A. Physical plasma-derived oxidants sensitize pancreatic cancer cells to ferroptotic cell death. Free Radic Biol Med 2021;166:187-200. [PMID: 33636332 DOI: 10.1016/j.freeradbiomed.2021.02.026] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
218 Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378:607-620. [PMID: 21620466 DOI: 10.1016/s0140-6736(10)62307-0] [Cited by in Crossref: 1377] [Cited by in F6Publishing: 849] [Article Influence: 125.2] [Reference Citation Analysis]
219 Xu Q, Zhang TP, Zhao YP. Advances in early diagnosis and therapy of pancreatic cancer. Hepatobiliary Pancreat Dis Int. 2011;10:128-135. [PMID: 21459718 DOI: 10.1016/s1499-3872(11)60021-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
220 Heinrich S, Lang H. Neoadjuvant Therapy of Pancreatic Cancer: Definitions and Benefits. Int J Mol Sci 2017;18:E1622. [PMID: 28933761 DOI: 10.3390/ijms18081622] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 5.4] [Reference Citation Analysis]
221 Walter FM, Mills K, Mendonça SC, Abel GA, Basu B, Carroll N, Ballard S, Lancaster J, Hamilton W, Rubin GP, Emery JD. Symptoms and patient factors associated with diagnostic intervals for pancreatic cancer (SYMPTOM pancreatic study): a prospective cohort study. Lancet Gastroenterol Hepatol 2016;1:298-306. [PMID: 28404200 DOI: 10.1016/S2468-1253(16)30079-6] [Cited by in Crossref: 34] [Cited by in F6Publishing: 23] [Article Influence: 5.7] [Reference Citation Analysis]
222 Postlewait LM, Kooby DA. Laparoscopic distal pancreatectomy for adenocarcinoma: safe and reasonable? J Gastrointest Oncol 2015;6:406-17. [PMID: 26261727 DOI: 10.3978/j.issn.2078-6891.2015.034] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
223 Braun LM, Lagies S, Klar RFU, Hussung S, Fritsch RM, Kammerer B, Wittel UA. Metabolic Profiling of Early and Late Recurrent Pancreatic Ductal Adenocarcinoma Using Patient-Derived Organoid Cultures. Cancers (Basel) 2020;12:E1440. [PMID: 32492856 DOI: 10.3390/cancers12061440] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
224 van Roey R, Brabletz T, Stemmler MP, Armstark I. Deregulation of Transcription Factor Networks Driving Cell Plasticity and Metastasis in Pancreatic Cancer. Front Cell Dev Biol 2021;9:753456. [PMID: 34888306 DOI: 10.3389/fcell.2021.753456] [Reference Citation Analysis]
225 Adamu M, Nitschke P, Petrov P, Rentsch A, Distler M, Reissfelder C, Welsch T, Saeger H, Weitz J, Rahbari NN. Validation of prognostic risk scores for patients undergoing resection for pancreatic cancer. Pancreatology 2018;18:585-91. [DOI: 10.1016/j.pan.2018.05.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
226 Karamouzis MV, Athanasiadis I, Samelis G, Vallilas C, Bokas A, Nikolaidi A, Dimitriadou A, Sarantis P, Pistamaltzian N, Schizas D, Papalampros A, Felekouras E, Dimitroulis D, Antoniou E, Sotiropoulos G, Papakotoulas P. The Impact of Thromboprophylaxis on the Survival of Patients with Advanced Pancreatic Cancer. The Pancreatic Cancer and Tinzaparin (PaCT) Study. Cancers (Basel) 2021;13:2884. [PMID: 34207591 DOI: 10.3390/cancers13122884] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
227 Serda M, Malarz K, Mrozek-Wilczkiewicz A, Wojtyniak M, Musioł R, Curley SA. Glycofullerenes as non-receptor tyrosine kinase inhibitors- towards better nanotherapeutics for pancreatic cancer treatment. Sci Rep 2020;10:260. [PMID: 31937861 DOI: 10.1038/s41598-019-57155-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
228 Zhang H, Zhang Y, Xia T, Lu L, Luo M, Chen Y, Liu Y, Li Y. The Role of Keratin17 in Human Tumours. Front Cell Dev Biol 2022;10:818416. [DOI: 10.3389/fcell.2022.818416] [Reference Citation Analysis]
229 Casolino R, Braconi C, Malleo G, Paiella S, Bassi C, Milella M, Dreyer SB, Froeling FEM, Chang DK, Biankin AV, Golan T. Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine. Ann Oncol 2021;32:183-96. [PMID: 33248227 DOI: 10.1016/j.annonc.2020.11.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
230 Frigerio I, Regi P, Giardino A, Scopelliti F, Girelli R, Bassi C, Gobbo S, Martini PT, Capelli P, D'Onofrio M, Malleo G, Maggino L, Viviani E, Butturini G. Downstaging in Stage IV Pancreatic Cancer: A New Population Eligible for Surgery? Ann Surg Oncol 2017;24:2397-403. [PMID: 28516291 DOI: 10.1245/s10434-017-5885-4] [Cited by in F6Publishing: 35] [Reference Citation Analysis]
231 Shen YN, Bai XL, Jin G, Zhang Q, Lu JH, Qin RY, Yu RS, Pan Y, Chen Y, Sun PW, Guo CX, Li X, Ma T, Li GG, Gao SL, Lou JY, Que RS, Lau WY, Liang TB. A preoperative nomogram predicts prognosis of up front resectable patients with pancreatic head cancer and suspected venous invasion. HPB (Oxford) 2018;20:1034-43. [PMID: 29929784 DOI: 10.1016/j.hpb.2018.04.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
232 Templeton S, Moser M, Wall C, Shaw J, Chalchal H, Luo Y, Zaidi A, Ahmed S. Outcomes of Patients with Borderline Resectable Pancreatic Cancer Treated with Combination Chemotherapy. J Gastrointest Cancer 2021;52:529-35. [PMID: 32440849 DOI: 10.1007/s12029-020-00417-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
233 Jin L, Shi N, Ruan S, Hou B, Zou Y, Zou X, Jin H, Jian Z. The role of intraoperative radiation therapy in resectable pancreatic cancer: a systematic review and meta-analysis. Radiat Oncol 2020;15:76. [PMID: 32272945 DOI: 10.1186/s13014-020-01511-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
234 Parikh PY, Lillemoe KD. Surgical management of pancreatic cancer--distal pancreatectomy. Semin Oncol 2015;42:110-22. [PMID: 25726056 DOI: 10.1053/j.seminoncol.2014.12.010] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
235 Li J, Yu T, Zhang L, Yang M, Gao S, Pu N, Li C, Wang C, Gong G, Cheng J, Wang L, Li G, Wang X, Chen Y. An iodine-125 seed strand combined with a metal stent versus a metal stent alone for obstructive jaundice caused by pancreatic ductal adenocarcinoma. Brachytherapy 2021;20:446-53. [PMID: 33309002 DOI: 10.1016/j.brachy.2020.10.004] [Reference Citation Analysis]
236 Wandmacher AM, Letsch A, Sebens S. Challenges and Future Perspectives of Immunotherapy in Pancreatic Cancer. Cancers (Basel) 2021;13:4235. [PMID: 34439389 DOI: 10.3390/cancers13164235] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
237 Gillen S, Schuster T, Friess H, Kleeff J. Palliative resections versus palliative bypass procedures in pancreatic cancer—a systematic review. The American Journal of Surgery 2012;203:496-502. [DOI: 10.1016/j.amjsurg.2011.05.004] [Cited by in Crossref: 41] [Cited by in F6Publishing: 25] [Article Influence: 4.1] [Reference Citation Analysis]
238 Habib JR, Kinny-Köster B, van Oosten F, Javed AA, Cameron JL, Lafaro KJ, Burkhart RA, Burns WR, He J, Thompson ED, Fishman EK, Wolfgang CL. Periadventitial dissection of the superior mesenteric artery for locally advanced pancreatic cancer: Surgical planning with the "halo sign" and "string sign". Surgery 2021;169:1026-31. [PMID: 33036782 DOI: 10.1016/j.surg.2020.08.031] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
239 Pietrasz D, Marthey L, Wagner M, Blanc JF, Laurent C, Turrini O, Raoul JL, Terrebonne E, Hentic O, Trouilloud I, Coriat R, Regenet N, Innominato P, Taieb J, Cunha AS, Bachet JB. Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-FRENCH, Prospective, Multicentric Cohort. Ann Surg Oncol. 2015;22 Suppl 3:S1196-S1205. [PMID: 26271395 DOI: 10.1245/s10434-015-4783-x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 7.1] [Reference Citation Analysis]
240 Andersson G, Lundgren S, Heby M, Nodin B, Elebro J, Jirström K. Clinical significance of stromal ER and PR expression in periampullary adenocarcinoma. Biomark Res 2019;7:26. [PMID: 31827798 DOI: 10.1186/s40364-019-0176-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
241 Petrelli F, Coinu A, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V, Aitini E, Barni S. FOLFIRINOX-Based Neoadjuvant Therapy in Borderline Resectable or Unresectable Pancreatic Cancer: A Meta-Analytical Review of Published Studies. Pancreas 2015;44:515-21. [DOI: 10.1097/mpa.0000000000000314] [Cited by in Crossref: 126] [Cited by in F6Publishing: 46] [Article Influence: 18.0] [Reference Citation Analysis]
242 Hackert T, Sachsenmaier M, Hinz U, Schneider L, Michalski CW, Springfeld C, Strobel O, Jäger D, Ulrich A, Büchler MW. Locally Advanced Pancreatic Cancer: Neoadjuvant Therapy With Folfirinox Results in Resectability in 60% of the Patients. Annals of Surgery 2016;264:457-63. [DOI: 10.1097/sla.0000000000001850] [Cited by in Crossref: 235] [Cited by in F6Publishing: 91] [Article Influence: 39.2] [Reference Citation Analysis]
243 Lan J, Chen Y, Wang S, Zhou Y. Distal pancreatectomy with en bloc celiac axis resection for pancreatic cancer: a pooled analysis of 109 cases. Updates Surg 2020;72:709-15. [PMID: 32495281 DOI: 10.1007/s13304-020-00826-2] [Reference Citation Analysis]
244 Heestand GM, Murphy JD, Lowy AM. Approach to Patients With Pancreatic Cancer Without Detectable Metastases. JCO 2015;33:1770-8. [DOI: 10.1200/jco.2014.59.7930] [Cited by in Crossref: 81] [Cited by in F6Publishing: 48] [Article Influence: 11.6] [Reference Citation Analysis]
245 Watanabe G, Ushida Y, Oba A, Ono Y, Sato T, Inoue Y, Takahashi Y, Saiura A, Ito H. Impact of Tumor Size on the Outcomes of Patients with Resectable Distal Pancreatic Cancer: Lessons Learned from a Series of 158 Radical Resections. Ann Surg Oncol 2021. [PMID: 34403004 DOI: 10.1245/s10434-021-10560-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
246 Liu A, Shao C, Jin G, Liu R, Hao J, Shao Z, Liu Q, Hu X. Downregulation of CPE regulates cell proliferation and chemosensitivity in pancreatic cancer. Tumour Biol 2014;35:12459-65. [PMID: 25374060 DOI: 10.1007/s13277-014-2564-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
247 de Waha A, Dibra A, Byrne RA, Ndrepepa G, Mehilli J, Fusaro M, Laugwitz K, Massberg S, Schömig A, Kastrati A. Everolimus-Eluting Versus Sirolimus-Eluting Stents: A Meta-Analysis of Randomized Trials. Circ: Cardiovascular Interventions 2011;4:371-7. [DOI: 10.1161/circinterventions.111.963256] [Cited by in Crossref: 49] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
248 Antonios A, Gharios J, Tohme C. Resectable pancreatic adenocarcinomas: will neoadjuvant FOLFIRINOX replace upfront surgery in the standard of care? Future Oncology 2017;13:951-3. [DOI: 10.2217/fon-2017-0050] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
249 Windsor JA, Barreto SG. The concept of 'borderline resectable' pancreatic cancer: limited foundations and limited future? J Gastrointest Oncol 2017;8:189-93. [PMID: 28280624 DOI: 10.21037/jgo.2016.12.06] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
250 Rossi ML, Rehman AA, Gondi CS. Therapeutic options for the management of pancreatic cancer. World J Gastroenterol 2014; 20(32): 11142-11159 [PMID: 25170201 DOI: 10.3748/wjg.v20.i32.11142] [Cited by in CrossRef: 75] [Cited by in F6Publishing: 68] [Article Influence: 9.4] [Reference Citation Analysis]
251 Akhlaghpoor S, Aziz-Ahari A, Amoui M, Tolooee S, Poorbeigi H, Sheybani S. Short-term effectiveness of radiochemoembolization for selected hepatic metastases with a combination protocol. World J Gastroenterol 2012; 18(37): 5249-5259 [PMID: 23066320 DOI: 10.3748/wjg.v18.i37.5249] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
252 D'Onofrio M, Beleù A, Sarno A, De Robertis R, Paiella S, Viviani E, Frigerio I, Girelli R, Salvia R, Bassi C. US-Guided Percutaneous Radiofrequency Ablation of Locally Advanced Pancreatic Adenocarcinoma: A 5-Year High-Volume Center Experience. Ultraschall Med 2020. [PMID: 32797463 DOI: 10.1055/a-1178-0474] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
253 Zhuang S, Chen T, Li Y, Wang Y, Ai L, Geng Y, Zou M, Liu K, Xu H, Wang L, Zhao Z, Chang Z, Gu Y. A transcriptional signature detects homologous recombination deficiency in pancreatic cancer at the individual level. Mol Ther Nucleic Acids 2021;26:1014-26. [PMID: 34786207 DOI: 10.1016/j.omtn.2021.10.014] [Reference Citation Analysis]
254 Khalvati F, Zhang Y, Baig S, Lobo-Mueller EM, Karanicolas P, Gallinger S, Haider MA. Prognostic Value of CT Radiomic Features in Resectable Pancreatic Ductal Adenocarcinoma. Sci Rep 2019;9:5449. [PMID: 30931954 DOI: 10.1038/s41598-019-41728-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 7.7] [Reference Citation Analysis]
255 Tsuchikawa T, Hirano S, Nakamura T, Okamura K, Tamoto E, Shichinohe T. Concomitant major vessel resection in pancreatic adenocarcinoma. Postgrad Med 2015;127:273-6. [PMID: 25823640 DOI: 10.1080/00325481.2015.1032180] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
256 Rashid OM, Pimiento JM, Gamenthaler AW, Nguyen P, Ha TT, Hutchinson T, Springett G, Hoffe S, Shridhar R, Hodul PJ, Johnson BL, Illig K, Armstrong PA, Centeno BA, Fulp WJ, Chen D, Malafa MP. Outcomes of a Clinical Pathway for Borderline Resectable Pancreatic Cancer. Ann Surg Oncol 2016;23:1371-9. [DOI: 10.1245/s10434-015-5006-1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
257 Hoffe S, Rao N, Shridhar R. Neoadjuvant vs adjuvant therapy for resectable pancreatic cancer: the evolving role of radiation. Semin Radiat Oncol 2014;24:113-25. [PMID: 24635868 DOI: 10.1016/j.semradonc.2013.11.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
258 Belli C, Cereda S, Anand S, Reni M. Neoadjuvant therapy in resectable pancreatic cancer: a critical review. Cancer Treat Rev. 2013;39:518-524. [PMID: 23122322 DOI: 10.1016/j.ctrv.2012.09.008] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
259 Andriulli A, Festa V, Botteri E, Valvano MR, Koch M, Bassi C, Maisonneuve P, Sebastiano PD. Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies. Ann Surg Oncol 2012;19:1644-62. [PMID: 22012027 DOI: 10.1245/s10434-011-2110-8] [Cited by in Crossref: 126] [Cited by in F6Publishing: 106] [Article Influence: 11.5] [Reference Citation Analysis]
260 Gilabert M, Raoul JL, Rousseau F. How to treat pancreatic adenocarcinoma in elderly: How far can we go in 2017? J Geriatr Oncol 2017;8:407-12. [PMID: 28888554 DOI: 10.1016/j.jgo.2017.08.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
261 Salom F, Prat F. Current role of endoscopic ultrasound in the diagnosis and management of pancreatic cancer. World J Gastrointest Endosc 2022; 14(1): 35-48 [DOI: 10.4253/wjge.v14.i1.35] [Reference Citation Analysis]
262 Attaluri A, Kandala SK, Zhou H, Wabler M, DeWeese TL, Ivkov R. Magnetic nanoparticle hyperthermia for treating locally advanced unresectable and borderline resectable pancreatic cancers: the role of tumor size and eddy-current heating. Int J Hyperthermia 2020;37:108-19. [PMID: 33426990 DOI: 10.1080/02656736.2020.1798514] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
263 Strauss VY, Shaw R, Virdee PS, Hurt CN, Ward E, Tranter B, Patel N, Bridgewater J, Parsons P, Radhakrishna G, O'Neill E, Sebag-Montefiore D, Hawkins M, Corrie PG, Maughan T, Mukherjee S. Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2). BMC Cancer 2019;19:121. [PMID: 30717707 DOI: 10.1186/s12885-019-5307-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
264 Napp J, Stammes MA, Claussen J, Prevoo HA, Sier CF, Hoeben FJ, Robillard MS, Vahrmeijer AL, Devling T, Chan AB, de Geus-oei L, Alves F. Fluorescence- and multispectral optoacoustic imaging for an optimized detection of deeply located tumors in an orthotopic mouse model of pancreatic carcinoma: MSOT for preoperative imaging of PDAC. Int J Cancer 2018;142:2118-29. [DOI: 10.1002/ijc.31236] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
265 Shaib WL, Zakka K, Shahin AA, Yared F, Switchenko JM, Wu C, Akce M, Alese OB, Patel PR, Mcdonald M, El-Rayes BF. Radiation as a Single-Modality Treatment in Localized Pancreatic Cancer. Pancreas 2020;49:822-9. [PMID: 32541638 DOI: 10.1097/MPA.0000000000001584] [Reference Citation Analysis]
266 Belfiore MP, Ronza FM, Romano F, Ianniello GP, De Lucia G, Gallo C, Marsicano C, Di Gennaro TL, Belfiore G. Percutaneous CT-guided irreversible electroporation followed by chemotherapy as a novel neoadjuvant protocol in locally advanced pancreatic cancer: Our preliminary experience. Int J Surg. 2015;21 Suppl 1:S34-S39. [PMID: 26118600 DOI: 10.1016/j.ijsu.2015.06.049] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 4.7] [Reference Citation Analysis]
267 Piątek M, Kuśnierz K, Bieńkowski M, Pęksa R, Kowalczyk M, Nawrocki S. Primarily resectable pancreatic adenocarcinoma - to operate or to refer the patient to an oncologist? Crit Rev Oncol Hematol 2019;135:95-102. [PMID: 30819452 DOI: 10.1016/j.critrevonc.2019.01.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
268 Fromer MW, Hawthorne J, Philips P, Egger ME, Scoggins CR, McMasters KM, Martin RCG. An Improved Staging System for Locally Advanced Pancreatic Cancer: A Critical Need in the Multidisciplinary Era. Ann Surg Oncol 2021. [PMID: 34089107 DOI: 10.1245/s10434-021-10174-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
269 Nakajima K, Ino Y, Naito C, Nara S, Shimasaki M, Ishimoto U, Iwasaki T, Doi N, Esaki M, Kishi Y, Shimada K, Hiraoka N. Neoadjuvant therapy alters the collagen architecture of pancreatic cancer tissue via Ephrin-A5. Br J Cancer 2021. [PMID: 34824448 DOI: 10.1038/s41416-021-01639-9] [Reference Citation Analysis]
270 Cools KS, Sanoff HK, Kim HJ, Yeh JJ, Stitzenberg KB. Impact of neoadjuvant therapy on postoperative outcomes after pancreaticoduodenectomy. J Surg Oncol 2018;118:455-62. [PMID: 30114330 DOI: 10.1002/jso.25183] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
271 Manrai M, Tilak TVSVGK, Dawra S, Srivastava S, Singh A. Current and emerging therapeutic strategies in pancreatic cancer: Challenges and opportunities. World J Gastroenterol 2021; 27(39): 6572-6589 [PMID: 34754153 DOI: 10.3748/wjg.v27.i39.6572] [Reference Citation Analysis]
272 Fan X, Lu P, Wang H, Bian S, Wu X, Zhang Y, Liu Y, Fu D, Wen L, Hao J, Tang F. Integrated single-cell multiomics analysis reveals novel candidate markers for prognosis in human pancreatic ductal adenocarcinoma. Cell Discov 2022;8:13. [PMID: 35165277 DOI: 10.1038/s41421-021-00366-y] [Reference Citation Analysis]
273 Li D, O'Reilly EM. Adjuvant and neoadjuvant systemic therapy for pancreas adenocarcinoma. Semin Oncol 2015;42:134-43. [PMID: 25726058 DOI: 10.1053/j.seminoncol.2014.12.012] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
274 Reni M, Zanon S, Balzano G, Nobile S, Pircher CC, Chiaravalli M, Passoni P, Arcidiacono PG, Nicoletti R, Crippa S. Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma. Ann Oncol. 2017;28:2786-2792. [PMID: 28945895 DOI: 10.1093/annonc/mdx495] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 11.8] [Reference Citation Analysis]
275 Swayden M, Iovanna J, Soubeyran P. Pancreatic cancer chemo-resistance is driven by tumor phenotype rather than tumor genotype. Heliyon 2018;4:e01055. [PMID: 30582059 DOI: 10.1016/j.heliyon.2018.e01055] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
276 Keane FK, Wo JY, Ferrone CR, Clark JW, Blaszkowsky LS, Allen JN, Kwak EL, Ryan DP, Lillemoe KD, Fernandez-del Castillo C, Hong TS. Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma. American Journal of Clinical Oncology 2018;41:607-12. [DOI: 10.1097/coc.0000000000000336] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
277 Damm M, Efremov L, Birnbach B, Terrero G, Kleeff J, Mikolajczyk R, Rosendahl J, Michl P, Krug S. Efficacy and Safety of Neoadjuvant Gemcitabine Plus Nab-Paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Cancer-A Systematic Review and Meta-Analysis. Cancers (Basel) 2021;13:4326. [PMID: 34503138 DOI: 10.3390/cancers13174326] [Reference Citation Analysis]
278 Li Z, Li X, Yu C, Wang M, Peng F, Xiao J, Tian R, Jiang J, Sun C. MicroRNA-100 regulates pancreatic cancer cells growth and sensitivity to chemotherapy through targeting FGFR3. Tumour Biol. 2014;35:11751-11759. [PMID: 25344675 DOI: 10.1007/s13277-014-2271-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
279 Páez D, Labonte MJ, Lenz HJ. Pancreatic cancer: medical management (novel chemotherapeutics). Gastroenterol Clin North Am. 2012;41:189-209. [PMID: 22341258 DOI: 10.1016/j.gtc.2011.12.004] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
280 Mian OY, Ram AN, Tuli R, Herman JM. Management options in locally advanced pancreatic cancer. Curr Oncol Rep 2014;16:388. [PMID: 24740136 DOI: 10.1007/s11912-014-0388-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
281 Wang X, Demir IE, Schorn S, Jäger C, Scheufele F, Friess H, Ceyhan GO. Venous resection during pancreatectomy for pancreatic cancer: a systematic review. Transl Gastroenterol Hepatol 2019;4:46. [PMID: 31304423 DOI: 10.21037/tgh.2019.06.01] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
282 Sodergren MH, Mangal N, Wasan H, Sadanandam A, Balachandran VP, Jiao LR, Habib N. Immunological combination treatment holds the key to improving survival in pancreatic cancer. J Cancer Res Clin Oncol 2020;146:2897-911. [PMID: 32748119 DOI: 10.1007/s00432-020-03332-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
283 Idichi T, Seki N, Kurahara H, Fukuhisa H, Toda H, Shimonosono M, Okato A, Arai T, Kita Y, Mataki Y, Kijima Y, Maemura K, Natsugoe S. Molecular pathogenesis of pancreatic ductal adenocarcinoma: Impact of passenger strand of pre-miR-148a on gene regulation. Cancer Sci 2018;109:2013-26. [PMID: 29660218 DOI: 10.1111/cas.13610] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
284 Hartwig W, Büchler MW. Pancreatic Cancer: Current Options for Diagnosis, Staging and Therapeutic Management. Gastrointest Tumors 2013;1:41-52. [PMID: 26673950 DOI: 10.1159/000354992] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
285 Liao K, Wang H, Chen Q, Wu Z, Zhang L. Prosthetic Graft for Superior Mesenteric-Portal Vein Reconstruction in Pancreaticoduodenectomy: A Retrospective, Multicenter Study. J Gastrointest Surg 2014;18:1452-61. [DOI: 10.1007/s11605-014-2549-6] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 3.9] [Reference Citation Analysis]
286 Roeder F. Neoadjuvant radiotherapeutic strategies in pancreatic cancer. World J Gastrointest Oncol 2016; 8(2): 186-197 [PMID: 26909133 DOI: 10.4251/wjgo.v8.i2.186] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
287 Rebelo A, Michalski CW, Ukkat J, Kleeff J. Pancreatic cancer surgery with vascular resection: current concepts and perspectives. Journal of Pancreatology 2019;2:1-5. [DOI: 10.1097/jp9.0000000000000013] [Cited by in Crossref: 6] [Article Influence: 2.0] [Reference Citation Analysis]
288 Gostimir M, Bennett S, Moyana T, Sekhon H, Martel G. Complete pathological response following neoadjuvant FOLFIRINOX in borderline resectable pancreatic cancer - a case report and review. BMC Cancer 2016;16:786. [PMID: 27724927 DOI: 10.1186/s12885-016-2821-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
289 Xue J, Jia E, Ren N, Lindsay A, Yu H. Circulating microRNAs as promising diagnostic biomarkers for pancreatic cancer: a systematic review. Onco Targets Ther 2019;12:6665-84. [PMID: 31692495 DOI: 10.2147/OTT.S207963] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
290 May JP, Ernsting MJ, Undzys E, Li SD. Thermosensitive liposomes for the delivery of gemcitabine and oxaliplatin to tumors. Mol Pharm 2013;10:4499-508. [PMID: 24152292 DOI: 10.1021/mp400321e] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 4.0] [Reference Citation Analysis]
291 Ettrich TJ, Berger AW, Perkhofer L, Daum S, König A, Dickhut A, Wittel U, Wille K, Geissler M, Algül H, Gallmeier E, Atzpodien J, Kornmann M, Muche R, Prasnikar N, Tannapfel A, Reinacher-Schick A, Uhl W, Seufferlein T. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group. BMC Cancer 2018;18:1298. [PMID: 30594153 DOI: 10.1186/s12885-018-5183-y] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 6.5] [Reference Citation Analysis]
292 Hu D, Ansari D, Zhou Q, Sasor A, Hilmersson KS, Bauden M, Jiang Y, Andersson R. Calcium-activated chloride channel regulator 1 as a prognostic biomarker in pancreatic ductal adenocarcinoma. BMC Cancer. 2018;18:1096. [PMID: 30419838 DOI: 10.1186/s12885-018-5013-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
293 Chen Z, Lv Y, Li H, Diao R, Zhou J, Yu T. Meta-analysis of FOLFIRINOX-based neoadjuvant therapy for locally advanced pancreatic cancer. Medicine (Baltimore) 2021;100:e24068. [PMID: 33546009 DOI: 10.1097/MD.0000000000024068] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
294 Yu Z, Zhao S, Wang L, Wang J, Zhou J. miRNA-339-5p Plays an Important Role in Invasion and Migration of Pancreatic Cancer Cells. Med Sci Monit 2019;25:7509-17. [PMID: 31588120 DOI: 10.12659/MSM.917038] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
295 Garcia PL, Council LN, Christein JD, Arnoletti JP, Heslin MJ, Gamblin TL, Richardson JH, Bjornsti MA, Yoon KJ. Development and histopathological characterization of tumorgraft models of pancreatic ductal adenocarcinoma. PLoS One. 2013;8:e78183. [PMID: 24194913 DOI: 10.1371/journal.pone.0078183] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
296 Kamyabi N, Bernard V, Maitra A. Liquid biopsies in pancreatic cancer. Expert Rev Anticancer Ther 2019;19:869-78. [PMID: 31533487 DOI: 10.1080/14737140.2019.1670063] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
297 Tao X, Chen Q, Li N, Xiang H, Pan Y, Qu Y, Shang D, Go VLW, Xue J, Sun Y, Zhang Z, Guo J, Xiao GG. Serotonin-RhoA/ROCK axis promotes acinar-to-ductal metaplasia in caerulein-induced chronic pancreatitis. Biomed Pharmacother 2020;125:109999. [PMID: 32070876 DOI: 10.1016/j.biopha.2020.109999] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
298 Hernandez MC, Bergquist JR, Leiting JL, Ivanics T, Yang L, Smoot RL, Nagorney DM, Truty MJ. Patient-Derived Xenografts Can Be Reliably Generated from Patient Clinical Biopsy Specimens. J Gastrointest Surg 2019;23:818-24. [PMID: 30756315 DOI: 10.1007/s11605-019-04109-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
299 Li Y, Kong R, Chen H, Zhao Z, Li L, Li J, Hu J, Zhang G, Pan S, Wang Y, Wang G, Chen H, Sun B. Overexpression of KLF5 is associated with poor survival and G1/S progression in pancreatic cancer. Aging (Albany NY) 2019;11:5035-57. [PMID: 31327760 DOI: 10.18632/aging.102096] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
300 Goff SL, Chabot JA. A Neoadjuvant Strategy for the Management of Nonmetastatic Pancreatic Cancer. The Cancer Journal 2012;18:602-8. [DOI: 10.1097/ppo.0b013e318279aade] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
301 Marro A, Bandukwala T, Mak W. Three-Dimensional Printing and Medical Imaging: A Review of the Methods and Applications. Curr Probl Diagn Radiol. 2016;45:2-9. [PMID: 26298798 DOI: 10.1067/j.cpradiol.2015.07.009] [Cited by in Crossref: 174] [Cited by in F6Publishing: 132] [Article Influence: 24.9] [Reference Citation Analysis]
302 Heby M, Lundgren S, Nodin B, Elebro J, Eberhard J, Jirström K. Relationship between mismatch repair immunophenotype and long-term survival in patients with resected periampullary adenocarcinoma. J Transl Med 2018;16:66. [PMID: 29540182 DOI: 10.1186/s12967-018-1444-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
303 Chao YJ, Sy ED, Hsu HP, Shan YS. Predictors for resectability and survival in locally advanced pancreatic cancer after gemcitabine-based neoadjuvant therapy. BMC Surg 2014;14:72. [PMID: 25258022 DOI: 10.1186/1471-2482-14-72] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
304 Li K, Zhou Y, Chen Y, Zhou L, Liang J. A novel natural product, britanin, inhibits tumor growth of pancreatic cancer by suppressing nuclear factor-κB activation. Cancer Chemother Pharmacol 2020;85:699-709. [PMID: 32185482 DOI: 10.1007/s00280-020-04052-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
305 Nitsche U, Wenzel P, Siveke JT, Braren R, Holzapfel K, Schlitter AM, Stöß C, Kong B, Esposito I, Erkan M, Michalski CW, Friess H, Kleeff J. Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience. Ann Surg Oncol 2015;22 Suppl 3:S1212-20. [PMID: 26350368 DOI: 10.1245/s10434-015-4851-2] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 7.9] [Reference Citation Analysis]
306 Liao R, Yang J, Zhou BY, Li DW, Huang P, Luo SQ, Du CY. Conditional survival of pancreatic ductal adenocarcinoma in surgical and nonsurgical patients: a retrospective analysis report from a single institution in China. World J Surg Oncol 2015;13:196. [PMID: 26048469 DOI: 10.1186/s12957-015-0608-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
307 Jacobson S, Dahlqvist P, Johansson M, Svensson J, Billing O, Sund M, Franklin O. Hyperglycemia as a risk factor in pancreatic cancer: A nested case-control study using prediagnostic blood glucose levels. Pancreatology 2021:S1424-3903(21)00159-9. [PMID: 34049822 DOI: 10.1016/j.pan.2021.05.008] [Reference Citation Analysis]
308 De Simoni O, Scarpa M, Tonello M, Pilati P, Tolin F, Spolverato Y, Gruppo M. Oligometastatic Pancreatic Cancer to the Liver in the Era of Neoadjuvant Chemotherapy: Which Role for Conversion Surgery? A Systematic Review and Meta-Analysis. Cancers (Basel) 2020;12:E3402. [PMID: 33213022 DOI: 10.3390/cancers12113402] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
309 Hindriksen S, Bijlsma MF. Cancer Stem Cells, EMT, and Developmental Pathway Activation in Pancreatic Tumors. Cancers (Basel) 2012;4:989-1035. [PMID: 24213498 DOI: 10.3390/cancers4040989] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
310 Lopez NE, Prendergast C, Lowy AM. Borderline resectable pancreatic cancer: Definitions and management. World J Gastroenterol 2014; 20(31): 10740-10751 [PMID: 25152577 DOI: 10.3748/wjg.v20.i31.10740] [Cited by in CrossRef: 84] [Cited by in F6Publishing: 66] [Article Influence: 10.5] [Reference Citation Analysis]
311 Franck C, Müller C, Rosania R, Croner RS, Pech M, Venerito M. Advanced Pancreatic Ductal Adenocarcinoma: Moving Forward. Cancers (Basel) 2020;12:E1955. [PMID: 32708493 DOI: 10.3390/cancers12071955] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
312 Lu F, Poruk KE, Weiss MJ. Surgery for oligometastasis of pancreatic cancer. Chin J Cancer Res. 2015;27:358-367. [PMID: 26361405 DOI: 10.3978/j.issn.1000-9604.2015.05.02] [Cited by in F6Publishing: 17] [Reference Citation Analysis]
313 Winter K, Talar-Wojnarowska R, Dąbrowski A, Degowska M, Durlik M, Gąsiorowska A, Głuszek S, Jurkowska G, Kaczka A, Lampe P, Marek T, Nasierowska-Guttmejer A, Nowakowska-Duława E, Rydzewska G, Strzelczyk J, Śledziński Z, Małecka-Panas E. Diagnostic and therapeutic recommendations in pancreatic ductal adenocarcinoma. Recommendations of the Working Group of the Polish Pancreatic Club. Prz Gastroenterol 2019;14:1-18. [PMID: 30944673 DOI: 10.5114/pg.2019.83422] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
314 Mangieri CW, Strode MA, Moaven O, Clark CJ, Shen P. Utilization of chemoradiation therapy provides strongest protective effect for avoidance of postoperative pancreatic fistula following pancreaticoduodenectomy: A NSQIP analysis. J Surg Oncol 2020;122:1604-11. [PMID: 32935353 DOI: 10.1002/jso.26202] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
315 Fujishiro T, Mashiko T, Masuoka Y, Yamada M, Furukawa D, Yazawa N, Kawashima Y, Ogawa M, Hirabayashi K, Nakagohri T. Conversion surgery for an initially unresectable, locally advanced pancreatic cancer after induction chemotherapy and carbon-ion radiotherapy: a case report. Surg Case Rep 2018;4:112. [PMID: 30203372 DOI: 10.1186/s40792-018-0522-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
316 Klaiber U, Leonhardt C, Strobel O, Tjaden C, Hackert T, Neoptolemos JP. Neoadjuvant and adjuvant chemotherapy in pancreatic cancer. Langenbecks Arch Surg 2018;403:917-32. [DOI: 10.1007/s00423-018-1724-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 7.8] [Reference Citation Analysis]
317 Schorn S, Demir IE, Reyes CM, Saricaoglu C, Samm N, Schirren R, Tieftrunk E, Hartmann D, Friess H, Ceyhan GO. The impact of neoadjuvant therapy on the histopathological features of pancreatic ductal adenocarcinoma - A systematic review and meta-analysis. Cancer Treat Rev 2017;55:96-106. [PMID: 28342938 DOI: 10.1016/j.ctrv.2017.03.003] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 9.8] [Reference Citation Analysis]
318 Heerkens HD, Hall WA, Li XA, Knechtges P, Dalah E, Paulson ES, van den Berg CAT, Meijer GJ, Koay EJ, Crane CH, Aitken K, van Vulpen M, Erickson BA. Recommendations for MRI-based contouring of gross tumor volume and organs at risk for radiation therapy of pancreatic cancer. Pract Radiat Oncol 2017;7:126-36. [PMID: 28089481 DOI: 10.1016/j.prro.2016.10.006] [Cited by in Crossref: 27] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
319 Mokdad AA, Minter RM, Zhu H, Augustine MM, Porembka MR, Wang SC, Yopp AC, Mansour JC, Choti MA, Polanco PM. Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis. J Clin Oncol. 2017;35:515-522. [PMID: 27621388 DOI: 10.1200/jco.2016.68.5081] [Cited by in Crossref: 178] [Cited by in F6Publishing: 72] [Article Influence: 29.7] [Reference Citation Analysis]
320 Kandel P, Wallace MB. Advanced EUS Guided Tissue Acquisition Methods for Pancreatic Cancer. Cancers (Basel) 2018;10:E54. [PMID: 29463004 DOI: 10.3390/cancers10020054] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
321 Byrne JD, Jajja MR, O'Neill AT, Bickford LR, Keeler AW, Hyder N, Wagner K, Deal A, Little RE, Moffitt RA, Stack C, Nelson M, Brooks CR, Lee W, Luft JC, Napier ME, Darr D, Anders CK, Stack R, Tepper JE, Wang AZ, Zamboni WC, Yeh JJ, DeSimone JM. Local iontophoretic administration of cytotoxic therapies to solid tumors. Sci Transl Med 2015;7:273ra14. [PMID: 25653220 DOI: 10.1126/scitranslmed.3009951] [Cited by in Crossref: 41] [Cited by in F6Publishing: 31] [Article Influence: 5.9] [Reference Citation Analysis]
322 Kassardjian A, Wang HL. SMAD4-Expressing Pancreatic Ductal Adenocarcinomas Have Better Response to Neoadjuvant Therapy and Significantly Lower Lymph Node Metastasis Rates. Pancreas 2020;49:1153-60. [PMID: 32897998 DOI: 10.1097/MPA.0000000000001636] [Reference Citation Analysis]
323 Lee SH, Kang CM, Kim H, Hwang HK, Song SY, Seong J, Kim MJ, Lee WJ. Pathological Complete Remission of Pancreatic Cancer Following Neoadjuvant Chemoradiation Therapy; Not the End of Battles. Medicine (Baltimore) 2015;94:e2168. [PMID: 26717359 DOI: 10.1097/MD.0000000000002168] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
324 Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goéré D, Seufferlein T, Haustermans K, Van Laethem J, Conroy T, Arnold D. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2015;26:v56-68. [DOI: 10.1093/annonc/mdv295] [Cited by in Crossref: 525] [Cited by in F6Publishing: 477] [Article Influence: 75.0] [Reference Citation Analysis]
325 Paniccia A, Edil BH, Schulick RD, Byers JT, Meguid C, Gajdos C, McCarter MD. Neoadjuvant FOLFIRINOX application in borderline resectable pancreatic adenocarcinoma: a retrospective cohort study. Medicine (Baltimore). 2014;93:e198. [PMID: 25501072 DOI: 10.1097/md.0000000000000198] [Cited by in Crossref: 44] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
326 Barcellini A, Peloso A, Pugliese L, Vitolo V, Cobianchi L. Locally Advanced Pancreatic Ductal Adenocarcinoma: Challenges and Progress. Onco Targets Ther 2020;13:12705-20. [PMID: 33335406 DOI: 10.2147/OTT.S220971] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
327 Kung JW, Parks RW. Vascular resections in minimally invasive surgery for pancreatic cancer. Laparoscopic, Endoscopic and Robotic Surgery 2021. [DOI: 10.1016/j.lers.2021.09.003] [Reference Citation Analysis]
328 Denbo JW, Bruno ML, Cloyd JM, Prakash L, Lee JE, Kim M, Crane CH, Koay EJ, Krishnan S, Das P, Minsky BD, Varadhachary G, Shroff R, Wolff R, Javle M, Overman MJ, Fogelman D, Aloia TA, Vauthey JN, Fleming JB, Katz MH. Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality. J Gastrointest Surg 2016;20:1975-85. [PMID: 27730398 DOI: 10.1007/s11605-016-3286-9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 4.5] [Reference Citation Analysis]
329 Albahde MAH, Abdrakhimov B, Li GQ, Zhou X, Zhou D, Xu H, Qian H, Wang W. The Role of Microtubules in Pancreatic Cancer: Therapeutic Progress. Front Oncol 2021;11:640863. [PMID: 34094924 DOI: 10.3389/fonc.2021.640863] [Reference Citation Analysis]
330 Kircher SM, Krantz SB, Nimeiri HS, Mulcahy MF, Munshi HG, Benson AB. Therapy of locally advanced pancreatic adenocarcinoma: unresectable and borderline patients. Expert Rev Anticancer Ther. 2011;11:1555-1565. [PMID: 21999129 DOI: 10.1586/era.11.125] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
331 Passoni P, Reni M, Cattaneo GM, Slim N, Cereda S, Balzano G, Castoldi R, Longobardi B, Bettinardi V, Gianolli L, Gusmini S, Staudacher C, Calandrino R, Di Muzio N. Hypofractionated image-guided IMRT in advanced pancreatic cancer with simultaneous integrated boost to infiltrated vessels concomitant with capecitabine: a phase I study. Int J Radiat Oncol Biol Phys 2013;87:1000-6. [PMID: 24267968 DOI: 10.1016/j.ijrobp.2013.09.012] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
332 Narayanan G, Hosein PJ, Arora G, Barbery KJ, Froud T, Livingstone AS, Franceschi D, Rocha Lima CM, Yrizarry J. Percutaneous irreversible electroporation for downstaging and control of unresectable pancreatic adenocarcinoma. J Vasc Interv Radiol. 2012;23:1613-1621. [PMID: 23177107 DOI: 10.1016/j.jvir.2012.09.012] [Cited by in Crossref: 139] [Cited by in F6Publishing: 132] [Article Influence: 15.4] [Reference Citation Analysis]
333 Truty MJ, Kendrick ML, Nagorney DM, Smoot RL, Cleary SP, Graham RP, Goenka AH, Hallemeier CL, Haddock MG, Harmsen WS, Mahipal A, McWilliams RR, Halfdanarson TR, Grothey AF. Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer. Ann Surg. 2021;273:341-349. [PMID: 30946090 DOI: 10.1097/sla.0000000000003284] [Cited by in Crossref: 77] [Cited by in F6Publishing: 30] [Article Influence: 77.0] [Reference Citation Analysis]
334 Bittner M, Grosu A, Brunner TB. Comparison of toxicity after IMRT and 3D-conformal radiotherapy for patients with pancreatic cancer – A systematic review. Radiotherapy and Oncology 2015;114:117-21. [DOI: 10.1016/j.radonc.2014.11.043] [Cited by in Crossref: 42] [Cited by in F6Publishing: 31] [Article Influence: 6.0] [Reference Citation Analysis]
335 Wang J, Yang S, He P, Schetter AJ, Gaedcke J, Ghadimi BM, Ried T, Yfantis HG, Lee DH, Gaida MM, Hanna N, Alexander HR, Hussain SP. Endothelial Nitric Oxide Synthase Traffic Inducer (NOSTRIN) is a Negative Regulator of Disease Aggressiveness in Pancreatic Cancer. Clin Cancer Res 2016;22:5992-6001. [PMID: 27401251 DOI: 10.1158/1078-0432.CCR-16-0511] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
336 Shi S, Yu X. Selecting chemotherapy for pancreatic cancer: Far away or so close? Semin Oncol 2019;46:39-47. [PMID: 30611527 DOI: 10.1053/j.seminoncol.2018.12.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
337 Habib JR, Wolfgang CL. Commentary: Anatomic versus biologic resectability: The role of predictive biomarkers in guiding surgical management. Surgery 2020;168:1017-8. [PMID: 32900493 DOI: 10.1016/j.surg.2020.07.032] [Reference Citation Analysis]
338 Braren RF, Siveke JT. Next-generation metabolic imaging in pancreatic cancer. Gut 2016;65:367-9. [DOI: 10.1136/gutjnl-2015-310518] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
339 Chen-Zhao X, Hernando O, López M, Sánchez E, Montero A, García-Aranda M, Ciérvide R, Valero J, Alonso R, Cárdenas-Rebollo JM, Vicente E, Quijano Y, Cubillo A, Álvarez R, Prados S, Plaza C, García J, Zucca D, Fernández-Letón P, Rubio C. A prospective observational study of the clinical and pathological impact of stereotactic body radiotherapy (SBRT) as a neoadjuvant strategy of chemoradiation in pancreatic cancer. Clin Transl Oncol 2020;22:1499-505. [PMID: 31974820 DOI: 10.1007/s12094-020-02287-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
340 Tamburrino D, Partelli S, Crippa S, Manzoni A, Maurizi A, Falconi M. Selection criteria in resectable pancreatic cancer: A biological and morphological approach. World J Gastroenterol 2014; 20(32): 11210-11215 [PMID: 25170205 DOI: 10.3748/wjg.v20.i32.11210] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
341 Hashemi-Sadraei N, Gbolahan OB, Salfity H, O'Neil B, House MG, Shahda S. Clinical Characteristics of Patients Experiencing Pathologic Complete Response Following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma. Am J Clin Oncol 2018;41:982-5. [PMID: 28968257 DOI: 10.1097/COC.0000000000000409] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
342 Gilbert JW, Wolpin B, Clancy T, Wang J, Mamon H, Shinagare AB, Jagannathan J, Rosenthal M. Borderline resectable pancreatic cancer: conceptual evolution and current approach to image-based classification. Ann Oncol. 2017;28:2067-2076. [PMID: 28407088 DOI: 10.1093/annonc/mdx180] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 9.3] [Reference Citation Analysis]
343 Lin C, Verma V, Lazenby A, Ly QP, Berim LD, Schwarz JK, Madiyalakan M, Nicodemus CF, Hollingsworth MA, Meza JL, Are C, Padussis J, Grem JL. Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic Adenocarcinoma. Am J Clin Oncol 2019;42:755-60. [PMID: 31513018 DOI: 10.1097/COC.0000000000000599] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
344 Porcelli L, Quatrale AE, Mantuano P, Leo MG, Silvestris N, Rolland JF, Carioggia E, Lioce M, Paradiso A, Azzariti A. Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity. Mol Oncol. 2013;7:308-322. [PMID: 23148997 DOI: 10.1016/j.molonc.2012.10.002] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 3.8] [Reference Citation Analysis]
345 Woo W, Carey ET, Choi M. Spotlight on liposomal irinotecan for metastatic pancreatic cancer: patient selection and perspectives. Onco Targets Ther 2019;12:1455-63. [PMID: 30863113 DOI: 10.2147/OTT.S167590] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
346 Yang L, Bai Y, Li Q, Chen J, Liu F, Weng X, Xu F. Analysis of the Curative Effect of Neoadjuvant Therapy on Pancreatic Cancer. Front Oncol 2021;11:695645. [PMID: 34485131 DOI: 10.3389/fonc.2021.695645] [Reference Citation Analysis]
347 Carbone C, Piro G, Fassan M, Tamburrino A, Mina MM, Zanotto M, Chiao PJ, Bassi C, Scarpa A, Tortora G, Melisi D. An angiopoietin-like protein 2 autocrine signaling promotes EMT during pancreatic ductal carcinogenesis. Oncotarget 2015;6:13822-34. [PMID: 25360865 DOI: 10.18632/oncotarget.2635] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.8] [Reference Citation Analysis]
348 Mondo EL, Noel MS, Katz AW, Schoeniger LO, Hezel AF. Unresectable locally advanced pancreatic cancer: treatment with neoadjuvant leucovorin, fluorouracil, irinotecan, and oxaliplatin and assessment of surgical resectability. J Clin Oncol. 2013;31:e37-e39. [PMID: 23233707 DOI: 10.1200/jco.2012.44.0339] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
349 Hayashi A, Fan J, Chen R, Ho Y, Makohon-moore AP, Lecomte N, Zhong Y, Hong J, Huang J, Sakamoto H, Attiyeh MA, Kohutek ZA, Zhang L, Boumiza A, Kappagantula R, Baez P, Bai J, Lisi M, Chadalavada K, Melchor JP, Wong W, Nanjangud GJ, Basturk O, O’reilly EM, Klimstra DS, Hruban RH, Wood LD, Overholtzer M, Iacobuzio-donahue CA. A unifying paradigm for transcriptional heterogeneity and squamous features in pancreatic ductal adenocarcinoma. Nat Cancer 2020;1:59-74. [DOI: 10.1038/s43018-019-0010-1] [Cited by in Crossref: 46] [Cited by in F6Publishing: 12] [Article Influence: 23.0] [Reference Citation Analysis]
350 Petrelli F, Tomasello G, Ghidini M, Lonati V, Passalacqua R, Barni S. Disease-free survival is not a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a systematic review of randomized trials. HPB 2017;19:944-50. [DOI: 10.1016/j.hpb.2017.07.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
351 Sharen G, Peng Y, Cheng H, Liu Y, Shi Y, Zhao J. Prognostic value of GLUT-1 expression in pancreatic cancer: results from 538 patients. Oncotarget 2017;8:19760-7. [PMID: 28178665 DOI: 10.18632/oncotarget.15035] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
352 Makar M, Zhao E, Tyberg A. Personalized Approach to the Role of Endoscopic Ultrasound in the Diagnosis and Management of Pancreaticobiliary Malignancies. J Pers Med 2021;11:180. [PMID: 33806458 DOI: 10.3390/jpm11030180] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
353 Bendersky N, Sulpice L, Farges O. Reply to the Letter to the Editor "Laparoscopic Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma: time for a Randomized Controlled Trial? Results of an All-inclusive National Observational Study". Ann Surg 2017;266:e85-6. [PMID: 29137001 DOI: 10.1097/SLA.0000000000001709] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
354 Holyoake DL, Ward E, Grose D, McIntosh D, Sebag-Montefiore D, Radhakrishna G, Patel N, Silva M, Mukherjee S, Strauss VY, Odondi L, Fokas E, Melcher A, Hawkins MA. A phase-I trial of pre-operative, margin intensive, stereotactic body radiation therapy for pancreatic cancer: the 'SPARC' trial protocol. BMC Cancer 2016;16:728. [PMID: 27619800 DOI: 10.1186/s12885-016-2765-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
355 De Bari B, Porta L, Mazzola R, Alongi F, Wagner AD, Schäfer M, Bourhis J, Ozsahin M. Hypofractionated radiotherapy in pancreatic cancer: Lessons from the past in the era of stereotactic body radiation therapy. Critical Reviews in Oncology/Hematology 2016;103:49-61. [DOI: 10.1016/j.critrevonc.2016.05.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
356 Balaban EP, Mangu PB, Yee NS. Locally Advanced Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary. JOP 2017;13:265-9. [DOI: 10.1200/jop.2016.017376] [Cited by in Crossref: 27] [Cited by in F6Publishing: 12] [Article Influence: 5.4] [Reference Citation Analysis]
357 Sun L, Cao J, Chen K, Cheng L, Zhou C, Yan B, Qian W, Li J, Duan W, Ma J, Qi D, Wu E, Wang Z, Liu Q, Ma Q, Xu Q. Betulinic acid inhibits stemness and EMT of pancreatic cancer cells via activation of AMPK signaling. Int J Oncol 2019;54:98-110. [PMID: 30365057 DOI: 10.3892/ijo.2018.4604] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
358 McCarthy PM, Rendo MJ, Uy MD, Adams AM, O'Shea AE, Nelson DW, Fenderson JL, Cebe KM, Krell RW, Clifton GT, Peoples GE, Vreeland TJ. Near Complete Pathologic Response to PD-1 Inhibitor and Radiotherapy in a Patient with Locally Advanced Pancreatic Ductal Adenocarcinoma. Onco Targets Ther 2021;14:3537-44. [PMID: 34103944 DOI: 10.2147/OTT.S311661] [Reference Citation Analysis]
359 Wolff RA. Adjuvant or Neoadjuvant Therapy in the Treatment in Pancreatic Malignancies: Where Are We? Surg Clin North Am 2018;98:95-111. [PMID: 29191281 DOI: 10.1016/j.suc.2017.09.009] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
360 Liu F, Tang Y, Sun J, Yuan Z, Li S, Sheng J, Ren H, Hao J. Regional intra-arterial vs. systemic chemotherapy for advanced pancreatic cancer: a systematic review and meta-analysis of randomized controlled trials. PLoS One. 2012;7:e40847. [PMID: 22815840 DOI: 10.1371/journal.pone.0040847] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
361 Cloyd JM, Ejaz A, Shen C, Dillhoff M, Williams TM, Noonan A, Pawlik TM, Tsung A. Pathologic complete response following neoadjuvant therapy for pancreatic ductal adenocarcinoma: defining the incidence, predictors, and outcomes. HPB (Oxford). 2020;22:1569-1576. [PMID: 32063480 DOI: 10.1016/j.hpb.2020.01.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
362 Heinemann V, Reni M, Ychou M, Richel DJ, Macarulla T, Ducreux M. Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies. Cancer Treat Rev. 2014;40:118-128. [PMID: 23849556 DOI: 10.1016/j.ctrv.2013.04.004] [Cited by in Crossref: 79] [Cited by in F6Publishing: 84] [Article Influence: 8.8] [Reference Citation Analysis]
363 Bicu F, Rink JS, Froelich MF, Cyran CC, Rübenthaler J, Birgin E, Röhrich M, Tollens F. Supplemental 18F-FDG-PET/CT for Detection of Malignant Transformation of IPMN-A Model-Based Cost-Effectiveness Analysis. Cancers (Basel) 2021;13:1365. [PMID: 33803522 DOI: 10.3390/cancers13061365] [Reference Citation Analysis]
364 Janssen QP, O'Reilly EM, van Eijck CHJ, Groot Koerkamp B. Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer.Front Oncol. 2020;10:41. [PMID: 32083002 DOI: 10.3389/fonc.2020.00041] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
365 Combs SE. Individualized radiotherapy (iRT) concepts for locally advanced pancreatic cancer (LAPC): indications and prognostic factors. Langenbecks Arch Surg 2015;400:749-56. [DOI: 10.1007/s00423-015-1309-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
366 Khushman M, Dempsey N, Cudris Maldonado J, Loaiza-bonilla A, Velez M, Carcas L, Dammrich D, Hurtado-cordovi J, Parajuli R, Pollack T, Harwood AP, Macintyre J, Tzeng CD, Merchan JR, Restrepo MH, Akunyili II, Ribeiro A, Narayanan G, Portelance L, Sleeman D, Levi JU, Rocha Lima CM, Hosein PJ. Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma. Pancreatology 2015;15:667-73. [DOI: 10.1016/j.pan.2015.08.010] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 7.7] [Reference Citation Analysis]
367 Mirkin KA, Greenleaf EK, Hollenbeak CS, Wong J. Correlation of clinical and pathological staging and response to neoadjuvant therapy in resected pancreatic cancer. International Journal of Surgery 2018;52:221-8. [DOI: 10.1016/j.ijsu.2018.01.043] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
368 Fang D, Zhang C, Xu P, Liu Y, Mo X, Sun Q, Abdelatty A, Hu C, Xu H, Zhou G, Xia H, Lan L. S100A16 promotes metastasis and progression of pancreatic cancer through FGF19-mediated AKT and ERK1/2 pathways. Cell Biol Toxicol 2021;37:555-71. [PMID: 33389337 DOI: 10.1007/s10565-020-09574-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
369 Liu J, Jiang S, Yang X, Li X, Wang N. The Significant Value of Preoperative Prognostic Nutritional Index for Survival in Pancreatic Cancers: A Meta-analysis.Pancreas. 2018;47:793-799.. [PMID: 29985846 DOI: 10.1097/MPA.0000000000001089] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
370 Liu W, Fu XL, Yang JY, Liu DJ, Li J, Zhang JF, Huo YM, Yang MW, Hua R, Sun YW. Efficacy of Neo-Adjuvant Chemoradiotherapy for Resectable Pancreatic Adenocarcinoma: A PRISMA-Compliant Meta-Analysis and Systematic Review. Medicine (Baltimore). 2016;95:e3009. [PMID: 27082545 DOI: 10.1097/MD.0000000000003009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
371 Jäger R, Weigel R, Forthuber B, Ganswindt U. Integrating radiation oncology into the management of pancreatic cancer. Eur Surg 2019;51:139-45. [DOI: 10.1007/s10353-019-0577-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
372 Liu J, Xie X, Xuan C, Li T, Wang L, Teng L, Liu J. High-Density Infiltration of V-domain Immunoglobulin Suppressor of T-cell Activation Up-regulated Immune Cells in Human Pancreatic Cancer. Pancreas 2018;47:725-31. [PMID: 29771768 DOI: 10.1097/MPA.0000000000001059] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
373 Mehtsun WT, Hashimoto DA, Ferrone CR. Status of 5-Year Survivors of the Whipple Procedure for Pancreatic Adenocarcinoma. Advances in Surgery 2019;53:253-69. [DOI: 10.1016/j.yasu.2019.04.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
374 Cassinotto C, Dohan A, Zogopoulos G, Chiche L, Laurent C, Sa-Cunha A, Cuggia A, Reinhold C, Gallix B. Pancreatic adenocarcinoma: A simple CT score for predicting margin-positive resection in patients with resectable disease. Eur J Radiol 2017;95:33-8. [PMID: 28987689 DOI: 10.1016/j.ejrad.2017.06.028] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
375 Parekh HD, Starr J, George TJ Jr. The Multidisciplinary Approach to Localized Pancreatic Adenocarcinoma. Curr Treat Options Oncol 2017;18:73. [PMID: 29143898 DOI: 10.1007/s11864-017-0515-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
376 Sun X, Lu Z, Wu Y, Min M, Bi Y, Shen W, Xu Y, Li Z, Jin Z, Liu Y. An endoscopic ultrasonography-guided interstitial brachytherapy based special treatment-planning system for unresectable pancreatic cancer. Oncotarget 2017;8:79099-110. [PMID: 29108290 DOI: 10.18632/oncotarget.15763] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
377 Hidalgo M, Álvarez R, Gallego J, Guillén-Ponce C, Laquente B, Macarulla T, Muñoz A, Salgado M, Vera R, Adeva J, Alés I, Arévalo S, Blázquez J, Calsina A, Carmona A, de Madaria E, Díaz R, Díez L, Fernández T, de Paredes BG, Gallardo ME, González I, Hernando O, Jiménez P, López A, López C, López-Ríos F, Martín E, Martínez J, Martínez A, Montans J, Pazo R, Plaza JC, Peiró I, Reina JJ, Sanjuanbenito A, Yaya R, Carrato A. Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain. Clin Transl Oncol 2017;19:667-81. [PMID: 27995549 DOI: 10.1007/s12094-016-1594-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
378 Maebayashi T, Ishibashi N, Aizawa T, Sakaguchi M, Sato T, Kawamori J, Tanaka Y. Treatment outcomes of concurrent hyperthermia and chemoradiotherapy for pancreatic cancer: Insights into the significance of hyperthermia treatment.Oncol Lett. 2017;13:4959-4964. [PMID: 28588736 DOI: 10.3892/ol.2017.6066] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
379 Whittle MC, Izeradjene K, Rani PG, Feng L, Carlson MA, DelGiorno KE, Wood LD, Goggins M, Hruban RH, Chang AE, Calses P, Thorsen SM, Hingorani SR. RUNX3 Controls a Metastatic Switch in Pancreatic Ductal Adenocarcinoma. Cell 2015;161:1345-60. [PMID: 26004068 DOI: 10.1016/j.cell.2015.04.048] [Cited by in Crossref: 112] [Cited by in F6Publishing: 113] [Article Influence: 16.0] [Reference Citation Analysis]
380 Xu X, Wu Q, Wang Z, Zheng S, Ge K, Jia C. Meta-analysis of FOLFIRINOX regimen as the first-line chemotherapy for locally advanced pancreatic cancer and borderline resectable pancreatic cancer. Clin Exp Med 2019;19:149-57. [PMID: 30498929 DOI: 10.1007/s10238-018-0540-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
381 Seaman ME, Contino G, Bardeesy N, Kelly KA. Molecular imaging agents: impact on diagnosis and therapeutics in oncology. Expert Rev Mol Med. 2010;12:e20. [PMID: 20633310 DOI: 10.1017/s1462399410001511] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
382 Schwarz L, Vernerey D, Bachet JB, Tuech JJ, Portales F, Michel P, Cunha AS. Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study). BMC Cancer 2018;18:762. [PMID: 30041614 DOI: 10.1186/s12885-018-4663-4] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 8.8] [Reference Citation Analysis]
383 Okada K, Kawai M, Hirono S, Satoi S, Yanagimoto H, Ioka T, Miyazawa M, Shimizu A, Kitahata Y, Yamaue H. Impact of treatment duration of neoadjuvant FIRINOX in patients with borderline resectable pancreatic cancer: a pilot trial. Cancer Chemother Pharmacol 2016;78:719-26. [PMID: 27501851 DOI: 10.1007/s00280-016-3121-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
384 Barbour AP, Samra JS, Haghighi KS, Donoghoe MW, Burge M, Harris MT, Chua YJ, Mitchell J, O'Rourke N, Chan H, Gebski VJ, Gananadha S, Croagh DG, Kench JG, Goldstein D; Australasian Gastro-Intestinal Trials Group (AGITG) GAP investigators. The AGITG GAP Study: A Phase II Study of Perioperative Gemcitabine and Nab-Paclitaxel for Resectable Pancreas Cancer. Ann Surg Oncol 2020;27:2506-15. [PMID: 31997125 DOI: 10.1245/s10434-020-08205-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
385 Sulpizio S, Franceschini N, Piattelli A, Di Sebastiano P, Innocenti P, Selvaggi F. Cathepsins and pancreatic cancer: The 2012 update. Pancreatology 2012;12:395-401. [DOI: 10.1016/j.pan.2012.07.011] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
386 Fu XF, Zhao HC, Yang CL, Chen CZ, Wang K, Gao F, Tian YZ, Zhao HL. MicroRNA-203-3p inhibits the proliferation, invasion and migration of pancreatic cancer cells by downregulating fibroblast growth factor 2. Oncol Lett 2021;22:626. [PMID: 34267818 DOI: 10.3892/ol.2021.12887] [Reference Citation Analysis]
387 Kunzmann V, Herrmann K, Bluemel C, Kapp M, Hartlapp I, Steger U. Intensified Neoadjuvant Chemotherapy with Nab-Paclitaxel plus Gemcitabine Followed by FOLFIRINOX in a Patient with Locally Advanced Unresectable Pancreatic Cancer. Case Rep Oncol 2014;7:648-55. [PMID: 25408659 DOI: 10.1159/000367966] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
388 Javed AA, Wright MJ, Siddique A, Blair AB, Ding D, Burkhart RA, Makary M, Cameron JL, Narang A, Herman J, Zheng L, Laheru D, Weiss MJ, Wolfgang C, He J. Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant Chemotherapy. J Gastrointest Surg 2019;23:112-21. [PMID: 30242644 DOI: 10.1007/s11605-018-3966-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 5.5] [Reference Citation Analysis]
389 Hahn S, Ayav A, Lopez A. Resection of Locally Advanced Pancreatic Neoplasms after Neoadjuvant Chemotherapy with Nab-Paclitaxel and Gemcitabine following FOLFIRINOX Failure. Case Rep Gastroenterol 2017;11:422-7. [PMID: 29033758 DOI: 10.1159/000478722] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
390 Fokas E, Eccles C, Patel N, Chu K, Warren S, Mckenna WG, Brunner TB. A treatment planning comparison of four target volume contouring guidelines for locally advanced pancreatic cancer radiotherapy. Radiotherapy and Oncology 2013;107:200-6. [DOI: 10.1016/j.radonc.2013.04.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
391 Zhang LP, Ren H, Du YX, Wang CF. Prognostic value of the preoperative fibrinogen-to-albumin ratio in pancreatic ductal adenocarcinoma patients undergoing R0 resection. World J Gastroenterol 2020; 26(46): 7382-7404 [PMID: 33362391 DOI: 10.3748/wjg.v26.i46.7382] [Reference Citation Analysis]
392 Motoi F, Satoi S, Honda G, Wada K, Shinchi H, Matsumoto I, Sho M, Tsuchida A, Unno M; Study Group of Preoperative therapy for Pancreatic cancer (PREP). A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study. J Gastroenterol 2019;54:194-203. [PMID: 30182219 DOI: 10.1007/s00535-018-1506-7] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
393 Illés D, Ivány E, Holzinger G, Kosár K, Adam MG, Kamlage B, Zsóri G, Tajti M, Svébis MM, Horváth V, Oláh I, Márta K, Váncsa S, Zádori N, Szentesi A, Czakó B, Hegyi P, Czakó L. New Onset of DiabetEs in aSsociation with pancreatic ductal adenocarcinoma (NODES Trial): protocol of a prospective, multicentre observational trial. BMJ Open 2020;10:e037267. [PMID: 33444177 DOI: 10.1136/bmjopen-2020-037267] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
394 Abrams RA. Radiotherapy in the adjuvant management of pancreatic adenocarcinoma: is it helpful? Expert Review of Gastroenterology & Hepatology 2014;6:149-61. [DOI: 10.1586/egh.12.3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
395 Barreto SG, Kleeff J. Synchronous arterial resections in pancreatic cancer - still a matter of debate? Eur J Surg Oncol 2021;47:480-2. [PMID: 32586727 DOI: 10.1016/j.ejso.2020.06.028] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
396 Alasadi A, Cao B, Guo J, Tao H, Collantes J, Tan V, Su X, Augeri D, Jin S. Mitochondrial uncoupler MB1-47 is efficacious in treating hepatic metastasis of pancreatic cancer in murine tumor transplantation models. Oncogene 2021;40:2285-95. [PMID: 33649533 DOI: 10.1038/s41388-021-01688-7] [Reference Citation Analysis]
397 Castillo Tuñón JM, Valle Rodas ME, Botello Martínez F, Rojas Holguín A, López Guerra D, Santos Naharro J, Jaén Torrejímeno I, Blanco Fernández G. Implementation of a regional reference center in pancreatic surgery. Experience after 631 procedures. Cir Esp (Engl Ed) 2021;99:745-56. [PMID: 34794902 DOI: 10.1016/j.cireng.2021.11.001] [Reference Citation Analysis]
398 Torgeson A, Tao R, Garrido-Laguna I, Willen B, Dursteler A, Lloyd S. Large database utilization in health outcomes research in pancreatic cancer: an update. J Gastrointest Oncol 2018;9:996-1004. [PMID: 30603118 DOI: 10.21037/jgo.2018.05.15] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
399 Polistina F, Natale GD, Bonciarelli G, Ambrosino G, Frego M. Neoadjuvant strategies for pancreatic cancer. World J Gastroenterol 2014; 20(28): 9374-9383 [PMID: 25071332 DOI: 10.3748/wjg.v20.i28.9374] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
400 Sahora K, Kuehrer I, Schindl M, Koelblinger C, Goetzinger P, Gnant M. NeoGemTax: gemcitabine and docetaxel as neoadjuvant treatment for locally advanced nonmetastasized pancreatic cancer. World J Surg. 2011;35:1580-1589. [PMID: 21523499 DOI: 10.1007/s00268-011-1113-8] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 3.7] [Reference Citation Analysis]
401 Auriemma WS, Berger AC, Bar-ad V, Boland PM, Cohen SJ, Roche-lima CMS, Morris GJ. Locally Advanced Pancreatic Cancer. Seminars in Oncology 2012;39:e9-e22. [DOI: 10.1053/j.seminoncol.2012.05.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
402 Franck C, Hass P, Malfertheiner P, Ricke J, Seidensticker M, Venerito M. Combined Systemic Chemotherapy and CT-Guided High-Dose-Rate Brachytherapy for Isolated Local Manifestation of Pancreatic Cancer after Surgical Resection. Digestion 2018;98:69-74. [DOI: 10.1159/000487359] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
403 Chen Y, Wang L, Luo S, Hu J, Huang X, Li PW, Zhang Y, Wu C, Tian BL. Enhancement of Antitumor Efficacy of Paclitaxel-Loaded PEGylated Liposomes by N,N-Dimethyl Tertiary Amino Moiety in Pancreatic Cancer. Drug Des Devel Ther 2020;14:2945-57. [PMID: 32801636 DOI: 10.2147/DDDT.S261017] [Reference Citation Analysis]
404 Joo I, Lee JM, Lee ES, Ahn SJ, Lee DH, Kim S, Ryu JK, Oh D, Kim K, Lee K, Jang J. Preoperative MDCT Assessment of Resectability in Borderline Resectable Pancreatic Cancer: Effect of Neoadjuvant Chemoradiation Therapy. American Journal of Roentgenology 2018;210:1059-65. [DOI: 10.2214/ajr.17.18310] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
405 Zhao Q, Hu F, Xiao Z, Li M, Wu X, Zhao Y, Wu Y, Yin J, Lin L, Zhang H, Zhang L, Cho CH, Shen J. Comprehensive molecular profiling of the B7 family in gastrointestinal cancer. Cell Prolif 2018;51:e12468. [PMID: 29999557 DOI: 10.1111/cpr.12468] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
406 Yamada M, Sugiura T, Okamura Y, Ito T, Yamamoto Y, Ashida R, Sasaki K, Nagino M, Uesaka K. Microscopic Venous Invasion in Pancreatic Cancer. Ann Surg Oncol. 2018;25:1043-1051. [PMID: 29302820 DOI: 10.1245/s10434-017-6324-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
407 Yamamoto T, Satoi S, Kawai M, Motoi F, Sho M, Uemura KI, Matsumoto I, Honda G, Okada KI, Akahori T, Toyama H, Kurata M, Yanagimoto H, Yamaue H, Unno M, Kon M, Murakami Y. Is distal pancreatectomy with en-bloc celiac axis resection effective for patients with locally advanced pancreatic ductal adenocarcinoma? -Multicenter surgical group study. Pancreatology 2018;18:106-13. [PMID: 29153701 DOI: 10.1016/j.pan.2017.11.005] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 4.6] [Reference Citation Analysis]
408 Sohal DP, Walsh RM, Ramanathan RK, Khorana AA. Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy. J Natl Cancer Inst. 2014;106:dju011. [PMID: 24563516 DOI: 10.1093/jnci/dju011] [Cited by in Crossref: 84] [Cited by in F6Publishing: 80] [Article Influence: 10.5] [Reference Citation Analysis]
409 Browning RJ, Able S, Ruan JL, Bau L, Allen PD, Kersemans V, Wallington S, Kinchesh P, Smart S, Kartsonaki C, Kamila S, Logan K, Taylor MA, McHale AP, Callan JF, Stride E, Vallis KA. Combining sonodynamic therapy with chemoradiation for the treatment of pancreatic cancer. J Control Release 2021;337:371-7. [PMID: 34274382 DOI: 10.1016/j.jconrel.2021.07.020] [Reference Citation Analysis]
410 Bouchart C, Navez J, Closset J, Hendlisz A, Van Gestel D, Moretti L, Van Laethem JL. Novel strategies using modern radiotherapy to improve pancreatic cancer outcomes: toward a new standard? Ther Adv Med Oncol 2020;12:1758835920936093. [PMID: 32684987 DOI: 10.1177/1758835920936093] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
411 Liu Q, Zhao G, Zhang X, Jiang N, Zhao Z, Wang Y, Xu S, Zhu L, Lau WY, Dai G, Liu R. Nab-paclitaxel plus S-1 with or without PD-1 inhibitor in pancreatic ductal adenocarcinoma with only hepatic metastases: a retrospective cohort study. Langenbecks Arch Surg 2021. [PMID: 34518900 DOI: 10.1007/s00423-021-02321-7] [Reference Citation Analysis]
412 Bispo M, Marques S, Rio-Tinto R, Fidalgo P, Devière J. The Role of Endoscopic Ultrasound in Pancreatic Cancer Staging in the Era of Neoadjuvant Therapy and Personalised Medicine. GE Port J Gastroenterol 2021;28:111-20. [PMID: 33791398 DOI: 10.1159/000509197] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
413 Mariette C, Brouquet A, Tzanis D, Laurenzi A, de la Rochefordière A, Mariani P, Piessen G, Sa Cunha A, Penna C. What is the impact of neoadjuvant chemoradiation on outcomes in gastro-intestinal cancer? Journal of Visceral Surgery 2017;154:185-95. [DOI: 10.1016/j.jviscsurg.2017.05.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
414 Smith LA, Jamieson NB, McKay CJ. Investigation and management of pancreatic tumours. Frontline Gastroenterol 2014;5:144-52. [PMID: 28839761 DOI: 10.1136/flgastro-2013-100364] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
415 Garrido-Laguna I, Hidalgo M. Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. Nat Rev Clin Oncol. 2015;12:319-334. [PMID: 25824606 DOI: 10.1038/nrclinonc.2015.53] [Cited by in Crossref: 350] [Cited by in F6Publishing: 325] [Article Influence: 50.0] [Reference Citation Analysis]
416 Xu CP, Xue XJ, Liang N, Xu DG, Liu FJ, Yu XS, Zhang JD. Effect of chemoradiotherapy and neoadjuvant chemoradiotherapy in resectable pancreatic cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 2014;140:549-559. [PMID: 24370686 DOI: 10.1007/s00432-013-1572-4] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 4.6] [Reference Citation Analysis]
417 Schizas D, Koumpoura A, Galari M, Economopoulou P, Vailas M, Sotiropoulou M, Dimitroulis D, Maroulis I, Felekouras E. A personalized approach to pancreatic ductal adenocarcinoma and its application in surgical practice. Per Med 2021;18:613-27. [PMID: 34676789 DOI: 10.2217/pme-2021-0031] [Reference Citation Analysis]
418 Neuzillet C, Sauvanet A, Hammel P. Prognostic factors for resectable pancreatic adenocarcinoma. Journal of Visceral Surgery 2011;148:e232-43. [DOI: 10.1016/j.jviscsurg.2011.07.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
419 Simionato F, Zecchetto C, Merz V, Cavaliere A, Casalino S, Gaule M, D'Onofrio M, Malleo G, Landoni L, Esposito A, Marchegiani G, Casetti L, Tuveri M, Paiella S, Scopelliti F, Giardino A, Frigerio I, Regi P, Capelli P, Gobbo S, Gabbrielli A, Bernardoni L, Fedele V, Rossi I, Piazzola C, Giacomazzi S, Pasquato M, Gianfortone M, Milleri S, Milella M, Butturini G, Salvia R, Bassi C, Melisi D. A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial. Ther Adv Med Oncol. 2020;12:1758835920947969. [PMID: 33403007 DOI: 10.1177/1758835920947969] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
420 Abe Y, Itano O, Kitago M, Shinoda M, Yagi H, Hibi T, Takano K, Chiba N, Kawachi S, Shimazu M, Kitagawa Y. Computer assisted surgery, preoperative planning and navigation for pancreatic cancer. J Hepatobiliary Pancreat Sci. 2014;21:251-255. [PMID: 24520054 DOI: 10.1002/jhbp.84] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
421 Neoptolemos JP, Kleeff J, Michl P, Costello E, Greenhalf W, Palmer DH. Therapeutic developments in pancreatic cancer: current and future perspectives. Nat Rev Gastroenterol Hepatol. 2018;15:333-348. [PMID: 29717230 DOI: 10.1038/s41575-018-0005-x] [Cited by in Crossref: 295] [Cited by in F6Publishing: 288] [Article Influence: 98.3] [Reference Citation Analysis]
422 Williet N, Di Bernardo T, Vernet C, Roche LS, Muron T, Roblin X, Magne N, Phelip JM. Intensification of induction chemotherapy before consolidation chemoradiotherapy improves progression-free survival and time without treatment in patients with locally advanced pancreatic cancers. Oncotarget 2018;9:31999-2009. [PMID: 30174792 DOI: 10.18632/oncotarget.25877] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
423 Yasuta S, Kobayashi T, Aizawa H, Takahashi S, Ikeda M, Konishi M, Kojima M, Kuno H, Uesaka K, Morinaga S, Miyamoto A, Toyama H, Takakura N, Sugimachi K, Takayama W. Relationship between surgical R0 resectability and findings of peripancreatic vascular invasion on CT imaging after neoadjuvant S-1 and concurrent radiotherapy in patients with borderline resectable pancreatic cancer. BMC Cancer. 2020;20:1184. [PMID: 33267820 DOI: 10.1186/s12885-020-07698-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
424 Dallongeville A, Corno L, Silvera S, Boulay-coletta I, Zins M. Initial Diagnosis and Staging of Pancreatic Cancer Including Main Differentials. Seminars in Ultrasound, CT and MRI 2019;40:436-68. [DOI: 10.1053/j.sult.2019.08.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
425 White RR, Lowy AM. Clinical Management: Resectable Disease. Cancer J 2017;23:343-9. [PMID: 29189330 DOI: 10.1097/PPO.0000000000000291] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
426 Wu J, Wang Y, Yang Y, Liu F, Jiang Z, Jiang Z. TNFSF9 promotes metastasis of pancreatic cancer by regulating M2 polarization of macrophages through Src/FAK/p-Akt/IL-1β signaling. Int Immunopharmacol 2022;102:108429. [PMID: 34906856 DOI: 10.1016/j.intimp.2021.108429] [Reference Citation Analysis]
427 Engebretson A, Matrisian L, Thompson C. Pancreatic cancer: Patient and caregiver perceptions on diagnosis, psychological impact, and importance of support. Pancreatology 2015;15:701-7. [PMID: 26092655 DOI: 10.1016/j.pan.2015.05.471] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
428 Sharma GG, Okada Y, Von Hoff D, Goel A. Non-coding RNA biomarkers in pancreatic ductal adenocarcinoma. Semin Cancer Biol 2020:S1044-579X(20)30204-2. [PMID: 33049362 DOI: 10.1016/j.semcancer.2020.10.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
429 Kwon J, Shin SH, Yoo D, Hong S, Lee JW, Youn WY, Hwang K, Lee SJ, Park G, Park Y, Lee W, Song KB, Lee JH, Hwang DW, Kim SC. Arterial resection during pancreatectomy for pancreatic ductal adenocarcinoma with arterial invasion: A single-center experience with 109 patients. Medicine (Baltimore) 2020;99:e22115. [PMID: 32925757 DOI: 10.1097/MD.0000000000022115] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
430 Andersson T, Falk K, Bjerså K, Forsberg A. Health Is Belonging: Lived Experiences during Recovery after Pancreaticoduodenectomy. ISRN Nurs 2012;2012:602323. [PMID: 23304548 DOI: 10.5402/2012/602323] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
431 D'Onofrio M, Crosara S, De Robertis R, Butturini G, Salvia R, Paiella S, Bassi C, Mucelli RP. Percutaneous Radiofrequency Ablation of Unresectable Locally Advanced Pancreatic Cancer: Preliminary Results. Technol Cancer Res Treat. 2017;16:285-294. [PMID: 27193941 DOI: 10.1177/1533034616649292] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
432 Huguet F, Mornex F, Orthuon A. [Radiation therapy of pancreatic cancer]. Cancer Radiother 2016;20 Suppl:S169-73. [PMID: 27523418 DOI: 10.1016/j.canrad.2016.07.036] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
433 van der Horst A, Versteijne E, Besselink MGH, Daams JG, Bulle EB, Bijlsma MF, Wilmink JW, van Delden OM, van Hooft JE, Franken NAP, van Laarhoven HWM, Crezee J, van Tienhoven G. The clinical benefit of hyperthermia in pancreatic cancer: a systematic review. Int J Hyperthermia 2018;34:969-79. [PMID: 29168401 DOI: 10.1080/02656736.2017.1401126] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
434 Lutfi W, Talamonti MS, Kantor O, Wang CH, Liederbach E, Stocker SJ, Bentrem DJ, Roggin KK, Winchester DJ, Marsh R. Perioperative chemotherapy is associated with a survival advantage in early stage adenocarcinoma of the pancreatic head. Surgery. 2016;160:714-724. [PMID: 27422328 DOI: 10.1016/j.surg.2016.05.029] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
435 Arscott WT, Nead KT, Bear A, Venigalla S, Shabason J, Lukens JN, Plastaras JP, Wojcieszynski A, Metz J, O'Hara M, Reiss KA, Teitelbaum U, Loaiza-Bonilla A, Drebin J, Lee MK 4th, Shroff SG, Ben-Josef E. Concurrent Nab-paclitaxel and Radiotherapy: Novel Radiosensitization for Borderline Resectable or Unresectable Pancreatic Cancer. Am J Clin Oncol 2021;44:469-74. [PMID: 34310350 DOI: 10.1097/COC.0000000000000854] [Reference Citation Analysis]
436 Zheng W, Skowron KB, Namm JP, Burnette B, Fernandez C, Arina A, Liang H, Spiotto MT, Posner MC, Fu YX, Weichselbaum RR. Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance. Oncotarget 2016;7:43039-51. [PMID: 27343548 DOI: 10.18632/oncotarget.9915] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 11.0] [Reference Citation Analysis]
437 Teo M, Crotty GF, O'Súilleabháin C, Ridgway PF, Conlon KC, Power DG, McDermott RS. Identification of distinct phenotypes of locally advanced pancreatic adenocarcinoma. J Gastrointest Cancer 2013;44:73-8. [PMID: 22829058 DOI: 10.1007/s12029-012-9419-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
438 Landau E, Kalnicki S. The Evolving Role of Radiation in Pancreatic Cancer. Surg Clin North Am 2018;98:113-25. [PMID: 29191268 DOI: 10.1016/j.suc.2017.09.008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
439 Belfiori G, Fiorentini G, Tamburrino D, Partelli S, Pagnanelli M, Gasparini G, Castoldi R, Balzano G, Rubini C, Zamboni G, Crippa S, Falconi M. Vascular resection during pancreatectomy for pancreatic head cancer: A technical issue or a prognostic sign? Surgery. 2021;169:403-410. [PMID: 32912782 DOI: 10.1016/j.surg.2020.08.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
440 Kim BR, Kim JH, Ahn SJ, Joo I, Choi SY, Park SJ, Han JK. CT prediction of resectability and prognosis in patients with pancreatic ductal adenocarcinoma after neoadjuvant treatment using image findings and texture analysis. Eur Radiol. 2019;29:362-372. [PMID: 29931561 DOI: 10.1007/s00330-018-5574-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
441 Wang Z, Qin J, Zhao J, Li J, Li D, Popp M, Popp F, Alakus H, Kong B, Dong Q, Nelson PJ, Zhao Y, Bruns CJ. Inflammatory IFIT3 renders chemotherapy resistance by regulating post-translational modification of VDAC2 in pancreatic cancer. Theranostics 2020;10:7178-92. [PMID: 32641986 DOI: 10.7150/thno.43093] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
442 Buckley AM, Lynam-Lennon N, O'Neill H, O'Sullivan J. Targeting hallmarks of cancer to enhance radiosensitivity in gastrointestinal cancers. Nat Rev Gastroenterol Hepatol 2020;17:298-313. [PMID: 32005946 DOI: 10.1038/s41575-019-0247-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 16.0] [Reference Citation Analysis]
443 Iovanna J, Mallmann MC, Gonçalves A, Turrini O, Dagorn JC. Current knowledge on pancreatic cancer. Front Oncol. 2012;2:6. [PMID: 22655256 DOI: 10.3389/fonc.2012.00006] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 4.5] [Reference Citation Analysis]
444 Janssen QP, Buettner S, Suker M, Beumer BR, Addeo P, Bachellier P, Bahary N, Bekaii-Saab T, Bali MA, Besselink MG, Boone BA, Chau I, Clarke S, Dillhoff M, El-Rayes BF, Frakes JM, Grose D, Hosein PJ, Jamieson NB, Javed AA, Khan K, Kim KP, Kim SC, Kim SS, Ko AH, Lacy J, Margonis GA, McCarter MD, McKay CJ, Mellon EA, Moorcraft SY, Okada KI, Paniccia A, Parikh PJ, Peters NA, Rabl H, Samra J, Tinchon C, van Tienhoven G, van Veldhuisen E, Wang-Gillam A, Weiss MJ, Wilmink JW, Yamaue H, Homs MYV, van Eijck CHJ, Katz MHG, Groot Koerkamp B. Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. J Natl Cancer Inst 2019;111:782-94. [PMID: 31086963 DOI: 10.1093/jnci/djz073] [Cited by in Crossref: 77] [Cited by in F6Publishing: 72] [Article Influence: 38.5] [Reference Citation Analysis]
445 Ye M, Zhang Q, Chen Y, Fu Q, Li X, Bai X, Liang T. Neoadjuvant chemotherapy for primary resectable pancreatic cancer: a systematic review and meta-analysis. HPB (Oxford) 2020;22:821-32. [PMID: 32001139 DOI: 10.1016/j.hpb.2020.01.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
446 Álvarez R, Alés I, Díaz R, de Paredes BG, Hidalgo M. Neoadjuvant treatment for borderline and resectable pancreatic ductal adenocarcinoma. Clin Transl Oncol 2017;19:1193-8. [PMID: 28612203 DOI: 10.1007/s12094-017-1680-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
447 Lin C, Hu Z, Yuan G, Su H, Zeng Y, Guo Z, Zhong F, Jiang K, He S. MicroRNA-1179 inhibits the proliferation, migration and invasion of human pancreatic cancer cells by targeting E2F5. Chemico-Biological Interactions 2018;291:65-71. [DOI: 10.1016/j.cbi.2018.05.017] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
448 Zimmermann C, Folprecht G, Zips D, Pilarsky C, Saeger HD, Grutzmann R. Neoadjuvant therapy in patients with pancreatic cancer: a disappointing therapeutic approach? Cancers (Basel) 2011;3:2286-301. [PMID: 24212810 DOI: 10.3390/cancers3022286] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
449 Artinyan A, Anaya DA, Mckenzie S, Ellenhorn JDI, Kim J. Neoadjuvant therapy is associated with improved survival in resectable pancreatic adenocarcinoma. Cancer 2011;117:2044-9. [DOI: 10.1002/cncr.25763] [Cited by in Crossref: 69] [Cited by in F6Publishing: 81] [Article Influence: 5.8] [Reference Citation Analysis]
450 Heinemann V, Haas M, Boeck S. Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer. Ann Oncol. 2013;24:2484-2492. [PMID: 23852311 DOI: 10.1093/annonc/mdt239] [Cited by in Crossref: 78] [Cited by in F6Publishing: 70] [Article Influence: 8.7] [Reference Citation Analysis]
451 Dobiasch S, Goerig NL, Fietkau R, Combs SE. Essential role of radiation therapy for the treatment of pancreatic cancer: Novel study concepts and established treatment recommendations. Strahlenther Onkol 2018;194:185-95. [DOI: 10.1007/s00066-017-1227-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 3.6] [Reference Citation Analysis]
452 De Lellis L, Veschi S, Tinari N, Mokini Z, Carradori S, Brocco D, Florio R, Grassadonia A, Cama A. Drug Repurposing, an Attractive Strategy in Pancreatic Cancer Treatment: Preclinical and Clinical Updates. Cancers (Basel) 2021;13:3946. [PMID: 34439102 DOI: 10.3390/cancers13163946] [Reference Citation Analysis]
453 Hammel P, Neuzillet C, Bendaoud S, Lekhal C, de Mestier L, Hentic O. Traitement médical du cancer du pancréas : en 10 ans, enfin des progrès. Bulletin du Cancer 2015;102:S62-71. [DOI: 10.1016/s0007-4551(15)31219-4] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
454 Atay S. Integrated transcriptome meta-analysis of pancreatic ductal adenocarcinoma and matched adjacent pancreatic tissues. PeerJ 2020;8:e10141. [PMID: 33194391 DOI: 10.7717/peerj.10141] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
455 de Geus SWL, Kasumova GG, Sachs TE, Ng SC, Kent TS, Moser AJ, Vahrmeijer AL, Callery MP, Tseng JF. Neoadjuvant therapy affects margins and margins affect all: perioperative and survival outcomes in resected pancreatic adenocarcinoma. HPB (Oxford) 2018;20:573-81. [PMID: 29426635 DOI: 10.1016/j.hpb.2017.12.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
456 Mu Y, Wang D, Bie L, Luo S, Mu X, Zhao Y. Glypican-1-targeted and gemcitabine-loaded liposomes enhance tumor-suppressing effect on pancreatic cancer. Aging (Albany NY) 2020;12:19585-96. [PMID: 33035197 DOI: 10.18632/aging.103918] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
457 Lutz MP, Zalcberg JR, Ducreux M, Aust D, Bruno MJ, Büchler MW, Delpero JR, Gloor B, Glynne-Jones R, Hartwig W, Huguet F, Laurent-Puig P, Lordick F, Maisonneuve P, Mayerle J, Martignoni M, Neoptolemos J, Rhim AD, Schmied BM, Seufferlein T, Werner J, van Laethem JL, Otto F. 3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer. Eur J Cancer 2017;79:41-9. [PMID: 28460245 DOI: 10.1016/j.ejca.2017.03.022] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 6.2] [Reference Citation Analysis]
458 Patel M, Hoffe S, Malafa M, Hodul P, Klapman J, Centeno B, Kim J, Helm J, Valone T, Springett G. Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer. J Surg Oncol 2011;104:155-61. [PMID: 21520097 DOI: 10.1002/jso.21954] [Cited by in Crossref: 72] [Cited by in F6Publishing: 66] [Article Influence: 6.5] [Reference Citation Analysis]
459 Abdel Mouti M, Pauklin S. TGFB1/INHBA Homodimer/Nodal-SMAD2/3 Signaling Network: A Pivotal Molecular Target in PDAC Treatment. Mol Ther 2021;29:920-36. [PMID: 33429081 DOI: 10.1016/j.ymthe.2021.01.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
460 Cassinotto C, Cortade J, Belleannée G, Lapuyade B, Terrebonne E, Vendrely V, Laurent C, Sa-Cunha A. An evaluation of the accuracy of CT when determining resectability of pancreatic head adenocarcinoma after neoadjuvant treatment. Eur J Radiol 2013;82:589-93. [PMID: 23287712 DOI: 10.1016/j.ejrad.2012.12.002] [Cited by in Crossref: 84] [Cited by in F6Publishing: 64] [Article Influence: 8.4] [Reference Citation Analysis]
461 Karanikas M, Esempidis A, Chasan ZT, Deftereou T, Antonopoulou M, Bozali F, Amarantidis K, Man YG. Pancreatic Cancer from Molecular Pathways to Treatment Opinion. J Cancer 2016;7:1328-39. [PMID: 27390608 DOI: 10.7150/jca.15419] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
462 Araujo RL, Gaujoux S, Huguet F, Gonen M, D'Angelica MI, DeMatteo RP, Fong Y, Kingham TP, Jarnagin WR, Goodman KA, Allen PJ. Does pre-operative chemoradiation for initially unresectable or borderline resectable pancreatic adenocarcinoma increase post-operative morbidity? A case-matched analysis. HPB (Oxford) 2013;15:574-80. [PMID: 23458208 DOI: 10.1111/hpb.12033] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
463 Sultana A, Cox T, Ghaneh P, Neoptolemos JP. Adjuvant therapy for pancreatic cancer. Recent Results Cancer Res. 2012;196:65-88. [PMID: 23129367 DOI: 10.1007/978-3-642-31629-6_5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
464 Hwang JW, Kim SC, Song KB, Yoon JH, Nam JS, Lee JH, Park KM, Lee YJ. Significance of radiologic location and extent of portal venous involvement on prognosis after resection for pancreatic adenocarcinoma. Pancreas 2015;44:665-71. [PMID: 25806602 DOI: 10.1097/MPA.0000000000000309] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
465 Awasthi N, Kronenberger D, Stefaniak A, Hassan MS, von Holzen U, Schwarz MA, Schwarz RE. Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical models of pancreatic cancer. Cancer Letters 2019;459:41-9. [DOI: 10.1016/j.canlet.2019.05.037] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
466 Torgeson A, Lloyd S, Boothe D, Tao R, Whisenant J, Garrido-laguna I, Cannon GM. Multiagent induction chemotherapy followed by chemoradiation is associated with improved survival in locally advanced pancreatic cancer: Radiation in Unresectable Pancreatic Ca. Cancer 2017;123:3816-24. [DOI: 10.1002/cncr.30780] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
467 Rammer M, Webersinke G, Haitchi-Petnehazy S, Maier E, Hackl H, Charoentong P, Malli T, Steinmair M, Petzer AL, Rumpold H. MicroRNAs and their role for T stage determination and lymph node metastasis in early colon carcinoma. Clin Exp Metastasis 2017;34:431-40. [PMID: 29134398 DOI: 10.1007/s10585-017-9863-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
468 Reilley MJ, Shroff R, Varadhachary GR. Adjuvant/Perioperative Therapy in Pancreatic and Periampullary Cancer. Indian J Surg 2015;77:403-8. [PMID: 26722204 DOI: 10.1007/s12262-015-1361-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
469 Dreher C, Habermehl D, Jäkel O, Combs SE. Effective radiotherapeutic treatment intensification in patients with pancreatic cancer: higher doses alone, higher RBE or both? Radiat Oncol 2017;12:203. [PMID: 29282139 DOI: 10.1186/s13014-017-0945-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
470 Scheufele F, Friess H. [Neoadjuvant treatment of primarily resectable and borderline resectable pancreatic cancer]. Chirurg 2020;91:391-5. [PMID: 31965198 DOI: 10.1007/s00104-019-01093-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
471 Russo S, Ammori J, Eads J, Dorth J. The role of neoadjuvant therapy in pancreatic cancer: a review. Future Oncol. 2016;12:669-685. [PMID: 26880384 DOI: 10.2217/fon.15.335] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
472 Kang H, Kim SS, Sung MJ, Jo JH, Lee HS, Chung MJ, Park JY, Park SW, Song SY, Park MS, Bang S. Radiographic portal or superior mesenteric vein invasion is an independent prognostic factor in non-metastatic pancreatic ductal adenocarcinoma: A missing block of clinical T staging? Pancreatology 2020;20:952-9. [PMID: 32561070 DOI: 10.1016/j.pan.2020.05.017] [Reference Citation Analysis]
473 Valeri S, Borzomati D, Nappo G, Perrone G, Santini D, Coppola R. Complete pathological response after FOLFIRINOX for locally advanced pancreatic cancer. The beginning of a new era? Case report and review of the literature. Pancreatology. 2014;14:425-430. [PMID: 25278312 DOI: 10.1016/j.pan.2014.07.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
474 Kosmidis C, Sapalidis K, Kotidis E, Mixalopoulos N, Zarogoulidis P, Tsavlis D, Baka S, Man YG, Kanellos J. Pancreatic cancer from bench to bedside: molecular pathways and treatment options. Ann Transl Med 2016;4:165. [PMID: 27275478 DOI: 10.21037/atm.2016.05.11] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
475 Katz MH, Landry J, Kindler HL. Current controversies in the stage-specific multidisciplinary management of pancreatic cancer. Am Soc Clin Oncol Educ Book. 2014;e157-e164. [PMID: 24857097 DOI: 10.14694/edbook_am.2014.34.e157] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
476 Kommalapati A, Tella SH, Goyal G, Ma WW, Mahipal A. Contemporary Management of Localized Resectable Pancreatic Cancer. Cancers (Basel) 2018;10:E24. [PMID: 29361690 DOI: 10.3390/cancers10010024] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
477 Chadha AS, Khoo A, Aliru ML, Arora HK, Gunther JR, Krishnan S. Recent Advances and Prospects for Multimodality Therapy in Pancreatic Cancer. Semin Radiat Oncol 2016;26:320-37. [PMID: 27619253 DOI: 10.1016/j.semradonc.2016.05.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
478 Harada K, Murayama Y, Kubo H, Matsuo H, Morimura R, Ikoma H, Fujiwara H, Okamoto K, Tanaka T, Otsuji E. Photodynamic diagnosis of peritoneal metastasis in human pancreatic cancer using 5-aminolevulinic acid during staging laparoscopy. Oncol Lett 2018;16:821-8. [PMID: 29963150 DOI: 10.3892/ol.2018.8732] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
479 Pan L, Fang J, Tong C, Chen M, Zhang B, Juengpanich S, Wang Y, Cai X. Survival benefits of neoadjuvant chemo(radio)therapy versus surgery first in patients with resectable or borderline resectable pancreatic cancer: a systematic review and meta-analysis. World J Surg Oncol. 2019;18:1. [PMID: 31892339 DOI: 10.1186/s12957-019-1767-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 6.7] [Reference Citation Analysis]
480 Abdkarimi S, Razi Soofiyani S, Elham G, Mashhadi Abdolahi H, Safarzadeh E, Baradaran B. Targeting immune checkpoints: Building better therapeutic puzzle in pancreatic cancer combination therapy. Eur J Cancer Care (Engl) 2020;29:e13268. [PMID: 32459388 DOI: 10.1111/ecc.13268] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
481 Kang WH, Yu YD, Yoon KC, Jo HS, Kim DS. Should we be reluctant to perform pancreatectomy in patients with chronic liver disease? A single center 10-year experience. Acta Chir Belg 2021;:1-7. [PMID: 34365897 DOI: 10.1080/00015458.2021.1963911] [Reference Citation Analysis]
482 Tol JA, Eshuis WJ, Besselink MG, van Gulik TM, Busch OR, Gouma DJ. Non-radical resection versus bypass procedure for pancreatic cancer - a consecutive series and systematic review. Eur J Surg Oncol 2015;41:220-7. [PMID: 25511567 DOI: 10.1016/j.ejso.2014.11.041] [Cited by in Crossref: 26] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
483 Baliyan V, Kordbacheh H, Parakh A, Kambadakone A. Response assessment in pancreatic ductal adenocarcinoma: role of imaging. Abdom Radiol (NY) 2018;43:435-44. [PMID: 29243123 DOI: 10.1007/s00261-017-1434-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
484 Jiang J, Liu R, Zhang Z, Zhang X, Qi R, Chen S, Zhang X, Xi Y, Guo Q, Zheng H, Hua B. Study on the treatment of pancreatic cancer with integrated traditional Chinese and Western medicine: A study protocol of a multicenter prospective cohort study. Medicine (Baltimore) 2019;98:e17975. [PMID: 31764804 DOI: 10.1097/MD.0000000000017975] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
485 Sudo K, Hara R, Nakamura K, Kita E, Tsujimoto A, Yamaguchi T. Phase II study of induction gemcitabine and S-1 followed by chemoradiotherapy and systemic chemotherapy using S-1 for locally advanced pancreatic cancer. Cancer Chemother Pharmacol 2017;80:195-202. [PMID: 28597040 DOI: 10.1007/s00280-017-3350-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
486 Wu Y, Lu ZP, Zhang JJ, Liu DF, Shi GD, Zhang C, Qin ZQ, Zhang JZ, He Y, Wu PF, Miao Y, Jiang KR. Association between ERCC2 Lys751Gln polymorphism and the risk of pancreatic cancer, especially among Asians: evidence from a meta-analysis. Oncotarget 2017;8:50124-32. [PMID: 28223548 DOI: 10.18632/oncotarget.15394] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
487 Ekici Y, Tezcaner T, Aydın HO, Boyvat F, Moray G. Arterial complication of irreversible electroporation procedure for locally advanced pancreatic cancer. World J Gastrointest Oncol 2016; 8(10): 751-756 [PMID: 27795815 DOI: 10.4251/wjgo.v8.i10.751] [Cited by in CrossRef: 3] [Article Influence: 0.5] [Reference Citation Analysis]
488 Hackert T, Ulrich A, Büchler MW. Can Neoadjuvant Therapy in Pancreatic Cancer Increase the Pool of Patients Eligible for Pancreaticoduodenectomy? Adv Surg 2017;51:1-10. [PMID: 28797331 DOI: 10.1016/j.yasu.2017.03.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
489 Kumar R, Jabbour SK. Neoadjuvant therapy for resectable and borderline resectable pancreatic cancer. J Radiat Oncol 2013;2:353-67. [DOI: 10.1007/s13566-013-0120-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
490 Jia S, Xu X, Zhou S, Chen Y, Ding G, Cao L. Fisetin induces autophagy in pancreatic cancer cells via endoplasmic reticulum stress- and mitochondrial stress-dependent pathways. Cell Death Dis 2019;10:142. [PMID: 30760707 DOI: 10.1038/s41419-019-1366-y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
491 Shridhar R, Takahashi C, Huston J, Meredith KL. Neoadjuvant therapy and pancreatic cancer: a national cancer database analysis. J Gastrointest Oncol 2019;10:663-73. [PMID: 31392047 DOI: 10.21037/jgo.2019.02.09] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
492 Mukherjee S, Symonds R. The Role of Radiotherapy in the Management of Upper Gastrointestinal and Hepato-biliary and Pancreatic Cancers: Current Status and Future Directions. Clinical Oncology 2014;26:519-21. [DOI: 10.1016/j.clon.2014.06.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
493 Ishido K, Kimura N, Wakiya T, Nagase H, Hara Y, Kanda T, Fujita H, Hakamada K. Development of a Biomarker-Based Scoring System Predicting Early Recurrence of Resectable Pancreatic Duct Adenocarcinoma. Ann Surg Oncol 2021. [PMID: 34608555 DOI: 10.1245/s10434-021-10866-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
494 Palmerini T, Benedetto U, Biondi-Zoccai G, Della Riva D, Bacchi-Reggiani L, Smits PC, Vlachojannis GJ, Jensen LO, Christiansen EH, Berencsi K. Long-Term Safety of Drug-Eluting and Bare-Metal Stents: Evidence From a Comprehensive Network Meta-Analysis. J Am Coll Cardiol. 2015;65:2496-2507. [PMID: 26065988 DOI: 10.1016/j.jacc.2015.04.017] [Cited by in Crossref: 294] [Cited by in F6Publishing: 227] [Article Influence: 42.0] [Reference Citation Analysis]
495 Xu X, Zhao Z, Guo S, Li J, Liu S, You Y, Ni B, Wang H, Bie P. Increased semaphorin 3c expression promotes tumor growth and metastasis in pancreatic ductal adenocarcinoma by activating the ERK1/2 signaling pathway. Cancer Lett 2017;397:12-22. [PMID: 28315433 DOI: 10.1016/j.canlet.2017.03.014] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
496 Weniger M, Moir J, Damm M, Maggino L, Kordes M, Rosendahl J, Ceyhan GO, Schorn S; RESPECT-study group. Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is feasible and lead to a similar oncological outcome compared to non-aged patients - Results of the RESPECT-Study. Surg Oncol 2020;35:285-97. [PMID: 32949968 DOI: 10.1016/j.suronc.2020.08.031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
497 Martin-Richard M, Ginès A, Ayuso JR, Sabater L, Fabregat J, Mendez R, Fernández-Esparrach G, Molero X, Vaquero EC, Cuatrecasas M, Ferrández A, Maurel J; Comité multidisciplinar para la actualización de las recomendaciones para el manejo de las lesiones pre-malignas y el adenocarcinoma de páncreas. [Recommendations for the diagnosis, staging and treatment of pre-malignant lesions and pancreatic adenocarcinoma]. Med Clin (Barc) 2016;147:465.e1-8. [PMID: 27726847 DOI: 10.1016/j.medcli.2016.07.033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
498 Palmerini T, Serruys P, Kappetein AP, Genereux P, Riva DD, Reggiani LB, Christiansen EH, Holm NR, Thuesen L, Makikallio T, Morice MC, Ahn J, Park S, Thiele H, Boudriot E, Sabatino M, Romanello M, Biondi-zoccai G, Cavalcante R, Sabik JF, Stone GW. Clinical outcomes with percutaneous coronary revascularization vs coronary artery bypass grafting surgery in patients with unprotected left main coronary artery disease: A meta-analysis of 6 randomized trials and 4,686 patients. American Heart Journal 2017;190:54-63. [DOI: 10.1016/j.ahj.2017.05.005] [Cited by in Crossref: 53] [Cited by in F6Publishing: 38] [Article Influence: 10.6] [Reference Citation Analysis]
499 Siqingaowa, Sekar S, Gopalakrishnan V, Taghibiglou C. Sterol regulatory element-binding protein 1 inhibitors decrease pancreatic cancer cell viability and proliferation. Biochem Biophys Res Commun 2017;488:136-40. [PMID: 28483521 DOI: 10.1016/j.bbrc.2017.05.023] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 6.4] [Reference Citation Analysis]
500 Maginn EN, de Sousa CH, Wasan HS, Stronach EA. Opportunities for translation: targeting DNA repair pathways in pancreatic cancer. Biochim Biophys Acta 2014;1846:45-54. [PMID: 24727386 DOI: 10.1016/j.bbcan.2014.04.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
501 Sugimoto M, Kobayashi T, Kobayashi S, Takahashi S, Konishi M, Mitsunaga S, Ikeda M, Gotohda N. Extrapancreatic Nerve Plexus Invasion on Imaging Predicts Poor Survival After Upfront Surgery for Anatomically Resectable Pancreatic Cancer. Pancreas 2020;49:675-82. [PMID: 32433406 DOI: 10.1097/MPA.0000000000001547] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
502 Tang K, Lu W, Qin W, Wu Y. Neoadjuvant therapy for patients with borderline resectable pancreatic cancer: A systematic review and meta-analysis of response and resection percentages. Pancreatology. 2016;16:28-37. [PMID: 26687001 DOI: 10.1016/j.pan.2015.11.007] [Cited by in Crossref: 89] [Cited by in F6Publishing: 79] [Article Influence: 12.7] [Reference Citation Analysis]
503 Yoshida A, Kitayama Y, Kiguchi K, Yamada T, Akasaka H, Sasaki R, Takeuchi T. Gold Nanoparticle-Incorporated Molecularly Imprinted Microgels as Radiation Sensitizers in Pancreatic Cancer. ACS Appl Bio Mater 2019;2:1177-83. [DOI: 10.1021/acsabm.8b00766] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
504 Furuhata A, Minamiguchi S, Shirahase H, Kodama Y, Adachi S, Sakurai T, Haga H. Immunohistochemical Antibody Panel for the Differential Diagnosis of Pancreatic Ductal Carcinoma From Gastrointestinal Contamination and Benign Pancreatic Duct Epithelium in Endoscopic Ultrasound-Guided Fine-Needle Aspiration. Pancreas. 2017;46:531-538. [PMID: 28099249 DOI: 10.1097/mpa.0000000000000774] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
505 Scopelliti F, Pea A, Conigliaro R, Butturini G, Frigerio I, Regi P, Giardino A, Bertani H, Paini M, Pederzoli P, Girelli R. Technique, safety, and feasibility of EUS-guided radiofrequency ablation in unresectable pancreatic cancer. Surg Endosc 2018;32:4022-8. [PMID: 29766302 DOI: 10.1007/s00464-018-6217-x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 20] [Article Influence: 10.3] [Reference Citation Analysis]
506 Shimura M, Mizuma M, Hayashi H, Mori A, Tachibana T, Hata T, Iseki M, Takadate T, Ariake K, Maeda S. A long-term survival case treated with conversion surgery following chemotherapy after diagnostic metastasectomy for pancreatic cancer with synchronous liver metastasis. Surg Case Rep. 2017;3:132. [PMID: 29285651 DOI: 10.1186/s40792-017-0409-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
507 Dávila Fajardo R, Lekkerkerker SJ, van der Horst A, Lens E, Bergman JJ, Fockens P, Bel A, van Hooft JE. EUS-guided fiducial markers placement with a 22-gauge needle for image-guided radiation therapy in pancreatic cancer. Gastrointest Endosc. 2014;79:851-855. [PMID: 24518121 DOI: 10.1016/j.gie.2013.12.027] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 5.0] [Reference Citation Analysis]
508 Chan G, Pua U. Irreversible Electroporation of the Pancreas. Semin Intervent Radiol 2019;36:213-20. [PMID: 31435129 DOI: 10.1055/s-0039-1693980] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
509 Zakem SJ, Mueller AC, Meguid C, Torphy RJ, Holt DE, Schefter T, Messersmith WA, McCarter MD, Del Chiaro M, Schulick RD, Goodman KA. Impact of neoadjuvant chemotherapy and stereotactic body radiation therapy (SBRT) on R0 resection rate for borderline resectable and locally advanced pancreatic cancer. HPB (Oxford) 2021;23:1072-83. [PMID: 33277184 DOI: 10.1016/j.hpb.2020.11.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
510 Buanes TA. Role of surgery in pancreatic cancer. World J Gastroenterol 2017; 23(21): 3765-3770 [PMID: 28638216 DOI: 10.3748/wjg.v23.i21.3765] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
511 O'Shea AE, Bohan PMK, Carpenter EL, McCarthy PM, Adams AM, Chick RC, Bader JO, Krell RW, Peoples GE, Clifton GT, Nelson DW, Vreeland TJ. Downstaging of Pancreatic Adenocarcinoma With Either Neoadjuvant Chemotherapy or Chemoradiotherapy Improves Survival. Ann Surg Oncol 2022. [PMID: 35583691 DOI: 10.1245/s10434-022-11800-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
512 Hackert T, Büchler MW, Werner J. Current state of surgical management of pancreatic cancer. Cancers (Basel). 2011;3:1253-1273. [PMID: 24212660 DOI: 10.3390/cancers3011253] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
513 Mitra A, Pai E, Dusane R, Ranganathan P, DeSouza A, Goel M, Shrikhande SV. Extended pancreatectomy as defined by the ISGPS: useful in selected cases of pancreatic cancer but invaluable in other complex pancreatic tumors. Langenbecks Arch Surg 2018;403:203-12. [PMID: 29362882 DOI: 10.1007/s00423-018-1653-6] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
514 Kaleağasıoğlu F, Berger MR. SIBLINGs and SPARC families: Their emerging roles in pancreatic cancer. World J Gastroenterol 2014; 20(40): 14747-14759 [PMID: 25356037 DOI: 10.3748/wjg.v20.i40.14747] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
515 O'Neill C, Hayat T, Hamm J, Healey M, Zheng Q, Li Y, Martin RCG 2nd. A phase 1b trial of concurrent immunotherapy and irreversible electroporation in the treatment of locally advanced pancreatic adenocarcinoma. Surgery 2020;168:610-6. [PMID: 32631655 DOI: 10.1016/j.surg.2020.04.057] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
516 Carrato A, Cerezo L, Feliu J, Macarulla T, Martín-Pérez E, Vera R, Álvarez J, Botella-Carretero JI. Clinical nutrition as part of the treatment pathway of pancreatic cancer patients: an expert consensus. Clin Transl Oncol 2021. [PMID: 34363594 DOI: 10.1007/s12094-021-02674-x] [Reference Citation Analysis]
517 Malouff TD, Krishnan S, Hallemeier CL, Haddock MG, Hoppe BS, Beltran C, Mahajan A, Trifiletti DM. Carbon Ion Radiotherapy in the Treatment of Pancreatic Cancer: A Review. Pancreas 2020;49:737-43. [PMID: 32590617 DOI: 10.1097/MPA.0000000000001566] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
518 Raufi AG, Manji GA, Chabot JA, Bates SE. Neoadjuvant Treatment for Pancreatic Cancer. Seminars in Oncology 2019;46:19-27. [DOI: 10.1053/j.seminoncol.2018.12.002] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 14.3] [Reference Citation Analysis]
519 Wei B, Wang C, Teng T, Guo P, Chen M, Xia F, Liu H, Xie J, Feng J, Huang H. Chemotherapeutic efficacy of cucurmosin for pancreatic cancer as an alternative of gemcitabine: a comparative metabolomic study. Gland Surg 2020;9:1428-42. [PMID: 33224818 DOI: 10.21037/gs-20-202] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
520 Habermehl D, Brecht IC, Bergmann F, Welzel T, Rieken S, Werner J, Schirmacher P, Büchler MW, Debus J, Combs SE. Chemoradiation in patients with isolated recurrent pancreatic cancer - therapeutical efficacy and probability of re-resection. Radiat Oncol 2013;8:27. [PMID: 23369246 DOI: 10.1186/1748-717X-8-27] [Cited by in Crossref: 36] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
521 Boone BA, Steve J, Krasinskas AM, Zureikat AH, Lembersky BC, Gibson MK, Stoller RG, Zeh HJ, Bahary N. Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer. J Surg Oncol. 2013;108:236-241. [PMID: 23955427 DOI: 10.1002/jso.23392] [Cited by in Crossref: 126] [Cited by in F6Publishing: 117] [Article Influence: 14.0] [Reference Citation Analysis]
522 Sudo K, Nakamura K, Yamaguchi T. S-1 in the treatment of pancreatic cancer. World J Gastroenterol 2014; 20(41): 15110-15118 [PMID: 25386059 DOI: 10.3748/wjg.v20.i41.15110] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 32] [Article Influence: 4.3] [Reference Citation Analysis]
523 Álamo JM, Marín LM, Suarez G, Bernal C, Serrano J, Barrera L, Gómez MA, Muntané J, Padillo FJ. Improving outcomes in pancreatic cancer: Key points in perioperative management. World J Gastroenterol 2014; 20(39): 14237-14245 [PMID: 25339810 DOI: 10.3748/wjg.v20.i39.14237] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
524 Yao L, Gu J, Mao Y, Zhang X, Wang X, Jin C, Fu D, Li J. Dynamic quantitative detection of ABC transporter family promoter methylation by MS-HRM for predicting MDR in pancreatic cancer. Oncol Lett 2018;15:5602-10. [PMID: 29552197 DOI: 10.3892/ol.2018.8041] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
525 Sakamoto T, Yagyu T, Uchinaka E, Miyatani K, Hanaki T, Kihara K, Matsunaga T, Yamamoto M, Tokuyasu N, Honjo S, Fujiwara Y. Sarcopenia as a prognostic factor in patients with recurrent pancreatic cancer: a retrospective study. World J Surg Oncol 2020;18:221. [PMID: 32828127 DOI: 10.1186/s12957-020-01981-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
526 Suzuki T, Mori S, Shimizu T, Tago K, Harada N, Park KH, Sakuraoka Y, Shiraki T, Iso Y, Aoki T, Kubota K. Clinical Significance of Neoadjuvant Chemotherapy With Gemcitabine Plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma. In Vivo 2019;33:2027-35. [PMID: 31662534 DOI: 10.21873/invivo.11700] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
527 Zaky AM, Wolfgang CL, Weiss MJ, Javed AA, Fishman EK, Zaheer A. Tumor-Vessel Relationships in Pancreatic Ductal Adenocarcinoma at Multidetector CT: Different Classification Systems and Their Influence on Treatment Planning. RadioGraphics 2017;37:93-112. [DOI: 10.1148/rg.2017160054] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 7.6] [Reference Citation Analysis]
528 Ma J, Sun D, Wang J, Han C, Qian Y, Chen G, Li X, Zhang J, Cui P, Du W, Wu Z, Chen S, Zheng X, Yue Z, Song J, Gao C, Cai S, Hu Y. Immune checkpoint inhibitors combined with chemotherapy for the treatment of advanced pancreatic cancer patients. Cancer Immunol Immunother 2020;69:365-72. [PMID: 31897660 DOI: 10.1007/s00262-019-02452-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
529 Herman JM, Wild AT, Wang H, Tran PT, Chang KJ, Taylor GE, Donehower RC, Pawlik TM, Ziegler MA, Cai H, Savage DT, Canto MI, Klapman J, Reid T, Shah RJ, Hoffe SE, Rosemurgy A, Wolfgang CL, Laheru DA. Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results. J Clin Oncol 2013;31:886-94. [PMID: 23341531 DOI: 10.1200/JCO.2012.44.7516] [Cited by in Crossref: 109] [Cited by in F6Publishing: 60] [Article Influence: 12.1] [Reference Citation Analysis]
530 Kim HJ, Park MS, Lee JY, Han K, Chung YE, Choi JY, Kim MJ, Kang CM. Incremental Role of Pancreatic Magnetic Resonance Imaging after Staging Computed Tomography to Evaluate Patients with Pancreatic Ductal Adenocarcinoma. Cancer Res Treat 2019;51:24-33. [PMID: 29397657 DOI: 10.4143/crt.2017.404] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
531 O’Reilly EM, Perelshteyn A, Jarnagin WR, Schattner M, Gerdes H, Capanu M, Tang LH, LaValle J, Winston C, DeMatteo RP. A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma. Ann Surg. 2014;260:142-148. [PMID: 24901360 DOI: 10.1097/sla.0000000000000251] [Cited by in Crossref: 92] [Cited by in F6Publishing: 39] [Article Influence: 11.5] [Reference Citation Analysis]
532 Sharma C, Eltawil KM, Renfrew PD, Walsh MJ, Molinari M. Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010. World J Gastroenterol 2011; 17(7): 867-897 [PMID: 21412497 DOI: 10.3748/wjg.v17.i7.867] [Cited by in CrossRef: 119] [Cited by in F6Publishing: 109] [Article Influence: 10.8] [Reference Citation Analysis]
533 Kumar N, Attri P, Dewilde S, Bogaerts A. Inactivation of human pancreatic ductal adenocarcinoma with atmospheric plasma treated media and water: a comparative study. J Phys D: Appl Phys 2018;51:255401. [DOI: 10.1088/1361-6463/aac571] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 4.3] [Reference Citation Analysis]
534 Berriochoa CA, Abdel-wahab M, Leyrer CM, Khorana A, Matthew Walsh R, Kumar AMS. Neoadjuvant chemoradiation for non-metastatic pancreatic cancer increases margin-negative and node-negative rates at resection: Neoadjuvant CRT for pancreatic cancer. Journal of Digestive Diseases 2017;18:642-9. [DOI: 10.1111/1751-2980.12551] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
535 Aaltonen P, Carpén O, Mustonen H, Puolakkainen P, Haglund C, Peltola K, Seppänen H. Long-term nationwide trends in the treatment of and outcomes among pancreatic cancer patients. Eur J Surg Oncol 2021:S0748-7983(21)00925-2. [PMID: 34844817 DOI: 10.1016/j.ejso.2021.11.116] [Reference Citation Analysis]
536 Adamska A, Domenichini A, Falasca M. Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies. Int J Mol Sci. 2017;18. [PMID: 28640192 DOI: 10.3390/ijms18071338] [Cited by in Crossref: 210] [Cited by in F6Publishing: 198] [Article Influence: 42.0] [Reference Citation Analysis]
537 Ibrahim AM, Wang YH. Viro-immune therapy: A new strategy for treatment of pancreatic cancer. World J Gastroenterol 2016; 22(2): 748-763 [PMID: 26811622 DOI: 10.3748/wjg.v22.i2.748] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
538 Zhong R, Farag MA, Chen M, He C, Xiao J. Recent advances in the biosynthesis, structure–activity relationships, formulations, pharmacology, and clinical trials of fisetin. eFood 2022;3. [DOI: 10.1002/efd2.3] [Reference Citation Analysis]
539 Fritz S, Sommer CM, Vollherbst D, Wachter MF, Longerich T, Sachsenmeier M, Knapp J, Radeleff BA, Werner J. Irreversible Electroporation of the Pancreas Is Feasible and Safe in a Porcine Survival Model. Pancreas 2015;44:791-8. [DOI: 10.1097/mpa.0000000000000331] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 2.4] [Reference Citation Analysis]
540 Jung J, Lee CH, Seol HS, Choi YS, Kim E, Lee EJ, Rhee JK, Singh SR, Jun ES, Han B, Hong SM, Kim SC, Chang S. Generation and molecular characterization of pancreatic cancer patient-derived xenografts reveals their heterologous nature. Oncotarget 2016;7:62533-46. [PMID: 27613834 DOI: 10.18632/oncotarget.11530] [Cited by in Crossref: 27] [Cited by in F6Publishing: 33] [Article Influence: 6.8] [Reference Citation Analysis]
541 Zhou C, Li H, Han X, Pang H, Wu M, Tang Y, Luo X. Prognostic Value and Molecular Mechanisms of Proteasome 26S Subunit, Non-ATPase Family Genes for Pancreatic Ductal Adenocarcinoma Patients after Pancreaticoduodenectomy. J Invest Surg 2021;:1-17. [PMID: 33525943 DOI: 10.1080/08941939.2020.1863527] [Reference Citation Analysis]
542 Elliott JT, Samkoe KS, Gunn JR, Stewart EE, Gardner TB, Tichauer KM, Lee TY, Hoopes PJ, Pereira SP, Hasan T, Pogue BW. Perfusion CT estimates photosensitizer uptake and biodistribution in a rabbit orthotopic pancreatic cancer model: a pilot study. Acad Radiol 2015;22:572-9. [PMID: 25683500 DOI: 10.1016/j.acra.2014.12.014] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
543 Oettle H. Progress in the knowledge and treatment of advanced pancreatic cancer: from benchside to bedside. Cancer Treat Rev. 2014;40:1039-1047. [PMID: 25087471 DOI: 10.1016/j.ctrv.2014.07.003] [Cited by in Crossref: 69] [Cited by in F6Publishing: 62] [Article Influence: 8.6] [Reference Citation Analysis]
544 Zhang LP, Ren H, Du YX, Zheng XH, Zhang ZM, Wang CF. Combination of preoperative fibrinogen and D-dimer as a prognostic indicator in pancreatic ductal adenocarcinoma patients undergoing R0 resection. World J Gastrointest Surg 2021;13:279-302. [PMID: 33796216 DOI: 10.4240/wjgs.v13.i3.279] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
545 Weledji EP, Enoworock G, Mokake M, Sinju M. How Grim is Pancreatic Cancer? Oncol Rev 2016;10:294. [PMID: 27471581 DOI: 10.4081/oncol.2016.294] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
546 Hayasaki A, Kishiwada M, Murata Y, Komatsubara H, Nakagawa Y, Maeda K, Shinkai T, Noguchi D, Gyoten K, Fujii T, Iizawa Y, Tanemura A, Kuriyama N, Sakurai H, Isaji S, Mizuno S. Phase I Study of Preoperative Chemoradiotherapy Using Gemcitabine Plus Nab-Paclitaxel for Patients Who Have Localized Pancreatic Ductal Adenocarcinoma With Contact or Invasion to Major Arteries. Pancreas 2021;50:1230-5. [PMID: 34714288 DOI: 10.1097/MPA.0000000000001902] [Reference Citation Analysis]
547 Motoi F, Unno M, Takahashi H, Okada T, Wada K, Sho M, Nagano H, Matsumoto I, Satoi S, Murakami Y, Kishiwada M, Honda G, Kinoshita H, Baba H, Hishinuma S, Kitago M, Tajima H, Shinchi H, Takamori H, Kosuge T, Yamaue H, Takada T. Influence of preoperative anti-cancer therapy on resectability and perioperative outcomes in patients with pancreatic cancer: project study by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci. 2014;21:148-158. [PMID: 23913634 DOI: 10.1002/jhbp.15] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 3.9] [Reference Citation Analysis]
548 Ning Z, Xie J, Chen Q, Zhang C, Xu L, Song L, Meng Z. HIFU is safe, effective, and feasible in pancreatic cancer patients: a monocentric retrospective study among 523 patients. Onco Targets Ther 2019;12:1021-9. [PMID: 30774386 DOI: 10.2147/OTT.S185424] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 4.3] [Reference Citation Analysis]
549 Huguet F, Mukherjee S, Javle M. Locally advanced pancreatic cancer: the role of definitive chemoradiotherapy. Clin Oncol (R Coll Radiol). 2014;26:560-568. [PMID: 25001636 DOI: 10.1016/j.clon.2014.06.002] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
550 Reni M, Zanon S, Balzano G, Passoni P, Pircher C, Chiaravalli M, Fugazza C, Ceraulo D, Nicoletti R, Arcidiacono PG, Macchini M, Peretti U, Castoldi R, Doglioni C, Falconi M, Partelli S, Gianni L. A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma. European Journal of Cancer 2018;102:95-102. [DOI: 10.1016/j.ejca.2018.07.007] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 5.5] [Reference Citation Analysis]
551 Singh A, Xu J, Mattheolabakis G, Amiji M. EGFR-targeted gelatin nanoparticles for systemic administration of gemcitabine in an orthotopic pancreatic cancer model. Nanomedicine 2016;12:589-600. [PMID: 26656632 DOI: 10.1016/j.nano.2015.11.010] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
552 Rose JB, Edwards AM, Rocha FG, Clark C, Alseidi AA, Biehl TR, Lin BS, Picozzi VJ, Helton WS. Sustained Carbohydrate Antigen 19-9 Response to Neoadjuvant Chemotherapy in Borderline Resectable Pancreatic Cancer Predicts Progression and Survival. Oncologist. 2020;25:859-866. [PMID: 32277842 DOI: 10.1634/theoncologist.2019-0878] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
553 Ding G, Xu X, Li D, Chen Y, Wang W, Ping D, Jia S, Cao L. Fisetin inhibits proliferation of pancreatic adenocarcinoma by inducing DNA damage via RFXAP/KDM4A-dependent histone H3K36 demethylation. Cell Death Dis 2020;11:893. [PMID: 33093461 DOI: 10.1038/s41419-020-03019-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
554 Distler M, Grützmann R. [New aspects of surgery for pancreatic cancer. Principles, results and evidence]. Pathologe 2012;33 Suppl 2:258-65. [PMID: 23108784 DOI: 10.1007/s00292-012-1639-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
555 Fujii T, Satoi S, Yamada S, Murotani K, Yanagimoto H, Takami H, Yamamoto T, Kanda M, Yamaki S, Hirooka S, Kon M, Kodera Y. Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head: an observational study using inverse probability of treatment weighting. J Gastroenterol 2017;52:81-93. [PMID: 27169844 DOI: 10.1007/s00535-016-1217-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
556 Chung SY, Chang JS, Lee BM, Kim KH, Lee KJ, Seong J. Dose escalation in locally advanced pancreatic cancer patients receiving chemoradiotherapy. Radiother Oncol 2017;123:438-45. [PMID: 28464997 DOI: 10.1016/j.radonc.2017.04.010] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 5.2] [Reference Citation Analysis]
557 Holyoake DLP, Robinson M, Silva M, Grose D, McIntosh D, Sebag-Montefiore D, Radhakrishna G, Mukherjee S, Hawkins MA. SPARC, a phase-I trial of pre-operative, margin intensified, stereotactic body radiation therapy for pancreatic cancer. Radiother Oncol 2021;155:278-84. [PMID: 33217498 DOI: 10.1016/j.radonc.2020.11.007] [Reference Citation Analysis]
558 Vitolo V, Cobianchi L, Brugnatelli S, Barcellini A, Peloso A, Facoetti A, Vanoli A, Delfanti S, Preda L, Molinelli S, Klersy C, Fossati P, Orecchia R, Valvo F. Preoperative chemotherapy and carbon ions therapy for treatment of resectable and borderline resectable pancreatic adenocarcinoma: a prospective, phase II, multicentre, single-arm study. BMC Cancer 2019;19:922. [PMID: 31521134 DOI: 10.1186/s12885-019-6108-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
559 Zhang M, Di CY, Guo P, Meng LB, Shan MJ, Qiu Y, Guo PY, Dong KQ, Xie Q, Wang Q. Screening and Identification of Key Biomarkers in Pancreatic Cancer: Evidence from Bioinformatic Analysis. J Comput Biol 2020;27:1079-91. [PMID: 31638423 DOI: 10.1089/cmb.2019.0189] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
560 Pai RK, Pai RK. Pathologic assessment of gastrointestinal tract and pancreatic carcinoma after neoadjuvant therapy. Mod Pathol 2018;31:4-23. [DOI: 10.1038/modpathol.2017.87] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
561 Seufferlein T, Ettrich TJ. Treatment of pancreatic cancer-neoadjuvant treatment in resectable pancreatic cancer (PDAC). Transl Gastroenterol Hepatol 2019;4:21. [PMID: 30976724 DOI: 10.21037/tgh.2019.03.05] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 7.7] [Reference Citation Analysis]
562 Smith JK, Chu QD, Tseng JF. Pancreatic Adenocarcinoma. In: Chu QD, Gibbs JF, Zibari GB, editors. Surgical Oncology. New York: Springer; 2015. pp. 283-313. [DOI: 10.1007/978-1-4939-1423-4_13] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
563 Laurence JM, Tran PD, Morarji K, Eslick GD, Lam VW, Sandroussi C. A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer. J Gastrointest Surg. 2011;15:2059-2069. [PMID: 21913045 DOI: 10.1007/s11605-011-1659-] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
564 de W Marsh R, Talamonti MS, Baker MS, Posner M, Roggin K, Matthews J, Catenacci D, Kozloff M, Polite B, Britto M, Wang C, Kindler H. Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study. J Surg Oncol 2018;117:354-62. [PMID: 29044544 DOI: 10.1002/jso.24872] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
565 Liu S, Zhang W, Liu K, Liu Y. LncRNA SNHG16 promotes tumor growth of pancreatic cancer by targeting miR-218-5p. Biomed Pharmacother 2019;114:108862. [PMID: 30981105 DOI: 10.1016/j.biopha.2019.108862] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 10.0] [Reference Citation Analysis]
566 Dreher C, Habermehl D, Ecker S, Brons S, El-Shafie R, Jäkel O, Debus J, Combs SE. Optimization of carbon ion and proton treatment plans using the raster-scanning technique for patients with unresectable pancreatic cancer. Radiat Oncol 2015;10:237. [PMID: 26590103 DOI: 10.1186/s13014-015-0538-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
567 Feng Z, Qian H, Li K, Lou J, Wu Y, Peng C. Development and Validation of a 7-Gene Prognostic Signature to Improve Survival Prediction in Pancreatic Ductal Adenocarcinoma. Front Mol Biosci 2021;8:676291. [PMID: 34095229 DOI: 10.3389/fmolb.2021.676291] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
568 Weniger M, Moir J, Damm M, Maggino L, Kordes M, Rosendahl J, Ceyhan GO, Schorn S;  RESPECT-study group. Respect - A multicenter retrospective study on preoperative chemotherapy in locally advanced and borderline resectable pancreatic cancer. Pancreatology. 2020;20:1131-1138. [PMID: 32739267 DOI: 10.1016/j.pan.2020.06.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
569 He YM, Xiao YS, Wei L, Zhang JQ, Peng CH. CUL4B promotes metastasis and proliferation in pancreatic cancer cells by inducing epithelial-mesenchymal transition via the Wnt/β-catenin signaling pathway. J Cell Biochem 2018;119:5308-23. [PMID: 29274277 DOI: 10.1002/jcb.26643] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
570 Matsumura K, Hayashi H, Uemura N, Zhao L, Higashi T, Yamao T, Kitamura F, Nakao Y, Yusa T, Itoyama R, Imai K, Yamashita YI, Baba H. Prognostic Impact of Coagulation Activity in Patients Undergoing Curative Resection for Pancreatic Ductal Adenocarcinoma. In Vivo 2020;34:2845-50. [PMID: 32871823 DOI: 10.21873/invivo.12111] [Reference Citation Analysis]
571 Kim KH, Hwang HK, Kang IC, Lee WJ, Kang CM. Oncologic impact of preoperative prognostic nutritional index change in resected pancreatic cancer following neoadjuvant chemotherapy. Pancreatology 2020;20:247-53. [PMID: 31889624 DOI: 10.1016/j.pan.2019.12.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
572 Tomihara H, Eguchi H, Yamada D, Gotoh K, Kawamoto K, Wada H, Asaoka T, Noda T, Takeda Y, Tanemura M, Mori M, Doki Y. Preoperative chemoradiotherapy does not compromise the feasibility of adjuvant chemotherapy for patients with pancreatic ductal adenocarcinoma. Surg Today 2017;47:218-26. [PMID: 27586014 DOI: 10.1007/s00595-016-1405-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
573 Shinoto M, Yamada S, Yasuda S, Imada H, Shioyama Y, Honda H, Kamada T, Tsujii H, Saisho H. Phase 1 trial of preoperative, short-course carbon-ion radiotherapy for patients with resectable pancreatic cancer. Cancer. 2013;119:45-51. [PMID: 22744973 DOI: 10.1002/cncr.27723] [Cited by in Crossref: 65] [Cited by in F6Publishing: 60] [Article Influence: 6.5] [Reference Citation Analysis]
574 Huang ZS, Yu CH. Choosing the appropriate strategy in managing malignant biliary obstruction. Shijie Huaren Xiaohua Zazhi 2015; 23(34): 5485-5492 [DOI: 10.11569/wcjd.v23.i34.5485] [Reference Citation Analysis]
575 Akahori T, Sho M, Kinoshita S, Nagai M, Nishiwada S, Tanaka T, Tamamoto T, Ohbayashi C, Hasegawa M, Kichikawa K, Nakajima Y. Prognostic Significance of Muscle Attenuation in Pancreatic Cancer Patients Treated with Neoadjuvant Chemoradiotherapy. World J Surg 2015;39:2975-82. [PMID: 26296840 DOI: 10.1007/s00268-015-3205-3] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 4.8] [Reference Citation Analysis]
576 Thomas TO, Small W Jr, Fleming M, Kang S, Hoefer RA. Intraoperative Radiation "Boost" to the Surgical Resection Bed following Pancreaticoduodenectomy for a Borderline Resectable Pancreatic Carcinoma: A Case Report. Front Oncol 2018;8:12. [PMID: 29629335 DOI: 10.3389/fonc.2018.00012] [Reference Citation Analysis]
577 Franke AJ, Rosati LM, Pawlik TM, Kumar R, Herman JM. The role of radiation therapy in pancreatic ductal adenocarcinoma in the neoadjuvant and adjuvant settings. Semin Oncol. 2015;42:144-162. [PMID: 25726059 DOI: 10.1053/j.seminoncol.2014.12.013] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
578 Habermehl D, Kessel K, Welzel T, Hof H, Abdollahi A, Bergmann F, Rieken S, Weitz J, Werner J, Schirmacher P. Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer. Radiat Oncol. 2012;7:28. [PMID: 22385572 DOI: 10.1186/1748-717x-7-28] [Cited by in Crossref: 67] [Cited by in F6Publishing: 34] [Article Influence: 6.7] [Reference Citation Analysis]
579 Shen YN, Guo CX, Pan Y, Chen YW, Tang TY, Li YW, Lu JH, Jin G, Qin RY, Yao WY, Liang TB, Bai XL. Preoperative prediction of peripancreatic vein invasion by pancreatic head cancer. Cancer Imaging 2018;18:49. [PMID: 30526690 DOI: 10.1186/s40644-018-0179-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
580 Gangl O, Sahora K, Kornprat P, Margreiter C, Primavesi F, Bareck E, Schindl M, Längle F, Öfner D, Mischinger H, Pratschke J, Gnant M, Függer R. Preparing for Prospective Clinical Trials: A National Initiative of an Excellence Registry for Consecutive Pancreatic Cancer Resections. World J Surg 2014;38:456-62. [DOI: 10.1007/s00268-013-2283-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
581 Hackert T. Surgery for Pancreatic Cancer after neoadjuvant treatment. Ann Gastroenterol Surg 2018;2:413-8. [PMID: 30460344 DOI: 10.1002/ags3.12203] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
582 Takeda Y, Nakamori S, Eguchi H, Kobayashi S, Marubashi S, Tanemura M, Konishi K, Yoshioka Y, Umeshita K, Mori M. Neoadjuvant gemcitabine-based accelerated hyperfractionation chemoradiotherapy for patients with borderline resectable pancreatic adenocarcinoma. Jpn J Clin Oncol. 2014;44:1172-1180. [PMID: 25425728 DOI: 10.1093/jjco/hyu143] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
583 Dudekula A, Munigala S, Zureikat AH, Yadav D. Operative Trends for Pancreatic Diseases in the USA: Analysis of the Nationwide Inpatient Sample from 1998-2011. J Gastrointest Surg 2016;20:803-11. [PMID: 26791389 DOI: 10.1007/s11605-015-3067-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
584 Guo X, Ling X, Du F, Wang Q, Huang W, Wang Z, Ding X, Bai M, Wu Z. Molecular Imaging of Pancreatic Duct Adenocarcinoma Using a Type 2 Cannabinoid Receptor-Targeted Near-Infrared Fluorescent Probe. Transl Oncol 2018;11:1065-73. [PMID: 30005208 DOI: 10.1016/j.tranon.2018.06.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
585 Cid-Arregui A, Juarez V. Perspectives in the treatment of pancreatic adenocarcinoma. World J Gastroenterol 2015; 21(31): 9297-9316 [PMID: 26309356 DOI: 10.3748/wjg.v21.i31.9297] [Cited by in CrossRef: 83] [Cited by in F6Publishing: 74] [Article Influence: 11.9] [Reference Citation Analysis]
586 Mornex F, Hatime M, Touch S, Elmorabit B, Pigne G, Enachescu C, Diaz O, Elkhoti Y. Radiotherapy of the pancreas: state of the art in 2012. Recent Results Cancer Res 2012;196:89-103. [PMID: 23129368 DOI: 10.1007/978-3-642-31629-6_6] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
587 Rodarte-shade M, Kahaleh M. Stent placement as a bridge to surgery in malignant biliary obstruction (pancreatic cancer, distal bile duct cancer, and hilar tumors). Gastrointestinal Intervention 2015;4:21-6. [DOI: 10.1016/j.gii.2015.02.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
588 Hidalgo M, Cascinu S, Kleeff J, Labianca R, Löhr JM, Neoptolemos J, Real FX, Van Laethem JL, Heinemann V. Addressing the challenges of pancreatic cancer: future directions for improving outcomes. Pancreatology. 2013;15:8-18. [PMID: 25547205 DOI: 10.1016/j.pan.2014.10.001] [Cited by in Crossref: 222] [Cited by in F6Publishing: 222] [Article Influence: 27.8] [Reference Citation Analysis]
589 Vogel JA, Rombouts SJ, de Rooij T, van Delden OM, Dijkgraaf MG, van Gulik TM, van Hooft JE, van Laarhoven HW, Martin RC, Schoorlemmer A, Wilmink JW, van Lienden KP, Busch OR, Besselink MG. Induction Chemotherapy Followed by Resection or Irreversible Electroporation in Locally Advanced Pancreatic Cancer (IMPALA): A Prospective Cohort Study. Ann Surg Oncol. 2017;24:2734-2743. [PMID: 28560601 DOI: 10.1245/s10434-017-5900-9] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 10.2] [Reference Citation Analysis]
590 Blair AB, Rosati LM, Rezaee N, Gemenetzis G, Zheng L, Hruban RH, Cameron JL, Weiss MJ, Wolfgang CL, Herman JM, He J. Postoperative complications after resection of borderline resectable and locally advanced pancreatic cancer: The impact of neoadjuvant chemotherapy with conventional radiation or stereotactic body radiation therapy. Surgery. 2018;163:1090-1096. [PMID: 29395234 DOI: 10.1016/j.surg.2017.11.027] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
591 Marthey L, Sa-Cunha A, Blanc JF, Gauthier M, Cueff A, Francois E, Trouilloud I, Malka D, Bachet JB, Coriat R. FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort. Ann Surg Oncol. 2015;22:295-301. [PMID: 25037971 DOI: 10.1245/s10434-014-3898-9] [Cited by in Crossref: 101] [Cited by in F6Publishing: 99] [Article Influence: 12.6] [Reference Citation Analysis]
592 Satoi S, Yamaue H, Kato K, Takahashi S, Hirono S, Takeda S, Eguchi H, Sho M, Wada K, Shinchi H, Kwon AH, Hirano S, Kinoshita T, Nakao A, Nagano H, Nakajima Y, Sano K, Miyazaki M, Takada T. Role of adjuvant surgery for patients with initially unresectable pancreatic cancer with a long-term favorable response to non-surgical anti-cancer treatments: results of a project study for pancreatic surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci 2013;20:590-600. [PMID: 23660962 DOI: 10.1007/s00534-013-0616-0] [Cited by in Crossref: 101] [Cited by in F6Publishing: 77] [Article Influence: 16.8] [Reference Citation Analysis]
593 Liermann J, Naumann P, Fortunato F, Schmid TE, Weber KJ, Debus J, Combs SE. Phytotherapeutics Oridonin and Ponicidin show Additive Effects Combined with Irradiation in Pancreatic Cancer in Vitro. Radiol Oncol 2017;51:407-14. [PMID: 29333119 DOI: 10.1515/raon-2017-0048] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
594 Frick MA, Vachani CC, Hampshire MK, Bach C, Arnold-Korzeniowski K, Metz JM, Hill-Kayser CE. Survivorship after treatment of pancreatic cancer: insights via an Internet-based survivorship care plan tool. J Gastrointest Oncol 2017;8:890-6. [PMID: 29184694 DOI: 10.21037/jgo.2017.08.07] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
595 Brunner TB, Sauer R, Fietkau R. Gemcitabine/cisplatin versus 5-fluorouracil/mitomycin C chemoradiotherapy in locally advanced pancreatic cancer: a retrospective analysis of 93 patients. Radiat Oncol 2011;6:88. [PMID: 21794119 DOI: 10.1186/1748-717X-6-88] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
596 Grose D, McIntosh D, Jamieson N, Carter R, Dickson E, Chang D, Marashi H, Wilson C, Alfayez M, Kerr A, O'Donoghue R, Haskins L, Duthie F, McKay CJ, Graham J. The role of induction chemotherapy + chemoradiotherapy in localised pancreatic cancer: initial experience in Scotland. J Gastrointest Oncol 2017;8:683-95. [PMID: 28890819 DOI: 10.21037/jgo.2017.04.01] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
597 Balaban EP, Mangu PB, Khorana AA, Shah MA, Mukherjee S, Crane CH, Javle MM, Eads JR, Allen P, Ko AH, Engebretson A, Herman JM, Strickler JH, Benson AB, Urba S, Yee NS. Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34:2654-2668. [PMID: 27247216 DOI: 10.1200/jco.2016.67.5561] [Cited by in Crossref: 190] [Cited by in F6Publishing: 90] [Article Influence: 31.7] [Reference Citation Analysis]
598 Yu J, Ploner A, Kordes M, Löhr M, Nilsson M, de Maturana MEL, Estudillo L, Renz H, Carrato A, Molero X, Real FX, Malats N, Ye W. Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinoma. Int J Cancer 2021;148:2048-58. [PMID: 33411965 DOI: 10.1002/ijc.33464] [Reference Citation Analysis]
599 Alizadeh Savareh B, Asadzadeh Aghdaie H, Behmanesh A, Bashiri A, Sadeghi A, Zali M, Shams R. A machine learning approach identified a diagnostic model for pancreatic cancer through using circulating microRNA signatures. Pancreatology. 2020;20:1195-1204. [PMID: 32800647 DOI: 10.1016/j.pan.2020.07.399] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
600 Guo XY, Xiao F, Li J, Zhou YN, Zhang WJ, Sun B, Wang G. Exosomes and pancreatic diseases: status, challenges, and hopes. Int J Biol Sci 2019;15:1846-60. [PMID: 31523187 DOI: 10.7150/ijbs.35823] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
601 Ingram MA, Lauren BN, Pumpalova Y, Park J, Lim F, Bates SE, Kastrinos F, Manji GA, Kong CY, Hur C. Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in borderline resectable/locally advanced pancreatic cancer patients. Cancer Rep (Hoboken) 2022;:e1565. [PMID: 35122419 DOI: 10.1002/cnr2.1565] [Reference Citation Analysis]
602 Tomimaru Y, Eguchi H, Satoh T, Tomokuni A, Asaoka T, Wada H, Marubashi S, Ogawa K, Takehara T, Mori M, Doki Y, Nagano H. Feasibility of pre-operative chemoradiotherapy with gemcitabine to treat pancreatic cancer in patients with impaired renal function. Jpn J Clin Oncol 2015;45:343-8. [PMID: 25589454 DOI: 10.1093/jjco/hyu224] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
603 Kim SY, Fink MA, Perini M, Houli N, Weinberg L, Muralidharan V, Starkey G, Jones RM, Christophi C, Nikfarjam M. Age 80 years and over is not associated with increased morbidity and mortality following pancreaticoduodenectomy: Pancreaticoduodenectomy in the elderly. ANZ J Surg 2018;88:E445-50. [DOI: 10.1111/ans.14039] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
604 Rykina-Tameeva N, Nahm CB, Mehta S, Gill AJ, Samra JS, Mittal A. Neoadjuvant therapy for pancreatic cancer changes the composition of the pancreatic parenchyma. HPB (Oxford) 2020;22:1631-6. [PMID: 32247587 DOI: 10.1016/j.hpb.2020.03.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
605 Zhang Q, Xia F, Sun Q, Cao W, Mo A, He W, Chen J, Zhang W, Chen W. Recurrence and Prognostic Value of Circulating Tumor Cells in Resectable Pancreatic Head Cancer: A Single Center Retrospective Study. Front Surg 2022;9:832125. [DOI: 10.3389/fsurg.2022.832125] [Reference Citation Analysis]
606 Satoi S, Toyokawa H, Yanagimoto H, Yamamoto T, Kamata M, Ohe C, Sakaida N, Uemura Y, Kitade H, Tanigawa N, Inoue K, Matsui Y, Kwon AH. Neo-adjuvant chemoradiation therapy using S-1 followed by surgical resection in patients with pancreatic cancer. J Gastrointest Surg. 2012;16:784-792. [PMID: 22160780 DOI: 10.1007/s11605-011-1795-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
607 Zhang C, Wu R, Smith LM, Baine M, Lin C, Reames BN. An evaluation of adjuvant chemotherapy following neoadjuvant chemotherapy and resection for borderline resectable and locally advanced pancreatic cancer. The American Journal of Surgery 2021. [DOI: 10.1016/j.amjsurg.2021.12.018] [Reference Citation Analysis]
608 Sen N, Falk S, Abrams R. Role of Chemoradiotherapy in the Adjuvant and Neoadjuvant Settings for Resectable Pancreatic Cancer. Clinical Oncology 2014;26:551-9. [DOI: 10.1016/j.clon.2014.06.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
609 Dhir M, Malhotra GK, Sohal DPS, Hein NA, Smith LM, O'Reilly EM, Bahary N, Are C. Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients. World J Surg Oncol. 2017;15:183. [PMID: 29017581 DOI: 10.1186/s12957-017-1240-2] [Cited by in Crossref: 65] [Cited by in F6Publishing: 57] [Article Influence: 13.0] [Reference Citation Analysis]
610 Choi YJ, Byun Y, Kang JS, Kim HS, Han Y, Kim H, Kwon W, Oh DY, Paik WH, Lee SH, Ryu JK, Kim YT, Lee K, Chie EK, Jang JY. Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX. Gut Liver. 2020;. [PMID: 32839360 DOI: 10.5009/gnl20070] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
611 Gong J, Tuli R, Shinde A, Hendifar AE. Meta-analyses of treatment standards for pancreatic cancer. Mol Clin Oncol 2016;4:315-25. [PMID: 26998283 DOI: 10.3892/mco.2015.716] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
612 Meijer LL, Garajová I, Caparello C, Le Large TYS, Frampton AE, Vasile E, Funel N, Kazemier G, Giovannetti E. Plasma miR-181a-5p Downregulation Predicts Response and Improved Survival After FOLFIRINOX in Pancreatic Ductal Adenocarcinoma. Ann Surg 2020;271:1137-47. [PMID: 30394883 DOI: 10.1097/SLA.0000000000003084] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
613 Jang J, Han Y, Lee H, Kim S, Kwon W, Lee K, Oh D, Chie EK, Lee JM, Heo JS, Park JO, Lim DH, Kim SH, Park SJ, Lee WJ, Koh YH, Park JS, Yoon DS, Lee IJ, Choi SH. Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial. Annals of Surgery 2018;268:215-22. [DOI: 10.1097/sla.0000000000002705] [Cited by in Crossref: 205] [Cited by in F6Publishing: 98] [Article Influence: 51.3] [Reference Citation Analysis]
614 Matsumoto T, Kubota K, Aoki T, Shimizu T, Mori S, Kato M, Asato H. A Novel Approach for Hepatic Arterial Reconstruction after Total Pancreatectomy with Common Hepatic Artery Resection Using Inferior Phrenic Artery. Dig Surg 2019;36:99-103. [PMID: 29414805 DOI: 10.1159/000486630] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
615 Yoshitomi H, Takano S, Furukawa K, Takayashiki T, Kuboki S, Ohtsuka M. Conversion surgery for initially unresectable pancreatic cancer: current status and unresolved issues. Surg Today 2019;49:894-906. [PMID: 30949842 DOI: 10.1007/s00595-019-01804-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
616 Abbott DE, Tzeng CW, Merkow RP, Cantor SB, Chang GJ, Katz MH, Bentrem DJ, Bilimoria KY, Crane CH, Varadhachary GR, Abbruzzese JL, Wolff RA, Lee JE, Evans DB, Fleming JB. The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma. Ann Surg Oncol. 2013;20 Suppl 3:S500-S508. [PMID: 23397153 DOI: 10.1245/s10434-013-2882-0] [Cited by in Crossref: 53] [Cited by in F6Publishing: 45] [Article Influence: 5.9] [Reference Citation Analysis]
617 Kurata Y, Shiraki T, Ichinose M, Kubota K, Imai Y. Effect and limitation of neoadjuvant chemotherapy for pancreatic ductal adenocarcinoma: consideration from a new perspective. World J Surg Oncol 2021;19:85. [PMID: 33752677 DOI: 10.1186/s12957-021-02192-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
618 Huart C, Chen JW, Le Calvé B, Michiels C, Wéra AC. Could Protons and Carbon Ions Be the Silver Bullets Against Pancreatic Cancer? Int J Mol Sci 2020;21:E4767. [PMID: 32635552 DOI: 10.3390/ijms21134767] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
619 Werner J, Combs SE, Springfeld C, Hartwig W, Hackert T, Büchler MW. Advanced-stage pancreatic cancer: therapy options. Nat Rev Clin Oncol. 2013;10:323-333. [PMID: 23629472 DOI: 10.1038/nrclinonc.2013.66] [Cited by in Crossref: 133] [Cited by in F6Publishing: 124] [Article Influence: 14.8] [Reference Citation Analysis]
620 He J, Blair AB, Groot VP, Javed AA, Burkhart RA, Gemenetzis G, Hruban RH, Waters KM, Poling J, Zheng L, Laheru D, Herman JM, Makary MA, Weiss MJ, Cameron JL, Wolfgang CL. Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated With Prolonged Survival in Patients With Pancreatic Cancer? Ann Surg. 2018;268:1-8. [PMID: 29334562 DOI: 10.1097/sla.0000000000002672] [Cited by in Crossref: 75] [Cited by in F6Publishing: 31] [Article Influence: 25.0] [Reference Citation Analysis]
621 Lambert A, Schwarz L, Ducreux M, Conroy T. Neoadjuvant Treatment Strategies in Resectable Pancreatic Cancer. Cancers (Basel) 2021;13:4724. [PMID: 34572951 DOI: 10.3390/cancers13184724] [Reference Citation Analysis]
622 Huguet F, Rivin Del Campo E, Antoni D, Vendrely V, Hammel P. [Role of radiation therapy in the management of pancreatic cancer]. Cancer Radiother 2018;22:552-7. [PMID: 30100126 DOI: 10.1016/j.canrad.2018.06.005] [Reference Citation Analysis]
623 Taieb J, Pointet AL, Van Laethem JL, Laquente B, Pernot S, Lordick F, Reni M. What treatment in 2017 for inoperable pancreatic cancers? Ann Oncol. 2017;28:1473-1483. [PMID: 28459988 DOI: 10.1093/annonc/mdx174] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
624 Coveler AL, Herman JM, Simeone DM, Chiorean EG. Localized Pancreatic Cancer: Multidisciplinary Management. Am Soc Clin Oncol Educ Book 2016;35:e217-26. [PMID: 27249726 DOI: 10.1200/EDBK_160827] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
625 Ren W, Xourafas D, Ashley SW, Clancy TE. Temporal Assessment of Prognostic Factors in Patients With Pancreatic Ductal Adenocarcinoma Undergoing Neoadjuvant Treatment and Resection. J Surg Res 2021;257:605-15. [PMID: 32947122 DOI: 10.1016/j.jss.2020.07.073] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
626 Katz MH, Shi Q, Ahmad SA, Herman JM, Marsh Rde W, Collisson E, Schwartz L, Frankel W, Martin R, Conway W, Truty M, Kindler H, Lowy AM, Bekaii-Saab T, Philip P, Talamonti M, Cardin D, LoConte N, Shen P, Hoffman JP, Venook AP. Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101. JAMA Surg. 2016;151:e161137. [PMID: 27275632 DOI: 10.1001/jamasurg.2016.1137] [Cited by in Crossref: 225] [Cited by in F6Publishing: 197] [Article Influence: 37.5] [Reference Citation Analysis]
627 Wan Y, Xu L, Liu Z, Yang M, Jiang X, Zhang Q, Huang J. Utilising network pharmacology to explore the underlying mechanism of Wumei Pill in treating pancreatic neoplasms. BMC Complement Altern Med 2019;19:158. [PMID: 31272505 DOI: 10.1186/s12906-019-2580-y] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 10.7] [Reference Citation Analysis]
628 Roskoski R. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 2014;79:34-74. [PMID: 24269963 DOI: 10.1016/j.phrs.2013.11.002] [Cited by in Crossref: 643] [Cited by in F6Publishing: 579] [Article Influence: 71.4] [Reference Citation Analysis]
629 Vernuccio F, Messina C, Merz V, Cannella R, Midiri M. Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: Role of the Radiologist and Oncologist in the Era of Precision Medicine. Diagnostics (Basel) 2021;11:2166. [PMID: 34829513 DOI: 10.3390/diagnostics11112166] [Reference Citation Analysis]
630 Poschke I, Faryna M, Bergmann F, Flossdorf M, Lauenstein C, Hermes J, Hinz U, Hank T, Ehrenberg R, Volkmar M. Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma. Oncoimmunology. 2016;5:e1240859. [PMID: 28123878 DOI: 10.1080/2162402x.2016.1240859] [Cited by in Crossref: 44] [Cited by in F6Publishing: 32] [Article Influence: 7.3] [Reference Citation Analysis]
631 Choi SI, Jeon AR, Kim MK, Lee YS, Im JE, Koh JW, Han SS, Kong SY, Yoon KA, Koh YH, Lee JH, Lee WJ, Park SJ, Hong EK, Woo SM, Kim YH. Development of Patient-Derived Preclinical Platform for Metastatic Pancreatic Cancer: PDOX and a Subsequent Organoid Model System Using Percutaneous Biopsy Samples. Front Oncol 2019;9:875. [PMID: 31572675 DOI: 10.3389/fonc.2019.00875] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
632 Turaga KK, Tsai S, Wiebe LA, Evans DB, Gamblin TC. Novel multimodality treatment sequencing for extrahepatic (mid and distal) cholangiocarcinoma. Ann Surg Oncol 2013;20:1230-9. [PMID: 23064778 DOI: 10.1245/s10434-012-2648-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
633 Muyinda IJ, Park JG, Jang EJ, Yoo BC. KRAS, A Prime Mediator in Pancreatic Lipid Synthesis through Extra Mitochondrial Glutamine and Citrate Metabolism. Int J Mol Sci 2021;22:5070. [PMID: 34064761 DOI: 10.3390/ijms22105070] [Reference Citation Analysis]
634 Combs SE, Habermehl D, Kessel K, Bergmann F, Werner J, Brecht I, Schirmacher P, Jäger D, Büchler MW, Debus J. Intensity modulated radiotherapy as neoadjuvant chemoradiation for the treatment of patients with locally advanced pancreatic cancer. Outcome analysis and comparison with a 3D-treated patient cohort. Strahlenther Onkol 2013;189:738-44. [PMID: 23896630 DOI: 10.1007/s00066-013-0391-5] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 3.2] [Reference Citation Analysis]
635 Assfalg V, Hüser N, Michalski C, Gillen S, Kleeff J, Friess H. Palliative interventional and surgical therapy for unresectable pancreatic cancer. Cancers (Basel) 2011;3:652-61. [PMID: 24212634 DOI: 10.3390/cancers3010652] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
636 Sohal DPS, Duong M, Ahmad SA, Gandhi NS, Beg MS, Wang-Gillam A, Wade JL 3rd, Chiorean EG, Guthrie KA, Lowy AM, Philip PA, Hochster HS. Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2021;7:421-427. [PMID: 33475684 DOI: 10.1001/jamaoncol.2020.7328] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
637 Kurahara H, Maemura K, Mataki Y, Sakoda M, Iino S, Kawasaki Y, Arigami T, Mori S, Kijima Y, Ueno S, Shinchi H, Natsugoe S. Significance of Glucose Transporter Type 1 (GLUT-1) Expression in the Therapeutic Strategy for Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol 2018;25:1432-9. [PMID: 29404819 DOI: 10.1245/s10434-018-6357-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
638 Wong J, Solomon NL, Hsueh CT. Neoadjuvant treatment for resectable pancreatic adenocarcinoma. World J Clin Oncol 2016; 7(1): 1-8 [PMID: 26862486 DOI: 10.5306/wjco.v7.i1.1] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
639 Lou E, Peters KB, Sumrall AL, Desjardins A, Reardon DA, Lipp ES, Herndon JE 2nd, Coan A, Bailey L, Turner S, Friedman HS, Vredenburgh JJ. Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma. Cancer Med 2013;2:185-95. [PMID: 23634286 DOI: 10.1002/cam4.58] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
640 Servetto A, Santaniello A, Napolitano F, Foschini F, Marciano R, Mozzillo E, Cascetta P, Amato AR, Augurio MR, Maresca L, De Placido P, De Placido S, Formisano L, Bianco R. Use of FOLFIRINOX or Nab-Paclitaxel Plus Gemcitabine for the Treatment of Locally Advanced Pancreatic Adenocarcinoma: A Single Institution Observational Study. Cancers (Basel) 2021;13:4939. [PMID: 34638422 DOI: 10.3390/cancers13194939] [Reference Citation Analysis]
641 Nelson DW, Chang S, Grunkemeier G, Dehal AN, Lee DY, Fischer TD, Difronzo LA, O’connor VV. Resectable Distal Pancreas Cancer: Time to Reconsider the Role of Upfront Surgery. Ann Surg Oncol 2018;25:4012-9. [DOI: 10.1245/s10434-018-6765-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
642 Cheesman AR, Dimaio CJ. Role and technique of endoscopic ultrasound placement of fiducial markers in gastrointestinal malignancies. Techniques in Gastrointestinal Endoscopy 2017;19:213-8. [DOI: 10.1016/j.tgie.2017.10.009] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
643 Isaji S, Kishiwada M, Kato H. Surgery for Borderline Resectable Pancreatic Cancer: The Japanese Experience. In: Katz MH, Ahmad SA, editors. Multimodality Management of Borderline Resectable Pancreatic Cancer. Cham: Springer International Publishing; 2016. pp. 265-87. [DOI: 10.1007/978-3-319-22780-1_17] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
644 Ratnayake B, Savastyuk AY, Nayar M, Wilson CH, Windsor JA, Roberts K, French JJ, Pandanaboyana S. Recurrence Patterns for Pancreatic Ductal Adenocarcinoma after Upfront Resection Versus Resection Following Neoadjuvant Therapy: A Comprehensive Meta-Analysis. J Clin Med 2020;9:E2132. [PMID: 32640720 DOI: 10.3390/jcm9072132] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
645 Lv K, Yang J, Sun J, Guan J. Identification of key candidate genes for pancreatic cancer by bioinformatics analysis. Exp Ther Med 2019;18:451-8. [PMID: 31281439 DOI: 10.3892/etm.2019.7619] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
646 Tajima H, Makino I, Ohbatake Y, Nakanuma S, Hayashi H, Nakagawara H, Miyashita T, Takamura H, Ohta T. Neoadjuvant chemotherapy for pancreatic cancer: Effects on cancer tissue and novel perspectives. Oncol Lett 2017;13:3975-81. [PMID: 28599404 DOI: 10.3892/ol.2017.6008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
647 Ouyang H, Ma W, Liu F, Yue Z, Fang M, Quan M, Pan Z. Factors influencing survival of patients with pancreatic adenocarcinoma and synchronous liver metastases receiving palliative care. Pancreatology 2017;17:773-81. [PMID: 28734721 DOI: 10.1016/j.pan.2017.07.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
648 Kato K, Kondo S, Hirano S, Tanaka E, Shichinohe T, Tsuchikawa T, Matsumoto J. Adjuvant surgical therapy for patients with initially-unresectable pancreatic cancer with long-term favorable responses to chemotherapy. J Hepatobiliary Pancreat Sci. 2011;18:712-716. [PMID: 21455748 DOI: 10.1007/s00534-011-0391-8] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
649 Versteijne E, van Eijck CH, Punt CJ, Suker M, Zwinderman AH, Dohmen MA, Groothuis KB, Busch OR, Besselink MG, de Hingh IH, Ten Tije AJ, Patijn GA, Bonsing BA, de Vos-Geelen J, Klaase JM, Festen S, Boerma D, Erdmann JI, Molenaar IQ, van der Harst E, van der Kolk MB, Rasch CR, van Tienhoven G; Dutch Pancreatic Cancer Group (DPCG). Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial. Trials 2016;17:127. [PMID: 26955809 DOI: 10.1186/s13063-016-1262-z] [Cited by in Crossref: 100] [Cited by in F6Publishing: 89] [Article Influence: 16.7] [Reference Citation Analysis]
650 Pflüger MJ, Felsenstein M, Schmocker R, Wood LD, Hruban R, Fujikura K, Rozich N, van Oosten F, Weiss M, Burns W, Yu J, Cameron J, Pratschke J, Wolfgang CL, He J, Burkhart RA. Gastric cancer following pancreaticoduodenectomy: Experience from a high-volume center and review of existing literature. Surg Open Sci 2020;2:32-40. [PMID: 32954246 DOI: 10.1016/j.sopen.2020.06.003] [Reference Citation Analysis]
651 Combs SE, Habermehl D, Kessel KA, Bergmann F, Werner J, Naumann P, Jäger D, Büchler MW, Debus J. Prognostic impact of CA 19-9 on outcome after neoadjuvant chemoradiation in patients with locally advanced pancreatic cancer. Ann Surg Oncol 2014;21:2801-7. [PMID: 24916745 DOI: 10.1245/s10434-014-3607-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
652 Vincent P, Maeder ME, Hunt B, Linn B, Mangels-Dick T, Hasan T, Wang KK, Pogue BW. CT radiomic features of photodynamic priming in clinical pancreatic adenocarcinoma treatment. Phys Med Biol 2021;66. [PMID: 34261044 DOI: 10.1088/1361-6560/ac1458] [Reference Citation Analysis]
653 Tashiro M, Yamada S, Sonohara F, Takami H, Suenaga M, Hayashi M, Niwa Y, Tanaka C, Kobayashi D, Nakayama G, Koike M, Fujiwara M, Fujii T, Kodera Y. Clinical Impact of Neoadjuvant Therapy on Nutritional Status in Pancreatic Cancer. Ann Surg Oncol 2018;25:3365-71. [DOI: 10.1245/s10434-018-6699-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
654 Yin L, Miao Y, Yu J. Advances of pathological complete response after neoadjuvant therapy for pancreatic cancer. Journal of Pancreatology 2019;2:11-5. [DOI: 10.1097/jp9.0000000000000009] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
655 Jun E, Park Y, Lee W, Kwon J, Lee S, Kim MB, Lee JS, Song KB, Hwang DW, Lee JH, Hoffman RM, Kim SC. The identification of candidate effective combination regimens for pancreatic cancer using the histoculture drug response assay. Sci Rep 2020;10:12004. [PMID: 32686712 DOI: 10.1038/s41598-020-68703-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
656 Sa Cunha A. Les traitements néo-adjuvants peuvent permettre à des tumeurs non resécables de le devenir. Bulletin du Cancer 2015;102:S113-6. [DOI: 10.1016/s0007-4551(15)31230-3] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
657 Nitsche U, Kong B, Balmert A, Friess H, Kleeff J. Should every patient with pancreatic cancer receive perioperative/neoadjuvant therapy? Indian J Med Paediatr Oncol 2016;37:211-3. [PMID: 28144084 DOI: 10.4103/0971-5851.195731] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
658 Dai P, Li J, Li W, Qin X, Wu X, Di W, Zhang Y. Genetic polymorphisms and pancreatic cancer risk: A PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore) 2019;98:e16541. [PMID: 31393355 DOI: 10.1097/MD.0000000000016541] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
659 Murase Y, Ono H, Ogawa K, Yoshioka R, Ishikawa Y, Ueda H, Akahoshi K, Ban D, Kudo A, Tanaka S, Tanabe M. Inhibitor library screening identifies ispinesib as a new potential chemotherapeutic agent for pancreatic cancers. Cancer Sci 2021;112:4641-54. [PMID: 34510663 DOI: 10.1111/cas.15134] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
660 Bijou I, Wang J. Evolving trends in pancreatic cancer therapeutic development. Ann Pancreat Cancer 2019;2:17. [PMID: 33089149 DOI: 10.21037/apc.2019.09.01] [Reference Citation Analysis]
661 Suzuki R, Takagi T, Sugimoto M, Konno N, Sato Y, Irie H, Watanabe K, Nakamura J, Takasumi M, Hashimoto M, Hikichi T, Ohira H. Endoscopic ultrasound-guided fine needle aspiration for pancreatic cancer. Fukushima J Med Sci 2018;64:111-5. [PMID: 30197399 DOI: 10.5387/fms.2018-14] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
662 Téoule P, Tombers K, Rahbari M, Sandra-Petrescu F, Keese M, Rahbari NN, Reißfelder C, Rückert F. [Definition and treatment of superior mesenteric artery revascularization and dissection-associated diarrhea (SMARD syndrome) in Germany]. Chirurg 2021. [PMID: 34100984 DOI: 10.1007/s00104-021-01427-4] [Reference Citation Analysis]
663 Xia G, Wang H, Song Z, Meng Q, Huang X, Huang X. Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2). J Exp Clin Cancer Res 2017;36:107. [PMID: 28797284 DOI: 10.1186/s13046-017-0579-0] [Cited by in Crossref: 33] [Cited by in F6Publishing: 40] [Article Influence: 6.6] [Reference Citation Analysis]
664 Pecorelli N, Braga M, Doglioni C, Balzano G, Reni M, Cereda S, Albarello L, Castoldi R, Capretti G, Di Carlo V. Preoperative chemotherapy does not adversely affect pancreatic structure and short-term outcome after pancreatectomy. J Gastrointest Surg 2013;17:488-93. [PMID: 23132627 DOI: 10.1007/s11605-012-2063-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
665 Walczak S, Velanovich V. Improving prognosis and reducing decision regret for pancreatic cancer treatment using artificial neural networks. Decision Support Systems 2018;106:110-8. [DOI: 10.1016/j.dss.2017.12.007] [Cited by in Crossref: 33] [Cited by in F6Publishing: 3] [Article Influence: 8.3] [Reference Citation Analysis]
666 Pelzer U, Hilbig A, Sinn M, Stieler J, Bahra M, Dörken B, Riess H. Value of carbohydrate antigen 19-9 in predicting response and therapy control in patients with metastatic pancreatic cancer undergoing first-line therapy. Front Oncol 2013;3:155. [PMID: 23785668 DOI: 10.3389/fonc.2013.00155] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
667 Scarà S, Bottoni P, Scatena R. CA 19-9: Biochemical and Clinical Aspects. Adv Exp Med Biol 2015;867:247-60. [PMID: 26530370 DOI: 10.1007/978-94-017-7215-0_15] [Cited by in Crossref: 99] [Cited by in F6Publishing: 91] [Article Influence: 16.5] [Reference Citation Analysis]
668 Maxwell JE, Katz MHG. Radiotherapy for Resectable and Borderline Resectable Pancreas Cancer: When and Why? J Gastrointest Surg 2021;25:843-8. [PMID: 33205307 DOI: 10.1007/s11605-020-04838-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
669 Selvaggi F, Mascetta G, Daskalaki D, dal Molin M, Salvia R, Butturini G, Cellini C, Bassi C. Outcome of superior mesenteric-portal vein resection during pancreatectomy for borderline ductal adenocarcinoma: results of a prospective comparative study. Langenbecks Arch Surg 2014;399:659-65. [PMID: 24777762 DOI: 10.1007/s00423-014-1194-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
670 Saccomandi P, Lapergola A, Longo F, Schena E, Quero G. Thermal ablation of pancreatic cancer: A systematic literature review of clinical practice and pre-clinical studies. Int J Hyperthermia. 2018;35:398-418. [PMID: 30428728 DOI: 10.1080/02656736.2018.1506165] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
671 O Kane GM, Knox JJ. Locally advanced pancreatic cancer: An emerging entity. Curr Probl Cancer 2018;42:12-25. [PMID: 29153290 DOI: 10.1016/j.currproblcancer.2017.10.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
672 Borazanci E, Sckolnik S, Amini A. Neo-adjuvant therapy for pancreatic cancer: hope for the future. Expert Rev Gastroenterol Hepatol 2019;13:579-89. [PMID: 30979348 DOI: 10.1080/17474124.2019.1607294] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
673 Lan C, Yamashita YI, Hayashi H, Nakagawa S, Imai K, Mima K, Kaida T, Matsumoto T, Maruno M, Liu Z, Wu X, Wei F, Baba H. High Expression of Bloom Syndrome Helicase is a Key Factor for Poor Prognosis and Advanced Malignancy in Patients with Pancreatic Cancer: A Retrospective Study. Ann Surg Oncol 2022. [PMID: 35419757 DOI: 10.1245/s10434-022-11500-9] [Reference Citation Analysis]
674 Tang TY, Li X, Zhang Q, Guo CX, Zhang XZ, Lao MY, Shen YN, Xiao WB, Ying SH, Sun K, Yu RS, Gao SL, Que RS, Chen W, Huang DB, Pang PP, Bai XL, Liang TB. Development of a Novel Multiparametric MRI Radiomic Nomogram for Preoperative Evaluation of Early Recurrence in Resectable Pancreatic Cancer. J Magn Reson Imaging 2020;52:231-45. [PMID: 31867839 DOI: 10.1002/jmri.27024] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
675 Cho IR, Chung MJ, Bang S, Park SW, Chung JB, Song SY, Seong J, Hwang HK, Kang CM, Lee WJ, Park JY. Gemcitabine based neoadjuvant chemoradiotherapy therapy in patients with borderline resectable pancreatic cancer. Pancreatology. 2013;13:539-543. [PMID: 24075521 DOI: 10.1016/j.pan.2013.07.064] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
676 Nappo G, Donisi G, Zerbi A. Borderline resectable pancreatic cancer: Certainties and controversies. World J Gastrointest Surg 2021; 13(6): 516-528 [PMID: 34194610 DOI: 10.4240/wjgs.v13.i6.516] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
677 Gluth A, Werner J, Hartwig W. Surgical resection strategies for locally advanced pancreatic cancer. Langenbecks Arch Surg 2015;400:757-65. [DOI: 10.1007/s00423-015-1318-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
678 Perysinakis I, Aggeli C, Kaltsas G, Zografos GN. Neoadjuvant therapy for advanced pancreatic neuroendocrine tumors: an emerging treatment modality? Hormones 2016;15:15-22. [DOI: 10.1007/bf03401399] [Cited by in Crossref: 20] [Article Influence: 3.3] [Reference Citation Analysis]
679 Rahman SH, Urquhart R, Molinari M. Neoadjuvant therapy for resectable pancreatic cancer. World J Gastrointest Oncol 2017; 9(12): 457-465 [PMID: 29290916 DOI: 10.4251/wjgo.v9.i12.457] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
680 Ayres Pereira M, Chio IIC. Metastasis in Pancreatic Ductal Adenocarcinoma: Current Standing and Methodologies. Genes (Basel) 2019;11:E6. [PMID: 31861620 DOI: 10.3390/genes11010006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
681 Kinoshita H, Kanda T, Takata T, Sugihara T, Mae Y, Yamashita T, Onoyama T, Takeda Y, Isomoto H. Oligopeptide Transporter-1 is Associated with Fluorescence Intensity of 5-Aminolevulinic Acid-Based Photodynamic Diagnosis in Pancreatic Cancer Cells. Yonago Acta Med 2020;63:154-62. [PMID: 32884434 DOI: 10.33160/yam.2020.08.003] [Reference Citation Analysis]
682 Tajima H, Makino I, Gabata R, Okazaki M, Ohbatake Y, Shimbashi H, Nakanuma S, Saitoh H, Shimada M, Yamaguchi T, Okamoto K, Moriyama H, Kinoshita J, Nakamura K, Miyashita T, Ninomiya I, Fushida S, Ikeda H, Ohta T. A phase I study of preoperative (neoadjuvant) chemotherapy with gemcitabine plus nab-paclitaxel for resectable pancreatic cancer. Mol Clin Oncol 2021;14:26. [PMID: 33414907 DOI: 10.3892/mco.2020.2188] [Reference Citation Analysis]
683 D'Onofrio M, Ciaravino V, Cardobi N, De Robertis R, Tinazzi Martini P, Girelli R, Barbi E, Paiella S, Marrano E, Salvia R, Butturini G, Pederzoli P, Bassi C. The borderline resectable/locally advanced pancreatic ductal adenocarcinoma staging with computed tomography/magnetic resonance imaging. Endosc Ultrasound 2017;6:S79-82. [PMID: 29387697 DOI: 10.4103/eus.eus_67_17] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
684 Hall WA, Colbert LE, Nickleach D, Switchenko J, Liu Y, Gillespie T, Lipscomb J, Hardy C, Kooby DA, Prabhu RS, Kauh J, Landry JC. The influence of radiation therapy dose escalation on overall survival in unresectable pancreatic adenocarcinoma. J Gastrointest Oncol 2014;5:77-85. [PMID: 24772334 DOI: 10.3978/j.issn.2078-6891.2014.001] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
685 Rhee H, Park MS. The Role of Imaging in Current Treatment Strategies for Pancreatic Adenocarcinoma. Korean J Radiol 2021;22:23-40. [PMID: 32901458 DOI: 10.3348/kjr.2019.0862] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
686 Ohkuma R, Yada E, Ishikawa S, Komura D, Ishizaki H, Tamada K, Kubota Y, Hamada K, Ish